Podcasts about Joslin Diabetes Center

phd fat function obesity metabolic endo lino endocrinology adrenal endocrine brown fat adipose joslin diabetes center

Play Episode Listen Later Aug 21, 2024 15:36

In this episode, we talk about brown fat and some new discoveries in how it regulates metabolic function. Joining host Aaron Lohr is Marsel Lino, PhD, a research fellow at Joslin Diabetes Center in Boston. Dr. Lino presented an abstract at ENDO 2024 titled, “A New Layer of Endocrine Regulation: Brown Fat Secretes Exosomal MicroRNAs, Which Regulate Metabolic Functions and Distal Organs.” Show notes are available at https://www.endocrine.org/podcast/enp89-brown-fat-and-metabolic-function — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Personalising Diabetes Treatment

BFM :: Health & Living

Play Episode Listen Later Aug 6, 2024 32:47

Diabetes affects one in six people in Malaysia, and is one of the top causes of death, as slightly over half (56%) of patients do not have good blood glucose control. We face multiple challenges in reducing the impact of diabetes, including poor compliance to treatment and progression of the disease towards complications. Can precision medicine guide us in adopting a different approach to diabetes management? We find out from Dr Tye Sok Cin, a postdoctoral researcher with the Section on Genetics and Epidemiology, Joslin Diabetes Center, Harvard Medical School. (Sok Cin recently received the first-ever Andrew P. Goldberg Early Career Award by the American Diabetes Association for her work in diabetes research.)Image credit: Tridsanu Thopet via Shutterstock

treatments diabetes malaysia genetics harvard medical school epidemiology shutterstock american diabetes association personalising diabetes treatment joslin diabetes center

Uncovering the Prevalence of Type 1 Diabetes in Older Adults

Diabetes Discourse

Play Episode Listen Later May 9, 2024

Guest: Elena Toschi, MD Approximately over the last decade, lifespans in the general population have increased, along with a rise in the prevalence of type 1 diabetes in older adult patients. Since each patient has a unique disease, the clinician should personalize and devise the best approach to diabetes management and glycemic targets, as well as manage comorbidities and complications. To learn more, join Dr. Elena Toschi, Director of the Young Adult Program at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School.

director medicine assistant professor uncovering harvard medical school prevalence type1 older adults type 1 diabetes rmd reachmd joslin diabetes center diabetes and endocrinology diabetes discourse

Ep 4.4 - Nadine Joseph

AfterGate

Play Episode Listen Later Apr 27, 2024 102:45

Alvin and German conduct a great conversation with Biogen's, Biomedical Scientist, Nadine Joseph.'03. As a recipient of the NIH Dissertation Award, she boasts a background in the biotechnology sector, focusing her research on the molecular intricacies of learning, memory, and neurodegeneration. Passionate about bridging health disparities and promoting inclusivity in academia, she pursued her doctoral studies at The Scripps Research Institute after completing her undergraduate degree at Colgate University. Additionally, she holds a Master of Science degree from the University of Connecticut. Her academic journey also included research stints at esteemed institutions such as the Massachusetts Institute of Technology (MIT) and the Joslin Diabetes Center. During her time at Colgate, she actively engaged in various student organizations, including AASA and Sojourners, while also fulfilling the role of Resident Advisor for two years. She received her Bachelor of Arts in Education.

Pre and Post Run Fueling, AG1 Review, How to Plan a Race Season

race rsvp fueling boston marathon we back comkeep joslin diabetes center mug club

Play Episode Listen Later Feb 20, 2024 59:28

We BACK! Ok...so we went biweekly for February...thanks for sticking with us! We cover all the good stuff this week including: How Nina is fueling her runsA (hot take?) AG1 reviewHow we plan our racing seasonWhy Kara shouldn't be allowed to have subscription servicesWe also have a Nutrition Corner this week covering how and why it's important to fuel right after your runs. Help Maddie raise money for the Joslin Diabetes Center and the High Hopes Fund as she prepares to run the Boston Marathon.RSVP to Mug Club!Connect with us: @trailmix_pod on Instagram, Follow Nina and KaraLooking for a coach or sports nutritionist? Nina's your girl!Support us on Patreon! Thank you!!Join the gear swap! Got a question or topic suggestion? Send us an email trailmixsisters@gmail.comKeep it wild!

Good Ole Fashioned Catch Up

boston marathon aye fashioned good ole trail mix comkeep joslin diabetes center

Play Episode Listen Later Feb 6, 2024 44:18

Aye! We back baby, sorry for the unintentional week hiatus...life happens and we are busy folk outside of this podcast. This week on the Trail Mix podcast it's a good ole fashioned catch up. We do some catching up with each other, tend to some housecleaning, and make 2 big and exciting announcements. Check it out! Help Maddie raise money for the Joslin Diabetes Center and the High Hopes Fund as she prepares to run the Boston Marathon.Connect with us: @trailmix_pod on Instagram, Follow Nina and KaraLooking for a coach or sports nutritionist? Nina's your girl!Support us on Patreon! Thank you!!Join the gear swap! Got a question or topic suggestion? Send us an email trailmixsisters@gmail.comKeep it wild!

Gestational Diabetes & Black Maternal Health: A Conversation with Sue-Ellen Anderson Haynes

The Eavesdrop

Play Episode Listen Later Feb 4, 2024 66:06

About The Podcast. The Eavesdrop Podcast is a women's wellness podcast The Eavesdrop is a Women's Health Podcast that was created to educate, inform, and empower women to take charge of their physical, spiritual, and mental health. While the platform was created to discuss women's health concerns, no topic is ever off limits! Enjoy all inclusive conversations that will explore social issues affecting women, relationships, fashion tips, pop culture, and so much more! This Week's Episode. As we kick off Black History Month, we are having a candid conversation with Sue-Ellen Anderson-Haynes, MS, RDN,CDCES, LDN, NASM-CPT about Black Maternal Health and Mortality. Some conditions in pregnancy that affect African American Women disproportionately include: Pregnancy Induced Hypertension, Preeclampsia, Gestational Diabetes, and Postpartum Hemorrhage. Today we will review Gestational Diabetes and have a discussion about self advocacy and how to lower your risk of maternal and infant mortality and morbidity. If you are currently pregnant, considering pregnancy, recently given birth....This is the episode for you. About Sue-Ellen Anderson-Haynes Sue-Ellen is a co-author, health writer, speaker, recipe developer, and co-founder of cultured health (an app that connects dietitians to clients based on culture). She has been featured in multiple media outlets including PubMed, Insider, Harvard Health Publishing, EverdayHealth and more. Her experience includes working with many age groups in the areas of pediatrics, women's health, wellness, bariatrics, weight management and diabetes. She has training in the prenatal, pregnancy, and postpartum population from the worlds leading diabetes center - Joslin Diabetes Center in Boston Massachusetts, in addition, to other outpatient clinics, wellness centers, and hospitals across the U.S. She is a National Media Spokesperson for the Academy of Nutrition and Dietetics, Certified Diabetes Care and Education Specialist, National Academy of Sports Medicine Women's Fitness Specialist and holds her Certificate of Training in Adult Weight Management. She obtained her Masters of Science from Andrews University in Nutrition & Wellness, Summa Cum Laude, and Bachelors of Science in Food Science & Human Nutrition with minor in Health Science Education from the University of Florida. She is an active member of local, state, and national nutrition organizations. At the end of the day, she is first a wife and mother to her children and likes to be called “the organizer” of her home. She enjoys helping girls and women journey naturally to complete wellness, spending quality time with her family and cooking many dishes especially her traditional Jamaican meals. Learn More About Sue-Ellen Anderson-Haynes Follow on Instagram @360girlsandwomen @Gestational_Diabetes_Dietitian Check out her website: www.360girlsandwomen.com Follow on Facebook: 360girls&women Follow and Learn more about The Eavesdrop The Eavesdrop Instagram : IG @ therealeavesdrop_podcast ⁠The Eavesdrop Website⁠: www.theeavesdroppodcast.com ⁠ The Eavesdrop Twitter ⁠ Follow @ Drshalonnab Women's Health Telemedicine Services. Perfect Harmony Telemed www.perfectharmonytelehealth.com Perfect Harmony Women's Health Telemedicine: IG @perfectharmony_telemed

Burnt Out and Injured, 'tis the season

women injured burnt boston marathon tis the season comkeep joslin diabetes center

Play Episode Listen Later Jan 23, 2024 40:50

Help Maddie raise money for the Joslin Diabetes Center and the High Hopes Fund as she prepares to run the Boston Marathon.Women who inspire us: Katie Grossman Connect with us: @trailmix_pod on Instagram, Follow Nina and KaraLooking for a coach or sports nutritionist? Nina's your girl!Support us on Patreon! Thank you!!Join the gear swap! Got a question or topic suggestion? Send us an email trailmixsisters@gmail.comKeep it wild!

Patreon! Gel Review! Cold Weather Kits!

boston marathon kits cold weather comkeep joslin diabetes center

Play Episode Listen Later Jan 15, 2024 37:46

We are back this week with a good ole fashioned hodge podge of topics spanning from some much needed house cleaning, to a gel review, and finishing off with our go to kits for running in the cold. Also...we have a special announcement about Patreon! Help Maddie raise money for the Joslin Diabetes Center and the High Hopes Fund as she prepares to run the Boston Marathon. Connect with us: @trailmix_pod on Instagram, Follow Nina and KaraLooking for a coach or sports nutritionist? Nina's your girl!Support us on Patreon! Thank you!!Join the gear swap! Got a question or topic suggestion? Send us an email trailmixsisters@gmail.comKeep it wild!

Building Blocks to Better Health | Center for Sustainable Health Care Quality and Equity

Reducing Patient Risk

Play Episode Listen Later Oct 31, 2023 52:05

Join us for a candid discussion on how vaccines can lead to healthier outcomes for people living with diabetes. Our panelists will discuss the value of vaccines in communities of color, which vaccines are most effective in living well for those with diabetes, and how our community partners and advocacy organizations are a catalyst to promoting the value of vaccination. Moderator Anna Norton, MS President, Center for Sustainable Health Care Quality & Equity, National Minority Quality Forum Anna Norton has worked in the non-profit sector for 25 years as an advocate, fundraiser, speaker, and leader. She has been featured in an assortment of health-related magazines and books, including Balancing Pregnancy with Pre-Existing Diabetes, A Woman's Guide to Diabetes: A Path to Wellness and Diabetic Living. Anna graduated with a Bachelor of Science from the University of Florida and Master of Science in Education at Florida International University. Panelists Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP Endocrinology Clinical Pharmacy Specialist Cleveland Clinic Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP is an Endocrinology Clinical Pharmacy Specialist. She serves as the Co-Director of Endocrine Disorders in Pregnancy and the Director of Education and Training in Diabetes Technology at the Cleveland Clinic Endocrinology and Metabolism Institute. Dr. Isaacs earned her bachelor's degree in chemistry from the University of Illinois at Chicago, Doctor of Pharmacy Degree from Southern Illinois University Edwardsville (SIUE) and completed a pharmacy practice residency at the Philadelphia Veterans Affairs. Dr. Isaacs holds board certifications in pharmacotherapy, ambulatory care, and advanced diabetes management. She served on the American Diabetes Association (ADA) Professional Practice Committee from 2020-2023, the committee that updates the ADA Standards of Care. She is a National Board Member of the Association of Diabetes Care and Education Specialists (ADCES). Tasha Berry-Lewis Health Ministry Director New Spiritual Light Missionary Baptist Church Tasha R. Berry-Lewis is a Health Advocate based in the Chicagoland area. She brings a wealth of experience from her previous role in the federal government, where she specialized in Human Resources, focusing on Labor and Employee Relations, Benefits, Training, and Payroll. Tasha is also a distinguished 20-year military veteran, serving during the Gulf War in Dharan, Saudi Arabia. Since 2021, Tasha has been a part of the National Minority Quality Forum - Faith Health Alliance, where she has been providing educational services to churches in the Chicagoland area on various health-related topics, including influenza, and COVID-19 vaccines. Kristian Hurley Senior Vice President of Programs, Advocacy and Health Equity, Beyond Type 1 Kristian Hurley is the Senior Vice President of Programs, Advocacy, and Health Equity at Beyond Type 1, a global nonprofit that helps people living with diabetes to stay alive and thrive. She is an experienced leader with a history of tripling health impact and revenue by inspiring transformative change in communities through building coalitions to increase health equity. Dr. Enrique Caballero, MD Endocrinologist/Investigator, Division of Endocrinology Diabetes and Hypertension, Division of Global Health Equity, Brigham and Women's Hospital Dr. Caballero is an Endocrinologist, Clinical Investigator and Educator. He is the Faculty Director of International Innovation Programs and Faculty Director of Diabetes Education in the Office for External Education at Harvard Medical School. Dr. Caballero founded the Latino Diabetes Initiative at the Joslin Diabetes Center and the Diabetes Program within the Spanish Clinic at the Brigham and Women's Hospital, both affiliated with Harvard Medical School. He is currently Associate Scientist in the Division of Global Health Equity at the Brigham and Women's Hospital in Boston.

covid-19 women director university chicago master science education guide woman training care doctors office benefits wellness bachelor illinois hospitals equity labor sustainable pregnancy educators programs advocacy saudi arabia senior vice president human resources harvard medical school co director building blocks payroll chicagoland better health caballero brigham gulf war hypertension health equity pharmd florida international university isaacs health centers health advocates faculty director endocrinologists diabetes care bcps employee relations fccp healthcare quality cdces diabetes education bcacp joslin diabetes center global health equity beyond type associate scientist national board member diabetes technology bc adm clinical investigator diabetes program fadces

Digital Therapeutics Explained with Richard ‘RJ' Kedziora

Life Sciences 360

Play Episode Listen Later Sep 28, 2023 32:59 Transcription Available

Episode 024: Harsh Thakkar (@harshvthakkar) engages in a riveting discussion with RJ Kedziora (@RJKedziora), Co-Founder / Partner and Solutions Architect Estenda Solutions, Inc.In this episode, RJ uncovers the ins and outs of blending clinical information with imaging data, especially for patients with chronic conditions like diabetes and hypertension. RJ also dives into how data management has evolved and the exciting opportunities AI brings to healthcare. Harsh and RJ also explore the regulatory landscape surrounding AI in healthcare, discussing the EU and FDA's risk-based approach towards medical devices and AI applications. They emphasize the importance of transparency, data governance, and addressing biases in AI training datasets to ensure the technology serves a diverse population effectively.-----Links:*Estenda Solutions, Inc. Website*Upcoming HLTH Conference in Las Vegas*Would you rather watch the video episode? Subscribe to full-length videos on our YouTube channel.-----Show Notes:(5:45) Using AI in healthcare with examples from Joslin Diabetes Center. (10:47) AI in healthcare, data quality, and regulations. (15:59) AI in healthcare, data bias, and integration.(24:31) Digital health data analysis and expertise needed.(29:19) AI security challenges and solutions.For more, check out the podcast website - www.lifesciencespod.com

ai digital european union fda rj using ai harsh digital therapeutics co founder partner joslin diabetes center

Heard on the Street: Jason Gaglia, MD, Joslin Diabetes Center

TheSugarScience Podcast- curating the scientific conversation in type 1 diabetes

Play Episode Listen Later Jun 28, 2023 5:53

Check out “Heard on the Street” recorded during the ADA 2023 Conference. Hear from Dr. Jason Gaglia at Joslin Diabetes Center as he shares his exciting poster: Novel autologous dendritic cell therapy AVT001 for type 1 diabetes.

conference heard joslin diabetes center

Heard on the Street: Shilton Dhaver, Joslin Diabetes Center

TheSugarScience Podcast- curating the scientific conversation in type 1 diabetes

Play Episode Listen Later Jun 27, 2023 3:29

Check out “Heard on the Street” recorded during the ADA 2023 Conference. Hear from Shilton Dhaver at Joslin Diabetes Center as he shares his poster: relationship between glycemic control and body weight in non-alcoholic fatty liver disease in patients with type 1 diabetes.

conference heard joslin diabetes center

67: Chet Galaska – Causes and stigmas of diabetes

TWO NOBODYS

Play Episode Listen Later Jun 2, 2023 72:01

Chet Galaska discusses everything you need to know about diabetes from the perspective of those who have it. It's not as well understood by the general public as you'd think and this can lead to stigmas being placed on those who have the disease. -- Chet Galaska graduated from the University of Hartford with a Bachelor of Science in Business Administration. After working in several industrial operations, he co-founded and was president of a company that produces stainless steel castings for heavy industry. He has had type 1 diabetes since 1981 and has managed it well. Because of this he was asked to participate in a long term study by the Joslin Diabetes Center at Harvard University. Chet isn't a health care professional. He is simply a person who understands diabetes and sees the disease from the perspective of those who have it. It became clear to him that messaging about the disease underlies misperceptions that have damaging consequences. This is a huge problem in the world of diabetes that doesn't get recognized, let alone addressed. He realized that people need to know the facts if we're to motivate diabetics to do the hard things the disease demands. As a first step, he wrote The Diabetes Book: What Everyone Should Know and spoke to many groups about it. He then developed the Challenge Diabetes Program which was presented in participation with college, medical, civic, business, church and other organizations. In recognition of this work he was presented the Heroes Walking Among Us Award by the Massachusetts Foot and Ankle Society. These are doctors who deal first-hand with the consequences of diabetes ignorance. His purpose is to create an informed and supportive social environment that respects diabetics who fight the beast and encourages those who don't to take it seriously. He appears on podcasts to reach as many people as possible.

university science bachelor diabetes harvard university business administration hartford stigmas joslin diabetes center

Clearance of p16Ink4a-positive Cells in Mice: Effects on β-cell Mass and Proliferation

Aging-US

Play Episode Listen Later Jan 31, 2023 3:51

A new research paper was published on the cover of Aging (Aging-US)) Volume 15, Issue 2, entitled, “Clearance of p16Ink4a-positive cells in a mouse transgenic model does not change β-cell mass and has limited effects on their proliferative capacity.” Type 2 diabetes is partly characterized by decreased β-cell mass and function which have been linked to cellular senescence. Despite a low basal proliferative rate of adult β-cells, they can respond to growth stimuli, but this proliferative capacity decreases with age and correlates with increased expression of senescence effector, p16Ink4a. In a new study, researchers Nadine Bahour, Lucia Bleichmar, Cristian Abarca, Emeline Wilmann, Stephanie Sanjines, and Cristina Aguayo-Mazzucato from the Joslin Diabetes Center at Harvard Medical School hypothesized that selective deletion of p16Ink4a-positive cells would enhance the proliferative capacity of the remaining β-cells due to the elimination of the local senescence-associated secretory phenotype (SASP). “We aimed to investigate the effects of p16Ink4a-positive cell removal on the mass and proliferative capacity of remaining β-cells using INK-ATTAC mice as a transgenic model of senolysis.” Clearance of p16Ink4a-positive subpopulation was tested in mice of different ages, males and females, and with two different insulin resistance models: high-fat diet (HFD) and insulin receptor antagonist (S961). Clearance of p16Ink4a-positive cells did not affect the overall β-cell mass. β-cell proliferative capacity negatively correlated with cellular senescence load and clearance of p16Ink4a positive cells in 1-year-old HFD mice improved β-cell function and increased proliferative capacity in a subset of animals. Single-cell sequencing revealed that the targeted p16Ink4a subpopulation of β-cells is non-proliferative and non-SASP producing whereas additional senescent subpopulations remained contributing to continued local SASP secretion. “In conclusion, deletion of p16Ink4a cells did not negatively impact beta-cell mass and blood glucose under basal and HFD conditions and proliferation was restored in a subset of HFD mice opening further therapeutic targets in the treatment of diabetes.” DOI: https://doi.org/10.18632/aging.204483 Corresponding Author: Cristina Aguayo-Mazzucato - cristina.aguayo-mazzucato@joslin.harvard.edu Keywords: beta cells, mass, proliferation, senolysis, senescence Sign up for free Altmetric alerts about this article: https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204483 About Aging-US: Launched in 2009, Aging (Aging-US) publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at www.Aging-US.com and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ Twitter - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://youtube.com/Aging-US LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

covid-19 positive single soundcloud effects mass pinterest harvard medical school mice cells doi clearance proliferation joslin diabetes center hfd sasp altmetric

The Gary Null Show - 01.10.23

The Gary Null Show

Play Episode Listen Later Jan 10, 2023 63:17

Videos: BOMBSHELL docs reveal Covid-19 COVER-UP goes straight to the top | Redacted with Clayton Morris – Whiselblower Sasha Latypova My Apology Letter Regarding My Friendship with Jordan Peterson (THE SAAD TRUTH_1365) Harari: “With this kind of surveillance [under the skin], (you can detect dissent). I mean, you watch the big President, the big leader, give a speech on television — the television could be monitoring you and knowing whether you're angry or not just by analyzing the cues.” MacDonald Brainwashed (Tom words of wisdom) – The Rap Eating almonds daily boosts exercise recovery molecule by 69% among ‘weekend warriors' Appalachian State University, January 6, 2023 For those who exercise regularly, eating almonds each day might be the ideal new year's resolution. A randomized controlled trial in Frontiers in Nutrition showed that female and male participants who ate 57g almonds daily for one month had more of the beneficial fat 12,13-dihydroxy-9Z-octadecenoic acid (12,13-DiHOME) in their blood immediately after a session of intense exercise than control participants. This molecule, a so-called oxylipin (oxidized fat) is synthetized from linoleic acid by brown fat tissue, and has a beneficial effect on metabolic health and energy regulation. Corresponding author Dr. David C Nieman, a professor and director of the Appalachian State University Human Performance Laboratory at the North Carolina Research Campus, said, “Here we show that volunteers who consumed 57g of almonds daily for one month before a single ‘weekend warrior' exercise bout had more beneficial 12,13-DiHOME in their blood immediately after exercising than control volunteers. They also reported feeling less fatigue and tension, better leg-back strength, and decreased muscle damage after exercise than control volunteers.” The clinical trial involved 38 men and 26 women between the ages of 30 and 65, who didn't engage in regular weight training. Approximately half were randomized to the almond diet group, and the other half to the control group, who daily ate a calorie-matched cereal bar. The researchers took blood and urine samples before and after the four-week period of dietary supplementation. Performance measures included a 30 second Wingate anaerobic test, a 50 meter shuttle run test, and vertical jump, bench press, and leg-back strength exercises. Additional blood and urine samples were taken immediately after this 90 minute session of ‘eccentric exercise' and daily for four days afterwards. As expected, the 90 minute exercise led to an increase in the volunteers' self-reported feeling of muscle damage and muscle soreness, as well as an increased POMS score, indicating self-reported decreased vigor and increased fatigue, anxiety, and depression. The exercise also resulted in transient elevated levels of pro-inflammatory cytokines such as IL-6, IL-8, IL-10, and MCP-1 in the blood, consistent with minor muscle damage. However, these changes in cytokines were equal in the almond and cereal bar groups. Importantly, immediately after exercise, the concentration of the beneficial 12,13-DiHOME was 69% higher in blood plasma of participants in the almond group than in participants in the control group. 12,13-DiHOME is known to increase the transport of fatty acid and its uptake by skeletal muscle, with the overall effect of stimulating metabolic recovery after exercise. The reverse pattern was found for another oxylipin, the mildly toxic 9,10-Dihydroxy-12-octadecenoic acid (9,10-diHOME), which was 40% higher immediately after exercise in the blood of the control group than in the almond group. Unlike 12,13-DiHOME, 9,10-diHOME has been shown have negative effects on overall health and the body's recovery to exercise. Nieman and colleagues concluded that daily consumption of almonds leads to a change in metabolism, downregulating inflammation and oxidative stress from exercise and enabling the body to recover faster. “We conclude that almonds provide a unique and complex nutrient and polyphenol mixture that may support metabolic recovery from stressful levels of exercise. Almonds have high amounts of protein, healthy types of fats, vitamin E, minerals, and fiber. And the brown skin of almonds contains polyphenols that end up in the large intestine and help control inflammation and oxidative stress,” said Nieman. Omega-3 supplements can prevent childhood asthma Copenhagen University Hospital, December 29, 2022 Taking certain omega-3 fatty acid supplements during pregnancy can reduce the risk of childhood asthma by almost one third, according to a new study from the Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) and the University of Waterloo. The study, published in the New England Journal of Medicine, found that women who were prescribed 2.4 grams of long-chain omega-3 supplements during the third trimester of pregnancy reduced their children's risk of asthma by 31 per cent. Long-chain omega-3 fatty acids, which include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are found in cold water fish, and key to regulating human immune response. “We've long suspected there was a link between the anti-inflammatory properties of long-chain omega-3 fats, the low intakes of omega-3 in Western diets and the rising rates of childhood asthma,” said Professor Hans Bisgaard of COPSAC at the Copenhagen University Hospital. “This study proves that they are definitively and significantly related.” The testing also revealed that women with low blood levels of EPA and DHA at the beginning of the study benefitted the most from the supplements. For these women, it reduced their children's relative risk of developing asthma by 54 per cent. “The proportion of women with low EPA and DHA in their blood is even higher in Canada and the United States as compared with Denmark. So we would expect an even greater reduction in risk among North American populations,” said Professor Stark. “Identifying these women and providing them with supplements should be considered a front-line defense to reduce and prevent childhood asthma.” “Asthma and wheezing disorders have more than doubled in Western countries in recent decades,” said Professor Bisgaard. “We now have a preventative measure to help bring those numbers down.” Currently, one out of five young children suffer from asthma or a related disorder before school age. Study shows gardening may help reduce cancer risk, boost mental health University of Colorado at Boulder, January 6, 2023 The first-ever, randomized, controlled trial of community gardening found that those who started gardening ate more fiber and got more physical activity—two known ways to reduce risk of cancer and chronic diseases. They also saw their levels of stress and anxiety significantly decrease. The findings were published in The Lancet Planetary Health. “These findings provide concrete evidence that community gardening could play an important role in preventing cancer, chronic diseases and mental health disorders,” said senior author Jill Litt, a professor in the Department of Environmental Studies at CU Boulder. “No matter where you go, people say there's just something about gardening that makes them feel better,” said Litt, who is also a researcher with the Barcelona Institute for Global Health. Some small observational studies have found that people who garden tend to eat more fruits and vegetables and have a healthier weight. But it has been unclear whether healthier people just tend to garden, or gardening influences health. Only three studies have applied the gold standard of scientific research, the randomized controlled trial, to the pastime. None have looked specifically at community gardening. To fill the gap, Litt recruited 291 non-gardening adults, average age of 41, from the Denver area. More than a third were Hispanic and more than half came from low-income households. The gardening group received a free community garden plot, some seeds and seedlings, and an introductory gardening course through the nonprofit Denver Urban Gardens program and a study partner. By fall, those in the gardening group were eating, on average, 1.4 grams more fiber per day than the control group—an increase of about 7%. The authors note that fiber exerts a profound effect on inflammatory and immune responses, influencing everything from how we metabolize food to how healthy our gut microbiome is to how susceptible we are to diabetes and certain cancers. While doctors recommend about 25 to 38 grams of fiber per day, the average adult consumes less than 16 grams. “An increase of one gram of fiber can have large, positive effects on health,” said co-author James Hebert, director of University of South Carolina's cancer prevention and control program. The gardening group also increased their physical activity levels by about 42 minutes per week. Public health agencies recommend at least 150 minutes of physical activity per week, a recommendation only a quarter of the U.S. population meets. With just two to three visits to the community garden weekly, participants met 28% of that requirement. Study participants also saw their stress and anxiety levels decrease, with those who came into the study most stressed and anxious seeing the greatest reduction in mental health issues. The study also confirmed that even novice gardeners can reap measurable health benefits of the pastime in their first season. As they have more experience and enjoy greater yields, Litt suspects such benefits will increase. Researchers shed light on how exercise preserves physical fitness during aging Joslin Diabetes Center, December 6, 2023 Proven to protect against a wide array of diseases, exercise may be the most powerful anti-aging intervention known to science. However, while physical activity can improve health during aging, its beneficial effects inevitably decline. The cellular mechanisms underlying the relationship among exercise, fitness and aging remain poorly understood. In a paper published in the Proceedings of the National Academy of Sciences, researchers at Joslin Diabetes Center investigated the role of one cellular mechanism in improving physical fitness by exercise training and identified one anti-aging intervention that delayed the declines that occur with aging in the model organism. Together, the scientists' findings open the door to new strategies for promoting muscle function during aging. “Our data identify an essential mediator of exercise responsiveness and an entry point for interventions to maintain muscle function during aging.” That essential mediator is the cycle of fragmentation and repair of the mitochondria, the specialized structures, or organelles, inside every cell responsible for producing energy. Mitochondrial function is critical to health, and disruption of mitochondrial dynamics the cycle of repairing dysfunctional mitochondria and restoring the connectivity among the energy-producing organelles — has been linked to the development and progression of chronic, age-related diseases, such as heart disease and type 2 diabetes. “As we perceive that our muscles undergo a pattern of fatigue and restoration after an exercise session, they are undergoing this mitochondrial dynamic cycle,” said Blackwell, who is also acting section head of Immunobiology at Joslin. “In this process, muscles manage the aftermath of the metabolic demand of exercise and restore their functional capability.” “We determined that a single exercise session induces a cycle of fatigue and physical fitness recovery that is paralleled by a cycle of the mitochondrial network rebuilding,” said first author Juliane Cruz Campos, a postdoctoral fellow at Joslin Diabetes Center. “Aging dampened the extent to which this occurred and induced a parallel decline in physical fitness. That suggested that mitochondrial dynamics might be important for maintaining physical fitness and possibly for physical fitness to be enhanced by a bout of exercise.” Finally, the researchers tested known, lifespan-extending interventions for their ability to improve exercise capacity during aging. Worms with increased AMPK — a molecule that is a key regulator of energy during exercise which also promotes remodeling of mitochondrial morphology and metabolism — exhibited improved physical fitness. They also demonstrated maintenance of, but not enhancement of, exercise performance during aging. Worms engineered to lack AMPK exhibited reduced physical fitness during aging as well as impairment of the recovery cycle. They also did not receive the age-delaying benefits of exercise over the course of the lifespan. Nighttime electronic device use lowers melatonin levels Brigham and Women's Hospital, December 24 2022. The Proceedings of the National Academy of Science published the findings researchers at Boston's Brigham and Women's Hospital of a suppressive effect for evening use of light-emitting electronic devices on sleep and melatonin secretion. “Electronic devices emit light that is short-wavelength-enriched light, which has a higher concentration of blue light — with a peak around 450 nm — than natural light,” explained lead author Anne-Marie Chang. “This is different from natural light in composition, having a greater impact on sleep and circadian rhythms.” Twelve healthy adults were randomized to read a light-emitting eBook or a printed book in dim room light approximately four hours before bedtime for five evenings. At the end of the five day period, participants switched their assignments. Blood samples collected during portions of the study were analyzed for melatonin levels. Sleep latency, time and efficiency were assessed via polysomnography. eBook reading was associated with more time needed to fall asleep and less rapid eye movement sleep in comparison with reading a printed book. Evening melatonin levels were suppressed by an average of 55.12% in eBook readers, while those who read printed books had no suppression. Compared to printed book reading, the onset of melatonin release in response to dim light occurred 1 ½ hours later the day following reading of an eBook. “Our most surprising finding was that individuals using the e-reader would be more tired and take longer to become alert the next morning,” Dr Chang reported. “This has real consequences for daytime functioning, and these effects might be worse in the real world as opposed to the controlled environment we used.” “We live in a sleep-restricted society, in general,” she added. “It is important to further study the effects of using light-emitting devices, especially before bed, as they may have longer term health consequences than we previously considered.” Iron deficiency anemia associated with hearing loss Penn State University, December 29, 2022 In a study published online by JAMA Otolaryngology-Head & Neck Surgery, Kathleen M. Schieffer, B.S., of the Pennsylvania State University College of Medicine, Hershey, Pa., and colleagues examined the association between sensorineural hearing loss and conductive hearing loss and iron deficiency anemia in adults ages 21 to 90 years in the United States. Approximately 15 percent of adults report difficulty with hearing. Because iron deficiency anemia (IDA) is a common and easily correctable condition, further understanding of the association between IDA and all types of hearing loss may help to open new possibilities for early identification and appropriate treatment. For this study, using data obtained from deidentified electronic medical records from the Penn State Milton S. Hershey Medical Center in Hershey, Pa., iron deficiency anemia was determined by low hemoglobin and ferritin levels for age and sex in 305,339 adults ages 21 to 90 years; associations between hearing loss and IDA were evaluated. Of the patients in the study population, 43 percent were men; average age was 50 years. There was a 1.6 percent prevalence of combined hearing loss (defined as any combination of conductive hearing loss [hearing loss due to problems with the bones of the middle ear], sensorineural hearing loss, deafness, and unspecified hearing loss) and 0.7 percent prevalence of IDA. Both sensorineural hearing loss (SNHL; when there is damage to the cochlea or to the nerve pathways from the inner ear to the brain) (present in 1.1 percent of individuals with IDA) and combined hearing loss (present in 3.4 percent) were significantly associated with IDA. Analysis confirmed increased odds of SNHL and combined hearing loss among adults with IDA. “An association exists between IDA in adults and hearing loss. The next steps are to better understand this correlation and whether promptly diagnosing and treating IDA may positively affect the overall health status of adults with hearing loss,” the authors write.

Episode 164: Francois Moreau, PhD, Harvard Joslin Diabetes Center

TheSugarScience Podcast- curating the scientific conversation in type 1 diabetes

Play Episode Listen Later Jan 3, 2023 31:24

In this episode, Francois Moreau joins us to discuss the unique interaction of a viral insulin-like peptide with the IGF-1 receptor which produces a natural antagonist. Ask the Expert is a ~30 minute digital cafe experience where scientists and grad students can meet and exchange with thought leaders in the field of type 1 diabetes. Link below to sign up for a seat in the cafe!

harvard expert francois moreau igf joslin diabetes center

61. Recipe for Setting Healthy Goals in the New Year

The Happy Diabetic Kitchen

Play Episode Listen Later Jan 3, 2023 32:01

This is the Happy Diabetic Kitchen--- In this episode, we will hear from some of my very good friends in the diabetic community who will share their personal goals for the New Year! So, get ready! We are stepping into the New Year together exploring ideas for a happy healthy lifestyle way of eating! It's time to gather your thoughts, journals and goals for a New Year's refresh. As someone who's trying to live my best diabetic life, New Year's is an opportunity to reset, regroup, and revitalize. I want to have revolution of goals and ideas… not a revolt! Keep an open mind… Stay open to possibilities of trying something new. That said, it's best to get a head start on your New Year's resolutions now. It just isn't going to happen. But, if you stand firm in actually sticking to your resolutions this year. So, whether you want to get back on that fitness grind, sharpen certain skills or be more productive, we have invited some amazing folks who live in the diabetic space every day to tell you about their list of the top New Year's resolutions to give you inspiration for 2023. I think it will inspire you… Our guests on the podcast: Guest New Year Resolutions Jana Smolinski (Episode # 53) - Raising a Child with Diabetes: An Interview With Jana Smolenski. Jana is a school teacher and mom who raised a type one diabetic. Annie, her daughter was diagnosed at age 5. Jana has a lot of wisdom to share about how to support a small child in growing up with this disease. Max Mr. Divabetic - You know him as Mr. Divabetic, the fruit suit clad man-about-town. He is the resident master of ceremonies and happy healthcare anchor on Diva TalkRadio, a podcast channel featuring diabetes edu-tainment and information. When he re-appears from the studio booth and sheds his pineapple and watermelon jacket, he transforms into the mild-mannered, yet passionate Max Szadek, the founder and executive director of Divabetic and WEGO Health Activist Award nominee. Inspired by his former boss, Luther Vandross, who suffered in silence with his diabetes, Max founded Divabetic to encourage women and their families to accept a diabetes diagnosis boldly, with a Glam More, Fear Less attitude. With a background in entertainment and armed with a team of diabetes health and wellness educators, fashionistas. Mr. Divabetic's enthusiasm is infectious, and you can follow him on Twitter, Facebook, and his world-famous blog for diabetes news, updates, and all things pop culture. “I'm on a mission to change attitudes in those affected by diabetes to stay healthy and upbeat about their care so they can continue to enjoy the glamorous life.” - Max Szadek Max the Divabetic Janice Baker Janice Baker 25 - Interview With a Dietician Kim Stewart Kimberly Stuart ABOUT KIM Kimberly Stuart, she holds degrees from St. Olaf College and the University of Iowa. She learned lots of interesting things at these fine institutions, none of which prepared her for the lethal cocktail of parenthood and writing. Stuart is the author of eight published novels, including the Heidi Elliott series, Act Two, Stretch Marks, Operation Bonnet, Sugar, and Heart Land. She is a frequent public speaker and is passionate about helping others live great stories. Kimberly lives, plays, works in Des Moines, Iowa, where she makes her home with one forgiving husband, three wily kids and a black Schnauzer named Scout. Annie Smolinski 52 - Diabetes does not need to define you! Interview with Annie Smolenski, type 1 rock star! Bill Polansky Bill Polansky Dr. Bill Polonsky is Associate Clinical Professor in Psychiatry at the University of California San Diego. He received his PhD in clinical psychology from Yale University and has served as Senior Psychologist at the Joslin Diabetes Center in Boston, faculty member at Harvard Medical School and Chairman of the National Certification Board for Diabetes Educators. Cindy Lewis my wife/partner of 42 years. Cindy has been what I like to call a type 3 diabetic, she has been my support, my helper my supporter my diabetic champion since my diagnosis in 1998.

university new year interview child phd goals healthy iowa raising recipes sugar diabetes stuart fearless yale university psychiatry harvard medical school des moines luther vandross california san diego associate clinical professor stretch marks act two olaf college schnauzer diabetes educators joslin diabetes center senior psychologist wego health activist award national certification board divabetic cindy lewis max szadek

Breaking Down Barriers - Increasing technology adoption for people with insulin-requiring diabetes

Pharmacy Podcast Network

Play Episode Listen Later Nov 14, 2022 30:54 Transcription Available

Disclaimer: Intended audience is the US Healthcare Providers only. These podcasts are not a substitute for medical advice and/or services from a healthcare provider. These podcasts may not be relied upon in any way in connection with your personal health care related decisions and treatment. All such decisions and treatment should be discussed with a healthcare provider who is familiar with your individual needs. Kenneth Snow is Senior Director Medical Affairs. His responsibilities include the development and review of research studies to provide clinical evidence in support of Insulet's products. Prior to joining Insulet, Dr. Snow was Product Strategy Medical Director in the Pharmacy Services Section of CVS Health and served as Medical Director for Clinical Trial Services overseeing research projects for external clients with attention to analytical results and clinical conclusions. Prior to joining CVSHealth, Dr. Snow was Chief Medical Officer for NeuroMetrix, a medical device company involved in the diagnosis and treatment of diabetic neuropathy. Previously, Dr. Snow was on the staff of the Joslin Diabetes Center in Boston for 19 years including 5 years as Chief of the Adult Diabetes Section. In addition, he was an Assistant Professor of Clinical Medicine at Harvard Medical School. Dr. Snow attended MIT and Johns Hopkins School of Medicine. He did his internship and residency in Internal Medicine at Northwestern Memorial Hospitals in Chicago and his fellowship in Endocrinology at the New England Medical Center Hospitals in Boston. He received his MBA from the University of Massachusetts.

Why is the Gut Microbiome Important? (Part #2) | Suzanne Devkota Ph.D

The Dr. Gabrielle Lyon Show

Play Episode Listen Later Nov 8, 2022 57:18

Dr. Devkota is Director of the Human Microbiome Research Institute at Cedars-Sinai Medical Center in LA and an Associate Professor of Medicine at UCLA, as well as an adjunct investigator at the Joslin Diabetes Center at Harvard Medical School. She has been studying the effect of diet on the gut microbiome and inflammatory diseases for the past 12 years. investigating dietary drivers of gut microbiome structure and function in inflammatory bowel diseases and metabolic diseases. Her research has been published in top journals Nature, Science, and Cell, and is funded by the National Institutes of Health. She completed her masters at the University of Illinois at Urbana-Champaign in Nutritional Sciences, her Ph.D in Molecular Metabolism and Nutrition at The University of Chicago, and her post-doctoral training at the Joslin Diabetes Center at Harvard Medical School. In this episode we discuss: Do all diseases start in the gut? Prebiotics or Probiotics? What being Vegan or Vegetarian does to your gut health How to boost your immune system This episode is brought to you by One Farm, LMNT, 1stPhorm, Inside TrackerMentioned in this episode:Visit 1st Phorm Website for Free Shippinghttp://www.1stphorm.com/drlyonGet your free LMNT Sample Pack with any purchasehttps://drinklmnt.com/drlyonInside Tracker 20% Off the Entire Storehttps://info.insidetracker.com/drlyonFREE Gut Health Superfoodhttps://onefarm.com/coupon/tvt8hasn/

Why is the Gut Microbiome Important? (Part #1) | Suzanne Devkota Ph.D

The Dr. Gabrielle Lyon Show

Play Episode Listen Later Oct 25, 2022 68:20

Dr. Devkota is Director of the Human Microbiome Research Institute at Cedars-Sinai Medical Center in LA and an Associate Professor of Medicine at UCLA, as well as an adjunct investigator at the Joslin Diabetes Center at Harvard Medical School. She has been studying the effect of diet on the gut microbiome and inflammatory diseases for the past 12 years. investigating dietary drivers of gut microbiome structure and function in inflammatory bowel diseases and metabolic diseases. Her research has been published in top journals Nature, Science, and Cell, and is funded by the National Institutes of Health. She completed her master's at the University of Illinois at Urbana-Champaign in Nutritional Sciences, her Ph.D. in Molecular Metabolism and Nutrition at The University of Chicago, and her post-doctoral training at the Joslin Diabetes Center at Harvard Medical School. In this episode we discuss: Why fasting and other diets don't work Do you really need fiber in your diet? Why you should be worried about leaky gut Are food additives bad for you? This episode is brought to you by One Farm, LMNT, 1stPhorm, Inside Tracker https://www.devkotalab.com/ (Devkota Lab Website) https://www.instagram.com/suzannedevkota/ (Suzanne's IG) Mentioned in this episode: Inside Tracker 20% Off the Entire Store https://info.insidetracker.com/drlyon Visit 1st Phorm Website for Free Shipping http://www.1stphorm.com/drlyon Get your free LMNT Sample Pack with any purchase https://drinklmnt.com/drlyon FREE Gut Health Superfood https://onefarm.com/coupon/tvt8hasn/

#275 -Dr. William Hsu Topic: ” Fasting Nutrition for Longevity Lifestyle: Leveraging what nature has designed!”

Quantum Nurse: Out of the rabbit hole from stress to bliss. http://graceasagra.com/

Play Episode Listen Later Sep 26, 2022 40:51

Quantum Nurse www.quantumnurse.life presents Quantum Nurse Livestream Monday, Sept 26, 2022 @ 12:00 PM EST Guest: Dr. William Hsu Topic: " Fasting Nutrition for Longevity Lifestyle: Leveraging what nature has designed!" https://prolonfmd.com/products/prolon-professionals Bio: Chief Medical Officer, L-Nutra William Hsu is a visionary innovator working at the intersection of medicine, technology, and business. During his 20-year tenure as an endocrinologist at Harvard's Joslin Diabetes Center, world-renowned research, clinical care, and education center, Dr. Hsu's research focused on the pathophysiology of diabetes and the application of health technology in chronic conditions. As Vice President at Joslin, he led International Programs, providing advisory services to hospital systems and health ministries in the design of diabetes centers and programs around the globe. Driven to disrupt and improve the chronic care model and challenge the limitations of conventional medicine, Dr. Hsu joined L-Nutra as Chief Medical Officer in 2019, being attracted by the company's innovative Nutritechnology and the strength of the science supporting its mission. At L-Nutra, Dr. Hsu oversees the Medical, Scientific Affairs, and Regulatory Compliance Departments, leading clinical trials and research development efforts in metabolic health, diabetes, cancer, autoimmune, and neurodegenerative diseases. Also responsible for global education, Dr. Hsu advances the effective communication of scientific outcomes, which drives the adoption of Fasting-Mimicking Technology as a tool to enhance human healthspan. Dr. Hsu has served on multiple national-level professional committees, including the American Diabetes Association, where he helped set national Standards of Medical Care in Diabetes. He received his medical degree from Mount Sinai School of Medicine. He completed his internal medicine residency at Yale School of Medicine and his Endocrinology and Metabolism fellowship at Harvard Medical School, where he was also an Assistant Professor of Medicine. With Grace Asagra, RN MA (Holistic Nurse, US, originally from the Phil) Podcast: Quantum Nurse: Out of the Rabbit Hole from Stress to Bless www.quantumnurse.life Quantum Nurse - Bichute https://www.bitchute.com/channel/nDjE6Ciyg0ED/ Quantum Nurse – Apple https://podcasts.apple.com/us/podcast/quantum-nurse-out-of-the-rabbit-hole-from-stress-to-bliss/id1522579988 Quantum Nurse Earth Heroes TVhttp://www.earthheroestv.com/categories/the-freedom-broadcasters?via=grace Quantum Nurse Rumble https://rumble.com/c/c-764837 Quantum Nurse Base-12 Source Code DNA Activations - https://www.youtube.com/channel4vncZtvi2VJ0fHoiArJOA/UC-

How To Fast (Without The Fast?) w/ Dr. William Hsul

The Health Detective Podcast by FDNthrive

Play Episode Listen Later Aug 11, 2022 58:42

vice president medicine harvard assistant professor cornell university harvard medical school metabolism chief medical officers internal medicine yale school endocrinology american diabetes association hsu mount sinai school fasting mimicking diet l nutra joslin diabetes center william hsu

Behind the Study: Biological Age in Diabetes and Precision Medicine

Aging-US

Play Episode Listen Later Aug 1, 2022 5:36

Dr. Cristina Aguayo-Mazzucato from Beta Cell Aging Lab, Joslin Diabetes Center, Harvard Medical School, discusses an editorial she co-authored that was published by Aging (Aging-US) in Volume 14, Issue 11, entitled, “Biological age in diabetes and precision medicine.” DOI - https://doi.org/10.18632/aging.204123 (PDF download) Corresponding author - Cristina Aguayo-Mazzucato - cristina.aguayo-mazzucato@joslin.harvard.edu Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204123 Keywords - biological age, diabetes mellitus, chronological age, DNA methylation, clinical biomarkers About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at http://www.Aging-US.com or connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ Twitter - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/agingus LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

covid-19 dna study soundcloud pinterest diabetes harvard medical school biological doi precision medicine joslin diabetes center altmetric

#245 An Unknown Fountain of Youth – Learn the Benefits of Fasting w/Dr. William Hsu

Wealthy Wellthy Wise

Play Episode Listen Later Jul 22, 2022 58:13

My guest this week is Dr. William Hsu. After 20 years of a distinguished career as an endocrinologist at Harvard's Joslin Diabetes Center, Dr. William Hsu joined L-Nutra in 2019 as Chief Medical Officer. In this role, Dr. Hsu leads the clinical development effort at L-Nutra, oversees the Medical Affairs Department, and advances the education and adoption of fasting and Fasting Mimicking Diet as an innovative tool to extend human healthspan. Among his prior roles, he served as Vice President at Joslin Diabetes Center, a teaching affiliate of Harvard Medical School, responsible for its international education and healthcare advisory programs. He served on multiple national-level professional committees, including the American Diabetes Association, setting national standards of medical care in diabetes. His previous research interests focused on the pathophysiology of diabetes and the application of digital technology in chronic care. Dr. Hsu went to Cornell University for college and received his medical degree from Mount Sinai School of Medicine. He completed his Internal Medicine residency training at Yale School of Medicine and completed his fellowship training in Endocrinology and Metabolism at Harvard Medical School. He was Assistant Professor of Medicine at Harvard Medical School. Topics Mentioned: Changes in the function of hormones, cells, and genes Reduction of insulin resistance, lowering the risk for type 2 diabetes and helping to reverse it Reduces oxidative stress and inflammation in the body Promotes heart health by improving blood pressure, blood triglycerides, and LDL cholesterol Induces cellular repair throughout the entire body Promotes brain health by reducing oxidative stress and brain inflammation Prevents neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's diseases Dr. Hsu gives us the backstory and knowledge we need to better understand the sacred mechanism of fasting. Did you know that around 5-6am is when all the stress hormones surges? This is when the adrenal glands really begin to kick in. When reasonably applying fasting, there is major rejuvenation going on within the body. As Dr. Hsu says: “If we were to reduce or take away the source of calories for a period of time, the body is in this crisis moment, so it taps inside and goes to the fats– the central fats– it asks itself: ‘what can I get rid of?' And when that fasting period passes, when the nutrients come, now the body can form new parts to rejuvenate new cells.” Fast. Re-eat. Fast. Re-eat. These are the cycles of fasting and the cells way of remaining youthful…longer! I think we all want that ;) Fun fact: Fasting affects every cell in the body– including brain cells! After 5 days of prolonged fasting, people experience 4 levels of changes… Midsection weight loss (this fat is a source). Your body finds fasting as stress. So this is a stress that sharpens your mind & preserves your muscles. You feel better! Clarity of the mind. Focused. You feel a sense of achievement. Your cells are rejuvenated Dr. Hsu's pro tip? Repeat this 3x a year! To be your healthiest yet, Dr. Hsu has provided a code! You can use “wealthywellthy” for 15% for ProLon on ProLonFMD.com or ProLonFast.com. Links: Dr. Hsu's Twitter Dr. Hsu's Facebook Dr. Hsu's LinkedIn

121: Debbie Dutton and Troy Finn, University of New Hampshire

RAISE Podcast

Play Episode Listen Later Jul 21, 2022 56:56

Troy Finn leads campaign and fundraising efforts for the University of New Hampshire across 13 colleges and schools, athletics, centers, and institutes. He joined UNH in 2017 from Development Guild DDI where he provided campaign and fundraising counsel to institutions ranging from large, research-intensive public universities to private liberal arts colleges, schools, and non-profit organizations. Having been a member of fundraising teams during campaigns of historic magnitude at Harvard Chan School of Public Health, Columbia University Medical Center, and Dana-Farber Cancer Institute, Troy has led both front-line philanthropy efforts and back-end development operations. Troy obtained a master's degree in Management and Finance from Harvard University Extension School and a bachelor's degree in philosophy from the College of the Holy Cross. He's the youngest of ten kids and loves exploring the northern New England coast with his husband and their German Shepherds, Candide and Cunegonde.Debbie Dutton has served for the past nine years as the Vice President of Advancement and President of the Foundation at the University of New Hampshire (UNH) where she leads a team of 130 advancement professionals in the leadership phase of capital campaign that follows the University's most ambitious and successful capital campaign to date, Celebrate 150, the Campaign for UNH. During this effort, UNH has surpassed all previous records in fundraising and engagement and just closed the campaign June 2018 at $308M well above the $275M goal. Prior to this role, she served as vice president for development and alumni relations at Colby College. During her six-year tenure at Colby, and before being promoted to vice president, she served as campaign director and led the school's largest fundraising effort, the Reaching the World campaign, which surpassed its goal to raise $376 million when it concluded in 2010.Debbie's career in development began at the Maine chapter of the National Multiple Sclerosis Society. She has held development positions in major gifts and senior management at three Harvard teaching hospitals: the Massachusetts Eye and Ear Infirmary, Children's Hospital, and the Joslin Diabetes Center. She also was a senior leadership giving officer at Bates College.Debbie earned a Bachelor of Arts degree in journalism from the University of Maine and a Master of Science degree in business management from Lesley College. She lives in Kennebunk, Maine with her husband and their two children.

The Gary Null Show - 05.12.22

The Gary Null Show

Play Episode Listen Later May 12, 2022 61:29

Regular blueberry consumption may reduce risk of dementia, study finds University of Cincinnati, May 11, 2022 Researchers found that adding blueberries to the daily diets of certain middle-aged populations may lower the chances of developing late-life dementia. The findings were recently published in the journal Nutrients. Krikorian said his team has been conducting research on the benefits of berries for people with greater risk for Alzheimer's disease and dementia for several years. The researchers enrolled 33 patients from around the Cincinnati area between the ages of 50-65 who were overweight, prediabetic and had noticed mild memory decline with aging. Krikorian said this population has an increased risk for late-life dementia and other common conditions. Over a period of 12 weeks, the patients were asked to abstain from berry fruit consumption of any kind except for a daily packet of supplement powder to be mixed with water and consumed either with breakfast or dinner. Half of the participants received powders that contained the equivalent of one-half cup of whole blueberries, while the other half received a placebo. Krikorian said those in the blueberry-treated group showed improvement on cognitive tasks that depend on executive control. Patients in the blueberry group also had lower fasting insulin levels, meaning the participants had improved metabolic function and were able to more easily burn fat for energy. Krikorian said the blueberry group displayed an additional mild degree of higher mitochondrial uncoupling, a cellular process that has been associated with greater longevity and reduced oxidative stress. Oxidative stress can lead to symptoms like fatigue and memory loss. Regular exercise with dietary advice linked to better mobility in frail older people Yale University, May 11, 2022 A program of regular exercise along with expert dietary advice is linked to a reduction in mobility problems among frail older people living in the community, finds a trial published by The BMJ today. The combination of aerobic (walking), strength, flexibility, and balance exercises alongside personalized nutritional counseling reduced mobility disability by 22% over three years. Their findings are based on 1,519 men and women (average age 79 years) with physical frailty and sarcopenia (a combination of reduced physical function and low muscle mass) recruited from 16 clinical sites across 11 European countries between 2016 and 2019. Women in the intervention group lost less muscle strength (0.9 kg at 24 months) and less muscle mass (0.24 kg and 0.49 kg at 24 months and 36 months, respectively) than control women, but no significant group differences were seen in men. Study: Side effects emerge after approval for many US Yale University, May 9, 2022 Almost one-third of new drugs approved by U.S. regulators over a decade ended up years later with warnings about unexpected, sometimes life-threatening side effects or complications, a newanalysis found. The results covered all 222 prescription drugs approved by the U.S. Food and Drug Administration over ten yers. The 71 flagged drugs included top-sellers for treating depression, arthritis, infections and blood clots. Safety issues included risks for serious skin reactions, liver damage, cancer and even death. “The large percentage of problems was a surprise,” and they included side effects not seen during the review process, said Dr. Joseph Ross, the study's lead author at Yale University.”We know that safety concerns, new ones, are going to be identified once a drug is used in a wider population. That's just how it is,” Ross said. While most safety concerns were not serious enough to prompt recalls, the findings raise questions about how thoroughly drugs are tested before approval The study counted black-box warnings for dozens of drugs; these involved serious problems including deaths or life-threatening conditions linked with the drugs. There were also dozens of alerts for less serious potential harms and three drug withdrawals because of the potential for death or other serious harm. Among the drugs with added warnings: Humira, used for arthritis and some other illnesses; Abilify, used for depression and other mental illness; and Pradaxa, a blood thinner. The withdrawn drugs and the reason: Bextra, an anti-inflammatory medicine, heart problems; Raptiva, a psoriasis drug, rare nervous system illness; and Zelnorm, a bowel illness drug, heart problems. Exercise during pregnancy may yield metabolic benefits in grandchildren Harvard University, May 11, 2022 If grandma liked working out, her pain may be your gain. It may seem unlikely, but recent research out of the Joslin Diabetes Center says it just might be the case. Laurie Goodyear, a professor of medicine at Harvard Medical School, has found that a grandmother's exercise during pregnancy may make her grandchildren healthier metabolically, with less body fat, better insulin control and, in some, healthier bones. We are looking for epigenetic alterations in the DNA, because epigenetic alterations can be changed as rapidly as two generations. We analyze micro RNAs, some methylation situations in the F1 generation eggs and sperm to see what's going on. We are currently investigating how mothers' exercise affects their children's gametes. I'm confident in saying that women who are pregnant should try to be as physically active as they can, depending, of course, on the condition of their pregnancy. There's strong human data showing that exercise during pregnancy improves the mother's health; numerous animal studies showing improved first-generation health; and now we have evidence that maternal exercise will positively impact the health of the second generation. I'm not an obstetrician, and there are certainly conditions where a woman cannot perform exercise during pregnancy, but, when medically approved, being physically active is important—for the mother, the first generation, and now even the grandchildren. New Study Finds Simply Believing You Can Do Something To Improve It Is Linked With Higher Wellbeing University Of Southern Denmark And University Of Copenhagen, May 11, 2022 The number of people struggling with poor mental health and mental disorders has been rising around the world over the past few decades. Those who are struggling are increasingly facing difficulties accessing the kind of support they need – leaving many waiting months for help, if they even qualify for treatment. In our recent study, we asked 3,015 Danish adults to fill out a survey that asked questions about mental health – such as whether they believe they can do something to keep mentally healthy, whether they had done something in the past two weeks to support their mental health, and also whether they were currently struggling with a mental health problem. We then assessed their level of mental wellbeing using the Short Warwick–Edinburgh Mental Well-being Scale, which is widely used by healthcare professionals and researchers to measure mental wellbeing. As you'd expect, we found that mental wellbeing was highest among those who had done things to improve their mental health compared with the other participants. Interestingly, however, we found that – whether or not our respondents had actually taken action to improve their mental wellbeing – people who believed they could do something to keep mentally healthy tended to have higher mental wellbeing than those who didn't have this belief. So while it's most beneficial to take steps to improve your mental health, even just believing that you can improve it is associated with better overall mental wellbeing.The effect of night shifts—gene expression fails to adapt to new sleep patterns McGill University (Quebec). May 7, 2022 Have you ever considered that working night shifts may, in the long run, have an impact on your health? A team of researchers from the McGill University has discovered that genes regulating important biological processes are incapable of adapting to new sleeping and eating patterns and that most of them stay tuned to their daytime biological clock rhythms. “We now better understand the molecular changes that take place inside the human body when sleeping and eating behaviours are in sync with our biological clock. For example, we found that the expression of genes related to the immune system and metabolic processes did not adapt to the new behaviours,” says Dr. Boivin, a full professor at McGill University's Department of Psychiatry. It is known that the expression of many of these genes varies over the course of the day and night. Their repetitive rhythms are important for the regulation of many physiological and behavioural processes. “Almost 25% of the rhythmic genes lost their biological rhythm after our volunteers were exposed to our night shift simulation. 73% did not adapt to the night shift and stayed tuned to their daytime rhythm. And less than 3% partly adapted to the night shift schedule. “We think the molecular changes we observed potentially contribute to the development of health problems like diabetes, obesity, cardiovascular diseases more frequently seen in night-shift workers on the long term,” explains Dr. Boivin. Videos: 1. Will the Future Be Human? – Yuval Noah Harari (Start @ 2:13) 2. The Invention Of Whiteness.. (Start @ 0:28) 3. Jonathan Pie's Rant On Cultural Appropriation 4. Breakthrough deaths comprise increasing proportion of those who died from COVID-19 (5:44)

EP 1094B - Conquer Your Diabetes: Prevention, Control, Remission

YOU The Owners Manual Radio Show

Play Episode Listen Later May 3, 2022

The global epidemic of diabetes and prediabetes afflicts more than 1 billion people.The global epidemic of diabetes and prediabetes afflicts more than 1 billion people. Sadly, more than 50% of people with diabetes do not achieve their desired glucose control. Moreover, less than 25% achieve their blood pressure, cholesterol, and glucose goals.In his book, Conquer Your Diabetes: Prevention, Control, Remission, Dr. Martin Abrahamson and his co-author Sanjiv Chopra, MD put all the pieces of the diabetes puzzle together, including a concise history of the disease, underlying types and causes, prediabetes, obesity, weight loss, pregnancy, mental health, type 2 diabetes prevention and remission, and latest treatments.Dr. Abrahamson joins us today to tell us more about his book & his diabetes research. He is an Associate Professor of Medicine at Harvard Medical School and a previous Chief Medical Officer at Joslin Diabetes Center. He lectures globally on diabetes and has spearheaded educational initiatives on diabetes for physicians around the world.

medicine md associate professor diabetes conquer harvard medical school chief medical officers remission abrahamson diabetes prevention joslin diabetes center diabetes and endocrinology

EP 1094B - Conquer Your Diabetes: Prevention, Control, Remission

YOU The Owners Manual Radio Show

Play Episode Listen Later May 3, 2022

The global epidemic of diabetes and prediabetes afflicts more than 1 billion people. Sadly, more than 50% of people with diabetes do not achieve their desired glucose control. Moreover, less than 25% achieve their blood pressure, cholesterol, and glucose goals.In his book, Conquer Your Diabetes: Prevention, Control, Remission, Dr. Martin Abrahamson and his co-author Sanjiv Chopra, MD put all the pieces of the diabetes puzzle together, including a concise history of the disease, underlying types and causes, prediabetes, obesity, weight loss, pregnancy, mental health, type 2 diabetes prevention and remission, and latest treatments.Dr. Abrahamson joins us today to tell us more about his book & his diabetes research. He is an Associate Professor of Medicine at Harvard Medical School and a previous Chief Medical Officer at Joslin Diabetes Center. He lectures globally on diabetes and has spearheaded educational initiatives on diabetes for physicians around the world.

medicine md associate professor diabetes conquer harvard medical school chief medical officers remission abrahamson diabetes prevention joslin diabetes center

EP 1094B - Conquer Your Diabetes: Prevention, Control, Remission

RadioMD (All Shows)

Play Episode Listen Later May 3, 2022

medicine md associate professor diabetes conquer harvard medical school chief medical officers remission abrahamson diabetes prevention joslin diabetes center diabetes and endocrinology

Conquer Your Diabetes: Prevention · Control · Remission By Martin Abrahamson, MD and Sanjiv Chopra, MD

Speaking of Writers

Play Episode Listen Later Apr 11, 2022 16:38

The global epidemic of diabetes and pre diabetes afflicts more than 1 billion people. And sadly, more than 50% of people with the disease do not achieve their desired glucose control. In Conquer Your Diabetes: Prevention, Control, Remission, Drs. Martin Abrahamson and Sanjiv Chopra, two Harvard Medical School professors and master clinicians, provide a road map for people with diabetes to manage their condition and live rewarding and fulfilling lives. In 25 succinct chapters—many containing stories of real patients living successfully with the condition—the authors put all the pieces of the diabetes puzzle together, including information on its types and causes as well as the latest treatments. There's even material on gestational diabetes, the connection between diabetes and heart disease, and the relatively small amount of body weight (about 7%) that most people with pre diabetes need to lose to reduce their risk of developing Type 2 diabetes by more than half. Martin Abrahamson, MD, FACP is an Associate Professor of Medicine at Harvard Medical School and previous Chief Medical Officer at Joslin Diabetes Center. He lectures globally on diabetes and has spearheaded educational initiatives on diabetes for physicians around the world. Sanjiv Chopra, MD, MACP, FRCP is a Professor of Medicine and served as the Faculty Dean for Continuing Education at Harvard Medical School for 12 years. The author or co-author of 12 previous books, including Brotherhood: Dharma, Destiny and the American Dreamwhich he co-authored with his brother Deepak, he is the recipient of many prestigious teaching awards and a sought-after speaker lecturing internationally. Together, Drs. Abrahamson and Chopra direct the Division of Continuing Medical Education (CME) at Boston's Beth Israel Deaconess Medical Center, a major teaching affiliate of Harvard Medical School, and have been conducting CME meetings for more than a quarter of a century. --- Support this podcast: https://anchor.fm/steve-richards/support

158: The Choices We Make That Determine Our Path with Dr. Robert Gabbay

DocWorking: The Whole Physician Podcast

Play Episode Listen Later Mar 31, 2022 17:04

“For me, the beauty of diabetes was that it was the anchor but it allowed me to explore so many different areas of research and interest.” -Robert A. Gabbay, MD, PhD In episode 158 of the podcast, we welcome Dr. Robert Gabbay. Dr. Gabbay is Chief Scientific and Medical Officer of the American Diabetes Association and Associate Professor at Harvard Medical School. DocWorking Founder and CEO, Dr. Jen Barna talks with Dr. Gabbay about how it all started for him, his journey in medicine, how he balances it all and what advice he was given and what advice he would give to his younger self. He speaks about difficult decisions he made that affected the direction of his career. Dr. Gabbay also talks about the importance that mentors have had in his life and how they helped to shape him. Robert A. Gabbay, MD, PhD is Chief Scientific and Medical Officer of the American Diabetes Association and Associate Professor at Harvard Medical School. His research focuses on innovative models of diabetes care to improve diabetes outcomes and the lives of people with diabetes. Throughout his vibrant career he has had many accomplishments as a basic science researcher, developer of patient communication tools, creator of the first broad scale diabetes registry, designer of care management training programs, and leader of one of the largest primary care transformation efforts in the US around the Patient Centered Medical Home. The reach of his work has been recognized through leadership roles around the world to transform diabetes care including leading the International Diabetes Federation BRIDGES program that implements evidence based translational research to low resource global settings. Dr. Gabbay has received funding from the National Institute of Health Diabetes, Digestive and Kidneys Diseases (NIDDK), the Agency for Healthcare Research and Quality (AHRQ), and the Center for Medicare and Medicaid Innovation for his care transformation work. Along with an extensive peer reviewed publication record, his views have appeared in popular press such as the New York Times, CNN, the Washington Post, People, Oprah, and National Public Radio. Formerly, he held the role of Chief Medical Officer at Joslin Diabetes Center. Find full transcripts of DocWorking: The Whole Physician Podcast episodes on the DocWorking Blog DocWorking empowers physicians and entire health care teams to get on the path to achieving their dreams, both in and outside of work, with programs designed to help you maximize life with minimal time. Are you a physician who would like to tell your story? Please email Amanda, our producer, at Amanda@docworking.com to be considered. And if you like our podcast and would like to subscribe and leave us a 5 star review, we would be extremely grateful! We're everywhere you like to get your podcasts! Apple iTunes, Spotify, iHeart Radio, Google, Pandora, Stitcher, PlayerFM, ListenNotes, Amazon, YouTube, Podbean You can also find us on Instagram, Facebook, LinkedIn and Twitter. Some links in our blogs and show notes are affiliate links, and purchases made via those links may result in payments to DocWorking. These help toward our production costs. Thank you for supporting DocWorking: The Whole Physician Podcast! Occasionally, we discuss financial and legal topics. We are not financial or legal professionals. Please consult a licensed professional for financial or legal advice regarding your specific situation. Podcast produced by: Amanda Taran

ceo amazon spotify google new york times phd cnn md oprah winfrey washington post choices associate professor agency stitcher medicare determine national institutes harvard medical school chief medical officers national public radio digestive player fm listen notes american diabetes association medical officer healthcare research joslin diabetes center medicaid innovation chief scientific patient centered medical home quality ahrq docworking robert a gabbay docworking the whole physician podcast

BONUS: New study looks at APOL1 gene: do you have it?

Hot Topics in Kidney Health

Play Episode Listen Later Mar 31, 2022 29:37

Some diseases run in the family, when more than one person has the same kind of illness passed down through genes. One of those genes, called APOL1, has variations that are linked to an increased risk for kidney disease, especially in under-resourced communities of color. In today's bonus episode, we discuss how a clinical research study is looking to understand the effect of APOL1 on kidney transplant outcomes from living and deceased donors, and why it's important for you to be part of this research study. In this episode, you will hear from: Marva Moxey-Mims, MD, FASN Dr. Moxey-Mims is Professor of Pediatrics at George Washington University School of Medicine and Chief of the Division of Nephrology at Children's National Health System, Washington, D.C. Dr. Moxey-Mims serves as the Study Chair of the APOLLO Steering Committee and Chair of the Publications & Presentation Committee. Jonah Odim, MD Dr. Odim is Chief of the Clinical Transplantation Section at the National Institute of Allergy and Infectious Diseases (NIAID). Dr. Odim serves as a representative of the National Institutes of Health (NIH) on the APOLLO Steering Committee and member of the Dissemination Working Group. Glenda V. Roberts Glenda is the Director of External Relations & Patient Engagement for the Center for Dialysis Innovation at the University of Washington Kidney Research Institute. Glenda serves as a member of the APOLLO Community Advisory Committee, the Recruitment Committee, and the Dissemination Working Group. Sylvia E. Rosas, MD, MSCE Dr. Rosas is a nephrologist and epidemiologist at the Joslin Diabetes Center and the Beth Israel Deaconess Medical Center. Sylvia serves as the Principal Investigator of APOLLO Clinical Center 09 (Harvard University) and member of the Dissemination Working Group. Krista Lentine, MD, PhD, FAST, FAST Dr. Lentine is Medical Director of Living Donation, Co-Director of Clinical Research, and Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation at Saint Louis University (SLU). Krista serves as co-Principal Investigator for APOLLO Clinical Center 03 (Johns Hopkins | SLU), member of the Data, Ancillary Studies, and Publications & Presentation Committees, and chair of the Dissemination Working Group. Denay Richards Ms. Richards and her family were born in the Caribbean when her mother was diagnosed with ESRD. They moved to the United States, where her mother was told that she had about 3 months to live. On August 29th, 2000, Denay's father donated a kidney to her and in 2020 they celebrated their 20 year - “kidneyversary.” As a child, Denay loved helping her mother with the dialysis process, organizing medications, and attending hospital visits. It was this exposure to the medical field that encouraged Denay to pursue a career in surgery. In 2019 she graduated from Princeton University with a degree in Molecular Biology and as of 2021 is an MD/PhD student in a dual degree program with Robert Wood Johnson Medical School and Princeton University. In 2019, she earned a double board qualification as a fitness nutrition specialist and personal trainer under the International Sports Sciences Association. In 2020, Denay was diagnosed with an APOL1 mutation that is more prevalent in the African American community and has been linked to early kidney failure. Denay says that her diagnosis has empowered her to expand education about renal health, fitness/nutrition, and genetic predispositions for kidney failure to the world, especially disenfranchised populations that are at greater risk. Genetics and kidney disease: https://www.kidney.org/atoz/content/genetics-kidney-disease

Dr. Sanjoy Dutta, Ph.D. - CSO, JDRF International - Improving Lives Curing Type 1 Diabetes (T1D)

Progress, Potential, and Possibilities

Play Episode Listen Later Feb 23, 2022 52:16

Dr. Sanjoy Dutta, PhD, is the Chief Scientific Officer at JDRF International (https://www.jdrf.org/) a nonprofit organization that funds Type 1 Diabetes (T1D) research, provides a broad array of community and activist services to the T1D population, and actively advocates for regulation favorable to medical research and approval of new and improved treatment modalities. Dr. Dutta oversees all of JDRF's efforts to cure Type 1 Diabetes and improve the lives of those living with it, which includes beta cell therapies, immunotherapies, glucose control and related disease complications. He is also responsible for international partnerships with world-leading government, non-government, foundation and commercial organizations. Dr. Dutta joined JDRF in 2009. Prior to coming to JDRF, Dr. Dutta was the Associate Director of Translational Medicine and Clinical Biomarkers at Bristol-Myers Squibb, and Principal Scientist of Cardiovascular and Metabolic Diseases at Hoffmann-La Roche. Dr. Dutta obtained his doctorate from the department of biochemistry and molecular biology at the University of Southern California and was a JDRF Postdoctoral Fellow in the department of cell biology and the Joslin Diabetes Center at Harvard Medical School.

Ep. 95 Live longer…free of chronic health issues with Dr. William Hsu

Eat Real To Heal Podcast

Play Episode Listen Later Feb 23, 2022 93:28

After 20 years of a distinguished career as an endocrinologist at Harvard's Joslin Diabetes Center, Dr. William Hsu joined L-Nutra in 2019 as Chief Medical Officer. In this role, Dr. Hsu leads the clinical development effort at L-Nutra, oversees the Medical Affairs Department, and advances the education and adoption of fasting and Fasting Mimicking Diet as an innovative tool to extend human health span. Among his prior roles, he served as Vice President at Joslin Diabetes Center, a teaching affiliate of Harvard Medical School, responsible for its international education and healthcare advisory programs. He served on multiple national-level professional committees, including the American Diabetes Association, setting national standards of medical care in diabetes. His previous research interests focused on the pathophysiology of diabetes and the application of digital technology in chronic care. Dr. Hsu went to Cornell University for college and received his medical degree from Mount Sinai School of Medicine. He completed his Internal Medicine residency training at Yale School of Medicine and completed his fellowship training in Endocrinology and Metabolism at Harvard Medical School. He was Assistant Professor of Medicine at Harvard Medical School. Dr. Hsu is exceptional at explaining the science of healing in easy to digest ways. Listen to this episode to discover how fasting mimicking contributes to longevity and health in 4 ways: 1) weight loss, 2) cellular regeneration, 3) mental health, and 4) behaviour. As of 2000, there is more evidence stating that OVER-nutrition is exceeding cases of malnutrition, obesity, and diabetes. Learn how over-nutrition is the actual culprit that kicked off the epidemic of chronic disease. Lastly, devour this show to discover how to put your body into a state Autophagy to trigger regeneration and total health and why L-Nutra helps you live longer and healthier – disease free. Find Dr William Hsu at:Website: www.L-Nutra.comProducts: www.prolonfmd.comFacebook: LNutra Join the Best Chefs in the World – Green Moustache Chef Certification - https://www.greenmoustache.com/chef-course Discussed on the PODCAST:Professor Valter Longo – www.valterlongo.comProfessor Ohsumi, 2016 Nobel prize – https://bit.ly/3qM6IgJAutophagy – https://bit.ly/3GPt9HhDr Klaper – www.drKlaper.comTrueNorth - https://bit.ly/3fILqdBNutrition for Longevity – www.nutritionforlongevity.com/Jennifer Maynard Podcast - https://youtu.be/vB95pv6U0xQArticles links - https://l-nutra.com/science/Information on Fasting - www.Fasting.com Watch the trailer for Nicolette's new film Food Of Our Ancestors coming out soon in 2021 - https://bit.ly/3CIQyr1 If you are currently battling a Chronic Degenerative Disease, Nicolette is doing one on one consultations again. Go to www.nicolettericher.com to set up an appointment today! Our 22M Bike tour is still happening once the world returns to its new normal. Find out more about and support our 22 Million Campaign here - www.richerhealth.ca/ Join Nicolette at one of her retreats https://richerhealthretreatcentre.com/ Find out more about our non-profit society Sea to Sky Thrivers - https://seatoskythrivers.com/ Want to know more about Nicolette's Green Moustache Café's https://www.greenmoustache.com/ Sign up for the Eat Real to Heal Online Course - https://nicolettericher.com/eat-real-to-heal Buy the Eat Real to Heal Book here: https://amzn.to/3nMgEFG

Food Can Be The Best Medicine To Offset Disease with Dr. William Hsu

I AM Healthy & Fit

Play Episode Listen Later Jan 28, 2022 52:56

Ep 366 - Intermittent Fasting for Chronic Pain Management with Dr. William Hsu

SISTERHOOD OF SWEAT - Motivation, Inspiration, Health, Wealth, Fitness, Authenticity, Confidence and Empowerment

Play Episode Listen Later Jan 19, 2022 58:09

Are you interested in Intermittent fasting? Have you been struggling with chronic pain? In this episode, we're discussing all things fasting, how it works, how it helps and so much more. Today, I interview Dr. William Hsu. After 20 years of a distinguished career as an endocrinologist at Harvard's Joslin Diabetes Center, Dr. William Hsu joined L-Nutra in 2019 as Chief Medical Officer. In this role, Dr. Hsu leads the clinical development effort at L-Nutra, oversees the Medical Affairs Department, and advances the education and adoption of fasting and Fasting Mimicking Diet as an innovative tool to extend human healthspan. We discuss the impact fasting has on the body, as well as the importance of what you choose to eat after a fast. Dr. Hsu also discusses how fasting can help with weight management and chronic pain. Questions I asked: What is intermittent fasting and why should we do it? What are the impacts of fasting on the body? How does fasting help during menopause? How does fasting help your mental health? What does fasting do for your cells? If you're fasting, can you still have coffee and tea in the morning? When should you exercise during fasting? Should we avoid a bunch of junk while fasting? How can you prepare for a fast? What should people know about fasting and eating? Why does fasting change your relationship with food? How should you balance rest and fasting? How does your protocol help people with health goals? Can you discuss why you aren't starving during a fast? What foods help with longevity and aging? Where can listeners find more about you? How often do you fast? Topics Discussed: Fasting Aging Healthy foods. Chronic pain. Sustainable weight loss. Healthy menopause. Blood Sugar. Quotes from the show: “Everybody should get on a 12:12 fasting regimen.” Dr. William Hsu @SisterhoodSweat “Fasting impacts the body on so many levels.” Dr. William Hsu @SisterhoodSweat “What could be faster for weight loss than fasting?” Dr. William Hsu @SisterhoodSweat “Every culture has fasting practices because it purifies your thoughts.” Dr. William Hsu @SisterhoodSweat “It's best to exercise in the re-feeding phase of the fast.” Dr. William Hsu @SisterhoodSweat “Mediterranean diet is best for longevity.” Dr. William Hsu @SisterhoodSweat How you can stay in touch with Dr.Hsu: LinkedIn L-Nutra Prolon Fasting Nation Facebook Don't forget to DM me on Instagram, or email me at info@sisterhoodofsweat.com to join the Wild Horses Project! How you can stay in touch with Linda: Website Facebook Twitter Instagram Pinterest YouTube SoundCloud "Proud Sponsors of the Sisterhood of S.W.E.A.T" Essential Formulas

healthy dm harvard sustainable chronic quotes sisterhood intermittent fasting chief medical officers intermittent blood sugar hsu fasting mimicking diet chronic pain management l nutra joslin diabetes center william hsu

#359: Dr. William Hsu on Intermittent Fasting For Fat Loss, Time Restricted Eating and How To Follow A Fasting Mimicking Diet!

The Brian Keane Podcast

Play Episode Listen Later Dec 13, 2021 45:45

Dr. Hsu was the VP of International Programs and Medical Director of the Asian Clinic at Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School. After 20 years of a distinguished career as an endocrinologist, Dr. William Hsu joined L-Nutra in 2019 as Chief Medical Officer. In this role, Dr. Hsu leads the clinical development effort at L-Nutra, oversees the Medical Affairs Department, and advances the education and adoption of fasting and Fasting Mimicking Diet as an innovative tool to extend human health span. This podcast topic is a big interest for me personally as I've been looking into the research on intermittent fasting (and caloric restriction in general) for longevity and health; but we also talk alot about body composition and fat loss here too, so if intermittent or fasting in general is of interest to you, you'll really enjoy this episode. Here are some of the things we talked about: · How fasting is a ‘good' stressor that helps the cells in our body · The difference between fasting and starvation · Fat loss and fasting – metabolic and hormonal benefits · If coffee or supplements okay to have during a fasting period · How to make yourself a fat burning machine · Autophagy for health span · Diets and foods in the blue zones · How to use a fasting mimicking diet if you struggle with traditional fasting Social https://www.linkedin.com/in/william-hsu-md/ https://twitter.com/lnutraofficial?lang=en https://www.facebook.com/LNutra/ http://l-nutra.com BRIANS LINKS BKF Online Program: https://briankeanefitness.com/bkf-online/ GAA Lean Body Program: https://briankeanefitness.com/lean-body-program/

social harvard medical school medical director intermittent fasting chief medical officers fat loss hsu international programs time restricted eating fasting mimicking diet l nutra joslin diabetes center william hsu

Episode 86 Should You Fast? What Are the Facts About Fasting with World Expert Dr. William Hsu

Sandy K Nutrition - Health & Lifestyle Queen

Play Episode Play 59 sec Highlight Listen Later Nov 15, 2021 59:47

Today I had the honour of interviewing Dr. William Hsu who has had a distinguished career as an endocrinologist at Harvard's Joslin Diabetes Center for over 20 years. Dr. William Hsu joined L-Nutra in 2019 as Chief Medical Officer. In this role, Dr. Hsu leads the clinical development effort at L-Nutra, oversees the Medical Affairs Department, and advances the education and adoption of fasting and Fasting Mimicking Diet as an innovative tool to extend human healthspan.I am so happy to have had this discussion with Dr. Hsu because we hear so many different things from different "experts". There really is no better expert to discuss the benefits of intermittent fasting and prolonged fasting than Dr. Hsu, and we cover all of it here from the basics to the benefits to the different ways one can fast. We discussed the Prolon Fasting way of achieving all the benefits of fasting, all the while making it a bit easier on yourself using their well-studied method. So listen & learn and if this is a good option for you, use code SANDYK10 for 10% off your Prolon order here Prolon.com. Discuss if this is right for you with your own health provider, as we are not providing medical advise here - this podcast is for information purposes only.If you enjoyed this episode, please share. It means the world to us podcasters when you do this! Also, follow me! I'm on Twitter, YouTube, TikTok, Instagram, Facebook, Pinterest - Sandy K Nutrition everywhere.My contest is still running. I will be giving away a biological age DNA kit to a lucky winner, valued at $300 US in a draw. To enter, subscribe, rate, and review my podcast with a few kind words. In order to be considered, proof must be provided via email to sandy@sandyknutrition.ca. North American entries only. To review with a few kind words, you can go here: https://lovethepodcast.com/sandyknutrition.

tiktok dna harvard fasting north american chief medical officers expert dr hsu prolon fasting mimicking diet l nutra joslin diabetes center william hsu

"Fasting Mimicking Diet" with William Hsu, MD

The Whole Health Cure

Play Episode Listen Later Oct 1, 2021 32:50

William Hsu, MD is the Chief Medical Officer at L-Nutra - a company that is leading the science of Longevity Through Nutrition. To date, L-Nutra had numerous scientific breakthroughs, attracted over $36 million in funding and carried out 14 clinical trials. One of their key discoveries was unlocking the benefits of periodic fasting (fasting for more than two days). Their research showed that periodic fasting induces a special stress leading to cellular rejuvenation – a powerful mechanism for slowing cellular aging. Prior to joining L-Nutra as CMO, Dr. Hsu was the VP of International Programs and Medical Director of the Asian Clinic at Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School.In his role, Dr. Hsu continues to advance the science and research that L-Nutra and multiple global research centers conduct on the Fasting Mimicking Diet® and other proprietary prescriptive formulations. Dr. Hsu also advances global awareness and adoption of cutting edge nutri-technologies such as the Fasting Mimicking Diet within healthcare practices and associations, and among key opinion leaders, health policy makers, and payers in healthcare.Dr. Hsu received his medical degree from Mount Sinai School of Medicine. He completed his residency training in Internal Medicine at Yale University School of Medicine, and completed his fellowship training in Endocrinology and Metabolism at Harvard Medical School - Beth Israel Deaconess Medical Center and Joslin Diabetes Center.In this conversation Dr. Hsu talks about the research around fasting, referring to the work of Dr. Valter Longo (check out Episode 63!). Dr. Hsu describes what fasting is, and how fasting mimicking diet is different, explaining physiological versus cellular fasting. Dr. Hsu goes in detail on the benefits of fasting (explaining autophagy; weight loss, specifically belly fat; improved relationship with food; mental clarity and others), and explains why mimicking fasting can be a valuable, and often less intimidating way to improve health and reverse chronic disease. Tune in to learn more! For more information please visit:https://l-nutra.comhttps://prolonfast.com This podcast is brought to you by Emory Lifestyle Medicine & Wellness. To learn more about our work, please visithttps://bit.ly/EmoryLM

#26 Fasting Mimicking Diet with Dr. William Hsu

The Virgin Diabetic Podcast

Play Episode Listen Later Aug 18, 2021 25:33

In today's interview we are talking to Dr. William Hsu about Intermittent Fasting and Fasting Mimicking Diet. Dr. Hsu received his medical degree from Mount Sinai School of Medicine. He completed his Internal Medicine residency training at Yale School of Medicine and completed his fellowship training in Endocrinology and Metabolism at Harvard Medical School. He was Assistant Professor of Medicine at Harvard Medical School. After 20 years of a distinguished career as an endocrinologist at Harvard's Joslin Diabetes Center, Dr. William Hsu joined L-Nutra in 2019 as Chief Medical Officer. In this role, he leads the clinical development effort at L-Nutra, oversees the Medical Affairs Department, and advances the education and adoption of fasting and Fasting Mimicking Diet as an innovative tool to extend human healthspan.HIGHLIGHTS Definition of HEALTHSPANThe very basic concept of fasting.Fasting mimicking diet.Intermittent Fasting Diet vs Prolonged Fasting or Fasting Mimicking Diet.Recommended periods of time for the Mimicking Diet depending on your health condition.The importance of re-feeding.SUGAR-FREE QUOTES"Fasting is one of the most original diets that all living organisms have been on""In our country (USA) around 86% of people die of non-communicable disease that are preventable. These are, by large, driven by the way we eat"."You don't want to do periodic fasting so often that the body doesn't have time to replete all the nutrients."LINKS OF INTERESTLearn more on l-nutra.com Join their FB community at https://www.facebook.com/LNutra/Visit My Diabetes Concierge ProgramNeed someone to talk to about your Diabetes? Book a free consultation with Denise today https://reversemydiabetes.net/ Follow The Virgin Diabetic on Instagram @thevirgindiabetic Get The Virgin Diabetic Book https://amzn.to/3auCJl6Sign up to the Email list to get diabetes information and special recipes.Join us on Facebook for more info, discussions and articles https://www.facebook.com/reversemydiabetes/

My Nutrition, My Genes

Genetic Counselors and You

Play Episode Listen Later Jul 8, 2021 18:55

With areas opening back up across the country and world, many are looking forward to going outside during the summer. After being stuck at home during lockdown, many might be thinking more about their “summer body” and wondering whether a DNA test can optimize their nutritional health. In this episode, we talk with Jill West, a Registered Dietician Nutritionist, to share her thoughts. Jill has over 25 years of experience as a registered dietitian nutritionist, and has her own private practice Jill West Nutrition Consulting serving clients throughout the US. Prior to starting her own practice, she published the book, 400 Moms, about helping busy parents feed their kids. She has worked in several major medical centers including Joslin Diabetes Center, University of California, San Francisco Medical Center and University of California, Davis Health System.

university california dna nutrition moms genes joslin diabetes center

Dr. William Hsu: ProLon Diet—How to get the most from fasting

From Doctor To Patient

Play Episode Listen Later Jun 24, 2021 32:36

Enter the Entrepreneur: Holly Daniels Christensen, CEO and Founder of Dune Jewelry Co.

Eight by Kate

Play Episode Play 59 sec Highlight Listen Later Jun 9, 2021 31:40 Transcription Available

Kate and Bella chat with entrepreneur, Holly Daniels Christensen, CEO and Founder of Dune Jewelry Co.Can you go from crafting at your kitchen table to a multi-million-dollar business? As CEO, Holly Daniels Christensen has proved – yes! Using grit and the actual sand beneath her toes, that's exactly what this entrepreneur has done.The founder of Dune Jewelry left home at 15 years old, and never looked back. She held a variety of jobs with stints as a zookeeper, pharmacy technician, promotional model, bartender, cellphone, car and cruise salesperson. She also spent 14 successful years as a top agent in Boston's highly competitive real estate market. This unique bootstrap entrepreneur who proved she was unafraid of hard work was voted 2016 Woman-Owned Business of the Year for Massachusetts and New England by the Small Business Association (SBA). In 2018, Inc. magazine honored Dune Jewelry as No. 2590 on its 37th annual Inc. 5000 List which is the most prestigious ranking of the nation's fastest-growing private companies. The list represents a unique look at the most successful companies within the American economy's most dynamic segment—its independent small businesses. Currently, Dune Jewelry is the one-and-only experiential jewelry brand in the world.It all started in 2007, when this self-taught jewelry designer began making beach sand jewelry for friends and family at her kitchen table, then officially launched Dune Jewelry full time in 2010. Now, Dune employs a team of 25 people working in a 3,100 square foot studio space in Hyde Park, Massachusetts. Dune continuously fills orders for over 600 retail partners worldwide while their thriving e-commerce website focuses on selling personalized Experiential Jewelry that captures their customer's most cherished memories. Additionally, Holly has created an exclusive Sandbank that holds over 5,000 sands and earth elements gathered from iconic and memorable locations around the globe which customers can select from to customize their jewelry.Holly is an advocate for giving back to the community and is proud to spearhead many fundraisers each year for non-profit organizations such as SMILE Mass, Joslin Diabetes Center, and the Association to Preserve Cape Cod. In addition, Dune often donates a portion of their sales throughout the year to various charities such as the global relief organization All Hands and Hearts, the Surfrider Foundation and the P.A.W.S Project.Currently, Holly is hosting “Kitchen Table Talks” a 30-minute live show on Facebook and Instagram, where she shares updates on current events, favorite recipes, funny happenings and style hacks along with information on Dune's new brand collaborations and designs in development. Holly lives in Walpole, Massachusetts with her husband Eric, their two daughters Alexa and Lyla, and their rescue pup, Earle. She is dedicated to creating a future that motivates people to understand that continued hard work and perseverance is a direct path to success. Follow Holly Daniels Christensen on her personal Instagram: sandy__handsFor more information on Dune Jewelry visit, www.dunejewelry.comFollow Dune Jewelry on social media: Instagram: DuneJewelryFacebook: www.facebook.com/dunejewelryTwitter: @dunejewelry

49. Karin Hehenberger: Diabetes Diagnosis Drives Life-changing Innovations

Happiness through Hardship

Play Episode Listen Later May 26, 2021 46:58

A physician, investor, business executive, diabetes expert and double transplant recipient, Dr. Karin Hehenberger is wow-worthy and this week's guest on "Happiness through Hardship" - The Podcast. She spent 20 years in leadership positions at big brands, large investment firms and now as Founder and CEO of Lyfebulb - a patient empowerment platform. Diagnosed with diabetes as a teen, Karin has been dedicated to research and innovation nearly ever since. She's a true wonder woman personally and professionally and her story brings hope for many. This episode provides information and inspiration for those touched by diabetes or interested in learning more. Her organization, Lyfebulb, helps make life easier for patients (not just diabetes patients) by providing a platform with resources, services and support for those with chronic illnesses. Karin is not only highly accomplished, she has a loving soul, a huge heart and a focus on family, which you will hear on this episode. SHOW NOTES Lyfebulb: https://lyfebulb.com/ About Karin: https://lyfebulb.com/team/karin-hehenberger-md-phd/ Lyfebulb on Twitter: https://twitter.com/LyfeBulb JDRF: https://www.jdrf.org/ Beyond Type One: https://beyondtype1.org/ Joslin Diabetes Center: https://hms.harvard.edu/affiliates/joslin-diabetes-center I’m a huge believer in patient advocacy...I love when organizations like Lyfebulb help make life easier for the patient. Having been a cancer patient for over 16 years, it’s important to me to share my story and best practices on how to navigate with cancer. If you know someone who has been recently diagnosed or is dealing with regular cancer treatments - please send them my book “Happiness through Hardship” - a guide and journal for patients, caregivers and friends. I wrote it to help others through cancer and find a little joy along the way. CONNECT with us: www.PrettyWellness.com/podcast - for more information on the podcast episodes  www.PrettyWellness.com/cancer-resources - easily accessible cancer information  www.Instagram.com/prettywellness - for daily wellness tips www.CarynSullivan.com - for more information on media, speaking engagements and book partnerships Our Social Media:  www.Instagram.com/prettywellness www.Facebook.com/PrettyWellness www.Twitter.com/PrettyWellness To Buy the Book:  Happiness through Hardship - The Book: amzn.to/39PAjuT To Donate a Book to a Cancer Center:  PrettyWellness.com/book

ceo founders happiness innovation life changing drives diagnosed hardship diabetes diagnosis joslin diabetes center lyfebulb

Encore - Complications of Diabetes

EBPL Podcast from the East Brunswick Public Library

Play Episode Listen Later May 5, 2021 53:16

Recorded on 05/04/2021 at the East Brunswick Public Library. Learn how diabetes affects your body, including your heart, blood vessels, eyes, and kidneys and what you can do to lessen the effects. Presented by: Reema Patel, MD, FACE Medical Director, Joslin Diabetes Center, Raritan Bay Medical Center, Old Bridge Hackensack Meridian Health Board certified in diabetes, endocrinology and metabolism, and internal medicine

md diabetes complications joslin diabetes center

33 Dr. Georgia Ede, MD

The Meet Your Herdmates Sodcast

Play Episode Listen Later Feb 25, 2021 73:50

Georgia Ede, Nutritional Psychiatrist Georgia Ede M.D. is a Harvard-trained, board-certified psychiatrist specializing in nutrition science, brain metabolism, and mental health. She has two decades of clinical experience including many years as a college psychiatrist and nutrition consultant at Smith College and Harvard University Health Services, where she was the first psychiatrist to offer nutrition-based approaches as an alternative to conventional care for students, faculty and staff. Her pre-medical experience includes seven years as a research assistant at the Joslin Diabetes Center in Boston, the Institut für Diabetesforschung in Munich, and other academic laboratories in the fields of biochemistry, immunology and metabolism. Dr. Ede speaks internationally on dietary approaches to psychiatric disorders, the nutritional differences between plant and animal foods, Alzheimer’s prevention and management strategies, nutrition science, and public nutrition policy reform. Dr. Ede writes about food and the brain for Psychology Today, DietDoctor.com, and her own website DiagnosisDiet.com. Through her virtual consultation practice, she uses nutrition and metabolic interventions to help people around the world address root causes of mental health conditions and reduce the need for psychiatric medications. To improve public access to nutritional and metabolic services, she recently launched a live, online, small-group clinician training program in ketogenic diets for mental health which has already been completed by dozens of health professionals in 14 countries. Georgia Ede's website - https://www.diagnosisdiet.com/ "Little Shop of Horrors? The Risks and Benefits of Eating Plants" - https://youtu.be/YdRBFiBWQZQ "Brainwashed — The Mainstreaming of Nutritional Mythology" - https://youtu.be/WbNDrcoRi8g "The Real Game Changer" - https://youtu.be/rDcLr2nK_gs

benefits harvard alzheimer's disease risks munich horrors psychology today institut little shop smith college diet doctor joslin diabetes center

"We Must Change This" - Advocating for Type 1 Diabetes and COVID Vaccinations

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Feb 23, 2021 41:09

As the COVID vaccine roll out continues in the United States, many people with type 1 diabetes feel like they’re in danger of being left behind. Why is this happening and what can we do about it? Hear from long-time advocate Paul Madden. He's lived with type 1 for almost 60 years and he's been fighting for the rights of people with diabetes almost as long. Stacey & Paul talk about what the science says about COVID and all types of diabetes, why the priorities are different state to state and what we can all do to be better advocates. JDRF COVID Vaccine statement/info ADA COVID Vaccine statement/info In our Innovations segment this week, preventing type 1 in the tiniest possible patients.. a new European study on babies and a new study about closed loop and kids. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone Click here for Android Episode Transcription: Stacey Simms 0:00 Diabetes Connections is brought to you by Dario Health, manage your blood glucose levels, increase your possibilities by Gvoke HypoPen the first premixed auto injector for very low blood sugar, and by Dexcom, take control of your diabetes and live life to the fullest with Dexcom. Announcer 0:21 This is Diabetes Connections with Stacey Simms. Stacey Simms 0:27 This week, as the COVID vaccine rollout continues here in the United States, many people with type 1 diabetes feel like they're in danger of being left behind. Why is this happening? And what can we do about Paul Madden 0:40 The science is very clear that type one is comparable to the risk of type two diabetes, if you should happen to get COVID. And I would say make sure your governor's office knows that make sure the Department of Health knows that because we've got to change this and the science is clearly there. Stacey Simms 1:01 That's longtime advocate Paul Madden, one of many leading the charge to get people with all types of diabetes higher up in the vaccine priority lists in every state. We'll talk about what's going on here. And action we can all take in our innovation segment this week, preventing type one and the tiniest patients, a new European studies looking at babies, and another new study this one about closed loops and kids. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show, I am always so glad to have you here. We aim to educate and inspire about diabetes by sharing stories of connection with a focus on people who use insulin, my son was diagnosed with type one more than 14 years ago, he just turned 16. Recently, my husband lives with type two diabetes, I don't have diabetes of any kind. But I have a background in broadcasting. And that is how you get the podcast. And longtime listeners who have heard me say that over and over again, know that over the years, this podcast has evolved, you know, where I used to focus only on type one. And then I got a lot better educated, frankly, about the strength of the diabetes community overall, and learned that a lot of people with gestational or type two or other types of diabetes, listen to the show because of the focus on insulin use and the technology and a lot of the research. And it's topics like this one that I'm focusing on this week that really drive home, how much we have in common and how we need all hands on deck the entire diabetes community when we're talking about something like the COVID vaccine, and getting priorities in order. So I'm thrilled that our focus has kind of widened out over the years. And it's thanks to a lot of better education by listeners, you know, like you talking to me about the needs of the community. And I think people like Paul Madden, and you'll hear more about him and his advocacy coming up, really drive home how much we all need to stick together. I also want to point out if you don't already know in our Facebook group, Diabetes Connections, the group, we have an ongoing discussion and some posts about what is happening state to state I've asked people to share from their state health department what is happening where they live, so that if you want to check in, and you're not exactly sure where to find your prioritization in whatever state you live in, you can pop into Diabetes Connections, the group on Facebook and find that information out pretty quickly. And if you know the right website and your state, please come in and add it. I have to tell you about something that happened in North Carolina recently, and this became a mainstream news item where I live in North Carolina. And this was a billboard that went up I will share this in the Facebook group. And it was a billboard that went up I believe in late January. And it said Governor Roy Cooper, our governor here does not consider type 1 diabetes an underlying health issue. Think about that. That's what it says on the Billboard in late January when I believe this billboard went up. Type 1 diabetes was not considered a priority for vaccination in North Carolina. That has since changed, but a lot of people garnered a lot of attention. This billboard went up in Johnston County, which is in the eastern part of the state. It's kind of Southeast Raleigh. I don't know if it's deep enough east to be called down east, as we say here. It's not quite toward the beach or that area. I believe there is an Ava Gardner Museum though, in Johnston County. That's kind of its claim to fame. As far as I know. Please don't correct me on that. You can you can correct me if you want on that. Send me your Johnston county emails, but really interesting stuff that somebody paid for it. The billboard company was contacted by the media outlet that did the story here was a Raleigh TV station and they said this isn't an anonymous person who bought the ad space. All I know, they said is what's in the message. But since that billboard went up, and I think it's still up, things have changed. People with type one and type two are now in what they're calling group four here adults at increased risk of severe illness. As of this taping, I'm taping this on February 19. We are on group three frontline essential workers so Hopefully we will get to people with diabetes and others with severe illness who are under the age of 65. And don't fit the other groups pretty soon. I don't know, maybe by mid to late March, but it is really a moving target. And I think that's important to keep in mind as you listen to this interview. And you think about this discussion. I talked to Paul this week. And as I am taping on the 19th, everything he said, is still in effect, but it could change by the time this episode is released, which is February 23. So if you're listening to this live on that date, I will post on social media if things change and of course, come visit the Facebook group to find out more of what's happening in your state. I'm optimistic that type one is going to move up as people get better educated and advocacy steps up across the country. But you know, it is a moving target like much of the vaccinations across this country. Alright, Paul Madden, and what you can do coming up in just a moment, but first Diabetes Connections is brought to you by Dario. Health. You know, one of the things that makes diabetes management difficult for us. I mean, that really annoys me and Benny, it's not really the big picture stuff. It's the little thing that's all the little tasks adding up. Are you sick of running strips, do you need some direction or encouragement going forward with your diabetes management with visibility into your trends help you on your wellness journey? The Dario diabetes success plan offers all of that and more. No more waiting in line at the pharmacy no more searching online for answers. No more wondering about how you're doing with your blood sugar levels, find out more go to my dario.com forward slash Diabetes Connections. My guest this week is probably one of the busiest people in the diabetes landscape that you will ever meet. He really has. I don't think he's done at all. But oh my gosh, Paul Madden has been on the frontline of advocacy for a very long time. He worked for 30 years at the Joslin Diabetes Center in Boston. He also worked at Johnson and Johnson with Animas, he has been part leadership roles at children with diabetes. He's been a part of the diabetes education and camping Association, the Association of diabetes educators had a large leadership role advocating specifically for people with type one at the American Diabetes Association. And he spoke last year, you might have seen him he was at the White House announcement on insulin pricing. Paul was diagnosed with type one when he was nine years old. And that was almost 60 years ago. And he talks a little bit about that in my interview with him. But I have seen Paul on social media advocating for the COVID vaccine prioritization for people with type one. So I reached out and I was really happy that he agreed and had time to join me. This is also a video interview, it's over on the YouTube channel. And I'll link that up in the show notes. If you would prefer to watch that the video is a little bit different. It is a little bit longer. And you will see exactly what we're referring to here right at the beginning. But you can certainly listen to it just as easily. You're not going to miss anything. If you just listen to my interview with Paul Madden. Paul, thank you so much for joining me. Paul Madden 8:01 Stacey . I've watched your podcasts and I know that you're getting right information out to us all and our diabetes world all 34 plus million of us here in the US. Yeah, Stacey Simms 8:11 well, I appreciate that. I'm grateful that it's generally an audio podcast with these video segments put in because as you can see, my production is sometimes a little wonky. We hit this at the exact right time for the sun to be setting on my window. So we've got some interesting stripes on me with the light. But we'll work around that. Yes. You're here because you have so much great information about type one advocacy, specifically right now around the COVID vaccine and prioritization. Let's just take a step back. Can you talk a little bit about the situation? We are in the middle to late February at the moment where things stand? I mean, the US has a bunch of different policies where things stand for people with type one right Paul Madden 8:49 now. Yeah, I'll give you a couple of scenarios of where it stands right now, Stacey . And regrettably, we can't define it well for every state without going into this state COVID Medical policy, but generally the CDC put out their announcements, and they said something to the effect. I won't quote them, but I'll paraphrase. But they did recognize that type two diabetes was a higher risk and a priority for earlier vaccinations. And that is very correct. Unfortunately, their wording for type one was far more nebulous, far less clear. And they said that for type one insulin dependent diabetes, we suspect it could be a higher risk. Now the challenge is, as you know, Stacey , we have approximately 1.6 million people in the US with active type 1 diabetes of all ages, you older guys and gals and folks like me, and very young little babies, little kids and all the way in between the type two population. It's over 32 million and so very quickly within the first few months of COVID, after February, March, they saw the data from the hospitals from the treatment centers, the ICU that said, Wow, type two diabetes is about a 3.3 times greater risk of serious complications than the citizen without diabetes. So they correctly log that in there, unfortunately, and we're saddened by the fact and I and others, it's it's never alone. It's always a group of us. But I reached out to the ADA, the JDRF, the the diabetes patient advocacy coalition, the leadership and diabetes group, and I children with diabetes, a group that you and I know, well. And 18 groups finally signed on when we sent a letter to Dr. Redfield, who was in charge of CDC. And we said, Please, sir, there's some new data, some new science that started to come out beautiful science in November, December, and a new article just came out in January to say, type one? Absolutely. If you give COVID Is it the same high risk level and one study imply there could be a little bit higher risk than type two? So six states have made the change? And have said, Absolutely, let's do it. Some states haven't defined type one and type two in their state policy, because remember, the CDC allowed the states to determine who gets the vaccinations on their state schedules, I got involved very much in Massachusetts, because unfortunately, they did distinguish, and they still have not changed the Priority Ranking for type one. And we're very discouraged by that. very discouraged. So the type one population, our kids get no priority. If you're over 65, we can now start to get it just because of our age tomorrow. But that's not enough. We've got to get all people with type 1 diabetes at the same Priority Ranking for vaccinations. So that's what we dug in, we're trying to get, we have a sense that we're going to get a meeting with the COVID Committee, the medical leaders here in Massachusetts, I know others are doing the same. So we only again, know of six states that have put type one in with type two. But as I'm talking to more and more advocates throughout our country, I'm learning that some again, like I said earlier don't distinguish. And they allow type one and type two to be together both as a high priority ranking. But we don't think that's more than about 20 to 25% of our states. And we don't have a definite number on that. So we got to keep pushing. Stacey Simms 12:38 I'm in North Carolina, as you know, and they did not first but they did slide type one up. And you know, a question that came up early on. And again, we want it to all be the same we want, again, we want that type one higher, but who would check and what a burden to kind of put on these health care workers who are giving vaccinations? I mean, I get it, if you're going up to kids, if you're a 12 year old, they're gonna say type two. But if you're 40, is someone going to be standing there saying, Well, what type do you have? What's your a one? See, show me your insulin pump? You know, it just seemed to put a burden on folks. Paul Madden 13:12 Yeah, we certainly did with this. You know, we haven't done this, as you know, since the Spanish Flu 1918. But none of us were around, you know, maybe 30 people around, but they can't really relay the story very well. They were three years old. Stacey Simms 13:27 And I hate to use a little dark humor. But people with type 1 diabetes were not included. They hadn't even figured out insulin at the last time Paul Madden 13:34 we checked I was pretty insulin era. Exactly, exactly. Right. So we've got to keep pushing and you know it Stacey advocacy. And for everyone who's participating in this advocacy is about getting the science clear. Having good backing, making sure you have some spokespersons from healthcare who are specialists in diabetes. I am a psychologist. I'm a diabetes educator. I know my diabetes, my personal diabetes of 59 plus years, and I've been an educator in it for 47 years, so I know it well. But I also realized that I often need to make sure I've got several physicians and other healthcare providers lined up and that we have done. Several people that have said, Yes, the Joslin clinic came roaring through and said, What do you need from us? We've got it. And they just sent me another article today that I can submit to the governor's office and the COVID Committee. And that's the type of things that we have to do. There's not enough people that get paid to be advocates. And I want to stress that and I wish that there were and I know the diabetes organizations wish they they had so much money that they could easily hire more people to do these things. So it really relies on us. The volunteers also offered to put the pieces together again working though, and supporting those diabetes health care providers. Stacey Simms 15:00 So if someone isn't an individual, they're not affiliated with a formal advocacy group, and they're in a state like Massachusetts or another state where they haven't put the type one priority higher. What do you do? What do you call? Stacey Simms 15:18 Right back to Paul answering that question. But first Diabetes Connections is brought to you by Gvoke Hypopen. And you know, almost everybody who takes insulin has experienced a low blood sugar and that can be scary. A very low blood sugar is really scary. And that's what Gvoke Hypopen comes in. It's the first auto injector to treat very low blood sugar Gvoke Hypopen is pre mixed and ready to go. With no visible needle. That means it's easy to use in usability studies, 99% of people were able to give Gvoke correctly, I'm so glad to have something new, find out more go to Diabetes connections.com and click on the Gvoke logo. Gvoke shouldn't be used in patients with pheochromocytoma or insulinoma. Visit gvokeglucagon.com slash risk. Now back to Paul Madden answering my question of what are we supposed to do? Who do you call? Paul Madden 16:08 Yeah, I think most people bombard their diabetes specialist team phone number and email which was by the young people especially. And typically, the diabetes professionals in our states know who the advocates are. And if they don't, and they're seeing this, I want to encourage you to find out who your your statewide volunteer advocates are, and know the people from JDRF, from ADA, from the diabetes, DPAC group, patient advocacy coalition. They're quite a remarkable group. This is to pay staff and a bunch of wonderful volunteers, some very top senior business leaders who have been in diabetes for a long time, including the nonprofit world in diabetes, and they volunteered their time for this. So your medical professional should know. And then we the people living with diabetes should get to know these advocates also, because there will be other issues. This is a big one right now. But there's other big issues, the whole reimbursement, the medical switching, all of these things that make no sense whatsoever. Stacey Simms 17:14 Yeah. so in this situation, though, you would think it's better to call the people that are already working on it, rather than your congressman or your health department, or things like that? Paul Madden 17:24 Well, no, I think rather to coordinate with the people that are already working on it. But no, Stacey , you bring up a great point here, you and I and all of us have to be wonderful employers. And by that I mean, our state representatives, our federal senators and representatives, they work for us whether or not you voted for them, they are in office and taxpayer dollars, pay their salaries and benefits packages. And again, we've got to be a cooperative employee, employer, but we they do work for us. And we have to make sure they understand that this is a priority for 1.6 million people in the United States that live with diabetes. Absolutely. Yeah. Stacey Simms 18:08 I don't know if you can answer this. But I'm curious. Do you think that when the CDC put out those guidelines, and when states like Massachusetts aren't listening to advocates like yourself? I think not taking type 1 seriously? Do they maybe not understand it? They don't they think it's just kids? What do you think's going on? Paul Madden 18:26 Yeah, so maybe it's not a full understanding, but that the medical experts on the COVID committees, typically, and I'll speak for Mass. These are good doctors. Yeah, they know medicine, but they also are not diabetes specialist. And the thing again, I'll go back to the does hinder us some, when you're trying to collect quick data on a crisis like this a COVID crisis, it takes five to six months to get enough, a big enough and a big enough group of people with type 1 diabetes that have had COVID. I respect that they went after this from the very beginning with What does healthcare show us? What does the what's the medical condition? Because we got to rank order this I appreciate that I even though I'm a psychologist, I always go after what's the medicine say first before I start to speak, and I surround myself with bright people who are endocrinologist who are brilliant research scientists, and they share things with me so I can understand it. And I can pass it along. But we've got to get the message. I tell you what I think is happening. This is a frightening crisis financially, for every state for an awful lot of good families. Some adults are out of jobs for the first time in their lives. And maybe they have a child and maybe even two children that happened to have diabetes or some other added concern that costs a lot of money. Sometimes, you know, some people have gone into more of a survival and I respect that and we are in a survival state of mind. It's hard to process more information coming in. And I'm aware that there are many groups right now approaching and I'll speak specifically for mass COVID. Committee, but it's all of the committee's in every state of saying, How come my condition is not a priority? How come this is not a priority. And I just would say to all of us that our diabetes will stick with the science, get medical people aligned with you. I remain very discouraged right now. But I remain very positive in the way I state things, because we must change this. And that has to change soon. I think the committee's are sometimes so overwhelmed with so many emails, and so many calls. And that's why I go to groups like Joslin, like Harvard for their backing. And I've pulled called in a colleague who was a good friend of a friend who knows the governor. So we're doing those types of things that we all of us will know someone who knows someone. And boy, you got to do that you have to win advocacy work? Yeah. Stacey Simms 21:08 It's difficult to say the least I'm glad. I mean, I know how I would want to prioritize it. But I'm glad I'm not the person who has to prioritize it. Paul Madden 21:17 Very challenging, difficult. And that's why they can put a little bit of a protection in front of themselves by saying, we understand the science clearly says this now. So now we must change this. And if you stay on the science, and that's it, the science will guide you with the wisest of decisions. Yeah. Stacey Simms 21:37 I'm curious, Paul. And we will probably talk more about vaccinations as we go forward here. But how have you been this last year? You know,what have you been up to? I see all of your conference tags behind you. Obviously, we haven't been going to those conferences. How are you all doing? Paul Madden 21:53 Yeah, I you know, it's challenging for me. And let me personalize it. It's challenging, challenging for me, for my sister's family, my brother's family, for cousins, all of us. We've actually done some zoom calls with cousins. Who ever would have thought I would have done that I would have just driven you know, 50 miles away to see my cousin. Right. early on. I you know, I had launched my business in after going into semi retirement and we had some family, a family challenge with a health issue with a wonderful loving family member. So I decided, oh, she's 68 years old, you can step back a little bit and focus more on family right now. And I appreciate that I had that that luxury, truly do. But then I realized and he's doing great. cancer free for the first time in over a year after seven years of dealing with a challenging cancer. So we are so blessed. And I realized, oh boy, you better get going. So I launched my business in January of last year. 2020. Wow. Robust February, and then the day flew home from the diabetes technology meetings in Madrid. I saw in a CNN screen in English, the first case of Corona Coronavirus, identified in Madrid, I had no idea what that meant. The last Sunday in February. Wow. What did I know that four to five weeks later, because I've had diabetes for so many years. Because I am over 65. I said, I just took a breath and said, You know what? You need to shut down. I certainly kept doing some present zoom presentations, some FDA work and all of that. But I really basically shut down what I was doing. You know, Stacey Simms 23:34 from your perspective, you're much more dialed into this. Is this a question of sit tight, it's coming, push where you can? Or is there a voice in your head saying this is gonna take forever? We're not gonna get people with diabetes vaccinated until summer, or later, or? I'm not sure what I'm asking Paul. But I'm just sometimes I could lay awake at night and worry. Paul Madden 23:51 Yeah. And so they're opening it up for me at over 65 tomorrow in Massachusetts. So I'll get it the first one within the next three to four or five weeks. Okay, at least I have an identified timeline now. But I do worry about the rest of my younger friends. I do. And I would say again, you are and this is on a state level. Now, your state senators and state representatives work for you. The science is very clear. That type one is comparable to the risk of type two diabetes, if you should happen to get COVID. And I would say make sure your governor's office knows that. Make sure the Department of Health knows that and absolutely call and ask your state senator and state representatives to work on your behalf or your loved ones behalf because we've got to change this. And the science is clearly there. It's on the ADA web page. It's on the JDRF web page. And clearly you can get a hold of the science and you look up COVID and diabetes right now. Did this morning, and some of the more prominent good studies are listed, including now to type 1 diabetes to Stacey Simms 25:07 show wonder, I don't know if I agree with this, but I've heard a few people say that one of the issues was almost self created by at the very beginning of the pandemic, people feeling that there. And maybe it's because there wasn't enough information, but that people with type one who got COVID did not have as serious cases as people with type two, and somehow separating that out and saying, It's okay, we're gonna be okay. We don't have to worry as much because I remember seeing those posts back then. But as you're saying, the science doesn't bear that Paul Madden 25:35 out. If you get it, you know, if you have type one or type two diabetes, there's no you have no greater chance of getting coke. Right, you know, thank goodness, so, so mass, washing hands, social distancing, all those things are crucial. And I just say to everyone hang in, the light is at the end of the tunnel in the months ahead, and I want to shorten it to a few months, not several more months. And that's why I'm saying for people with diabetes, and for our loved ones, you know, and maybe it's your neighbor, it's three houses down, who signed, married, the governor's daughter, I don't care what the connection is. It's been important our health, it really is. And that's networking at the fullest. And it's amazing to me, some of that my grandmother, one of my grandma's was an incredible network. And I think I probably got it from her and then passed along by my mother. You know, that's what you've got to do right now. Stacey Simms 26:30 I'm curious to you know, do you think going forward, there are any lessons in this for the diabetes, the whole diabetes community, not just type one and lessons and all this? Paul Madden 26:40 Yeah. So I think there are a couple of lessons and thanks for asking. I think the lessons are that, based on the science, standing together, we can change wrong agendas throughout our country relative to diabetes care. In this case, I mean, care for COVID prevention, vaccination, but for everything, and I need it for every new technology and drug that gets out there. If we stand together, just because you get the CGM. And if your other friend who's a senior or 12 years old, doesn't have the CGM help push for them. We are one family of 34 plus million people with type one or type two diabetes. I know the rest have distinct differences. But there's a lot of commonalities. And together that's an awful lot of votes for anyone who is serious about continuing in the political world. And I think we have to approach it like that. And it is a question of the blunt statement, the quality and quantity of one because Paul Madden has had access I had like like you and your family does with your son. I have been blessed. My mother and father knew nothing. When I was diagnosed. 59 years ago, there were under 3 million people in this country with diabetes. Wow. And it was it was closer to two is what I'm told, right? 34 plus million now. It's unbelievable. So diabetes really wasn't discussed. In fact, it was all the poor kid. He's got it. Yeah. Because people didn't survive. And my mother and father with my medical team at you have and I will say and we had a family practitioner, he diagnosed it. I was nine years old. I was peeing the bed like Niagara Falls. I didn't know what was going on. And my sheets actually were sticky. So yes, folks, there is sugar in the urine. And I was heartbroken and I dropped 10 pounds. It was a healthy little boy. I would drop 10 pounds in five or six days. And the family doc said to my parents I was in the room and he said Mr. Mrs. Madden, Paul, I don't do diabetes and children, but the Joslin clinic is 15 miles away, and I'm gonna make a referral over there. And hallelujah for the next 30 years Dr. Leo Kroll and his team at Joslin imprinted on me beautifully on my parents, you know, my father walked me out into the courts when I was I guess it was 10 at that point, my first full summer with diabetes and walked me on the court to meet Bill Talbert, the first professional and the first athlete ever that was named number one or two in the world that happened to have insulin dependent diabetes, Bill & I became good friends for the next almost 50 years before bill passed in his late 80s. But that was the exposure my parents made sure I got and that's that's what all of you have to do to to the best of your ability. You know, one reason I have stepped down after two terms in six years on the children with diabetes board, I just tell everyone and as you know, Stacey , it's it's we call it children with diabetes, but approximately half of the people come now are adults with type 1 diabetes. And I forget the numbers, Jeff Hitchcock sentences that over 5000 people did the Virtual Education because we couldn't meet in person. Oh, it was amazing. It was amazing. And you will find that yes, absolutely. But the camaraderie you get from that, and we bring in some of the finest speakers in the world who say yes. And typically they do it for free. That's unbelievable. They fly from all over. And not just sometimes the US from other countries even, you know, so it's that type of cost and peer support, because let's face it, kids with diabetes don't live there. They don't probably don't have six other neighbors in their neighborhood that are also kids with diabetes. No, no, do us adults who have type one diabetes, I don't know anyone who lives within three miles of me, that's not fair. I do know one gentleman who's had type 1 diabetes for 65 years. And we've known each other for 50 plus years. But other than that, I don't know who else has type 1 diabetes in the neighborhood. So Martin, and I go off a walk sometimes. And it's an absolute pleasure. And we do support each other. And it's the power of support when you're dealing with something you wish the heck you didn't have. And you know, you got to move through it. So you have the fullest, most robust and the happiest of lives, that peer support can be rather powerful. That's why I think a well run diabetes camp, I think, the support education groups at some of the organizations. That's why I think the podcasts are so crucial. I think things like this station that you and others are doing consistently, a very powerful to convey information. And again, you and I know as long as people remember that Paul said, what he does with his diabetes, gives me great results. Yeah, but remember, folks, I do it with my medical team who's coached me and always coach me. And if I ever had a problem, I can't figure out the answer to what I do. I'm a diabetes educator. But but when it's a personal thing, you don't stay as objective and you don't sometimes pull out all the science, right? When you're talking about yourself or thinking about yourself, I pick up the phone, and the young people probably send the email more frequently than I do. That's okay. Whatever your line of communication is, that's the important thing to promote the most robust health so that diabetes is an element of your life, but never hinders your life. That's the goal. That's the goal. Stacey Simms 32:30 Paul, thank you so much. I could talk to you all day. You're inspiring on an I don't know, I'm gonna probably regret saying this. But you are inspiring on kind of like an everyday getting it done. level. You know, you and I are not people that are going to go up Mount Everest, I don't think you've been at Mount Everest. Paul Madden 32:47 You know, I have a few merits. I know, I'm not gonna do Everest. I'll leave that to the world crushes. Stacey Simms 32:56 But I just love it. And I'm so glad to hear your family members doing better than doing well. So stay well. Keep us posted. Thank you for your incredible advocacy. And let's follow up as more information comes in and you go give them Helen, Massachusetts, Paul. Paul Madden 33:11 Absolutely. Listening, call your state reps and Saturdays, please. Thanks. Unknown Speaker 33:23 You're listening to Diabetes Connections with Stacey Simms. Stacey Simms 33:29 More information about Paul and about the COVID vaccine and what we can do, and more advocacy from the groups that he mentioned. I'll put that all in the show notes at Diabetes, Connections comm you can always find the episode homepage there. I always say this, but it's a little difficult sometimes in the podcast apps to find the links. So if you have any trouble, just head on back to the homepage, and it is always there for you. I want to make this as easy as possible. So if there's a better way to do it, or you need more info, always contact me Stacey at Diabetes connections.com. We're going to talk about a new study looking at prevention of type one by focusing on babies. And a new study that I gotta tell you is a no duh. I mean, who was surprised by this kind of study, but that's coming up in just a moment. First, Diabetes Connections is brought to you by Dexcom. And do you know about Dexcom clarity, this is their diabetes management software. And for a long time, I just thought it was something our endo used, you can use it on both the desktop or as an app on your phone. It's an easy way to keep track of the big picture. I check it about once a week. And it really helps me and Benny just dial back and see longer term trends helps us not overreact to what happened for just one day, or even just one hour. The overlay reports help put context to Benny's glucose levels and patterns. You can even share the reports with your care team, which makes appointments a lot more productive. managing diabetes is not easy, but I feel like we have one of the very best CGM systems working for us. Find out more at Diabetes connections.com and click on the Dexcom logo. Our innovations segment this week features a couple of studies that focus on kids. And this very first one is really for the tiniest in the diabetes community. It's a study that just started and it's looking at the correlation of the antibodies that appear in people with type 1 diabetes, as well as intestinal flora in early childhood. So basically, what the heck is going on in the gut in people who go on to develop type 1 diabetes, the study, and I'm not sure I'm pronouncing it correctly, I'll link it up with a study is center one, a si en T one, a. And it's going to start in the spring this year, in a few European countries, as part of an international initiative to prevent type 1 diabetes, it follows another study that they're all doing called point, which is administering insulin orally in the hopes that it would somehow it says your train and sensitize the immune system at an early stage so that auto immunity against insulin does not occur. So if the results were both studies show what they're hoping they're going to combine them for what they hope will be a type one prevention strategy, really interesting stuff. And I will link up this study. Again, it's not open here in the States. This is happening in Europe, but really interesting study. And I will link up more information. Again, it's happening in Europe. So it's not open for people in the United States to take part in. But hey, I'll keep you posted. The other study I want to talk about this week, and I mentioned this earlier in the show as like a real Hey, no duh type moment. But hey, these things have to be studied. I will read from the endocrinology network where I saw this written up, and they say, a closed loop control insulin delivery system could be safe and effective for use in adolescents and young adults with type one diabetes, according to the results of the International diabetes closed loop trial. Shockingly, I added that results of the study indicated use of a closed loop control for six months resulted in improved time and range and reduced incidence of hyperglycemia. In younger patients with type one diabetes, I shouldn't get around because they do need to prove these things. We do need to you know, make sure that there is clinical evidence before we move forward. But you as you listen, know, many of you have been doing DIY for many years, and you know this to be the case, I will make it up. Interestingly, as in most of these studies, the biggest improvement was in overnights, right, a lot less overnight, low blood sugar hypoglycemia, which is amazing. And I can tell you just from experience with Benny on what I call a hybrid closed loop, but Tandem is control IQ is one of those used in this study. So they're calling a closed loop. But I mean, he wakes up almost every morning, not only in range, but he wakes up almost every morning between 90 and 115. I mean, you know, for a 16 year old, it's pretty amazing. And I think that overnight sleep for everybody, it gets so much better. And that in and of itself is such a great health benefit. So I'll leave that study up as well. Next week, we're gonna be circling back to tell me something good. So I need your good stuff for the show. You can hit me up Stacey at Diabetes connections.com. I will post to the Facebook group and I'd love to hear what's going on that you want to celebrate. Okay, before I let you go, I need to let you know that this was really weird. I had a crazy low blood sugar in the middle of this episode. Right after the dex comment that you heard. I pressed pause and I was feeling shaky and sweaty and I really was having trouble getting through it. I went downstairs and I checked my blood sugar with one of Benny's meters. And it was 46. So I scurried around and got some peanut butter crackers, I probably should have had a juice box, I wasn't really thinking clearly shockingly. And I sat down and ate the crackers and waited for my blood sugar to come up. And boy, I gotta tell you, it's no shock to most of you. I was so hungry after that. And we're about half an hour away from dinner and slaves making a great dinner and I was so hungry, but I waited. And now I'm upstairs again, where my office is recording the podcast. It's not the first time that I've had a low blood sugar like that, that I've measured it that low. And I've talked to my doctor about it, I actually had a low blood sugar, the first time that I remember really measuring it several years ago at friends for life. And I checked it in the middle of the vendor Hall and it was it was in the 40s. And of course you know, you've got what a great place to have a low if Rudy was bringing me gummies and tabs and taking care of me. But you know, again, I don't have diabetes. And I don't have I don't think this is the right name for it. But I don't have like chronic hypoglycemia or anything dangerous. My doctor just has told me that I'm the kind of person that needs to eat every couple of hours and I need to be careful that I don't just eat empty carbs during the day that lunch and breakfast, have protein and all that good stuff. So today for the first time in a long time. I had a lunch that was not smart and it was delicious, but it was very carb heavy and I've been eating really lower carb for the last couple of months. So I just didn't have a lot of stuff in the house. Slade was at the grocery store. I had cheese blintzes for lunch. They were delicious. I'm not sure if they were working 46 blood sugar a couple of hours later, but there you go. So True Confessions all man, low blood sugars, they just suck. They feel like garbage. And I'm really happy that I'm feeling better. But I was sweating and low and shaky. And I think that feeling of wanting to eat everything after it's so difficult, I will follow up if I need to. I take very good care of my health and I take these things seriously. But I wanted to let you know that that happened while I was taping the show. How weird All right, a classic episode coming up in just a couple of days. We're gonna be taking a look back at Jerry the bear. And this is not during the bear as you know him today. This is a much earlier incarnation of Jerry and the great people who created him. It was so much fun to talk to them five years ago now man, I love these classic episodes. I hope you're enjoying them. Stacey Simms 40:48 Thank you so much to my editor John Bukenas from audio editing solutions. Thank you so much for listening. I'm Stacey Simms. I'll see you back here in a couple of days. Until then, be kind to yourself. Benny 41:03 Diabetes Connections is a production of Stacey Simms Media. All rights reserved. All wrongs avenged

"What is the Community Buzzing About?" D-Data Exchange 2020 with Amy Tenderich

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Dec 1, 2020 45:15

The DiabetesMine D-Data Exchange is a great time to catch up on the latest technology and get a sneak peek at what’s coming. This is the conference where #WeAreNotWaiting was coined in 2013, which almost seems like ancient history now! We talk to founder Amy Tenderich about what's new and take some time to focus on their effort to reach more diverse voices. Watch the videos from Innovation Days here In Tell Me Something Good, a big diaversary to celebrate.. Stacey's son marks 14 years of type 1 diabetes this week. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone Click here for Android Episode Transcription Stacey Simms 0:00 Diabetes Connections is brought to you by One Drop created for people with diabetes by people who have diabetes by Gvoke HypoPen the first premix auto injector for very low blood sugar, and by Dexcom take control of your diabetes and live life to the fullest with Dexcom. Announcer 0:21 This is Diabetes Connections with Stacey Simms. Stacey Simms 0:27 This week, the DiabetesMine innovation days is always a great time to catch up on the latest technology and get a sneak peek at what's coming. This is the conference where we are not waiting. The phrase was coined in 2013 which almost seems like ancient history now Amy Tenderich 0:44 stuff that seemed like such a pipe dream at the time like this whole idea of a closed loop system it was like kind of eye roll or like but now we have a very viable do it yourself. Homemade pancreas closed loop system which I'm using By the way, I've been looping now for quite a while and it's a game changer. Stacey Simms 1:00 That’s Amy Tenderich, founder of DiabetesMine who puts this conference on twice a year. This time around. There was also a big focus on inclusion and representation. Lots of info share In Tell me something good a diaversary to celebrate 14 years of type one in my house. Betty was diagnosed the first weekend of December in 2006. And I just remembered a funny story from that week that I haven't told before. I was always the worst. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show. I am so glad to have you here I am your host, Stacey Simms, and we aim to educate and inspire about type 1 diabetes by sharing stories of connection. As I said in that intro, my son was diagnosed with type one right before he turned to 14 years ago this week, my husband lives with type two diabetes, I don't have diabetes, I have a background in broadcasting in radio and television, local news. And that is how you get a podcast. I'm going to be talking about Benny’s diaversary later on in the show, I will tell you a rather silly story that I just remembered about our first weekend home from the hospital. So about a week after we got home, and we went out we had theater tickets. I will tell you that story later on in the show. But stick around. It's a funny one. I think it just kind of sets the tone for how we manage diabetes and continue to this day. Oh my goodness. I also want to let you know that friends for life is having another conference of virtual conference. And if you are listening as the show is first airing friends for life is happening this Friday, and through the weekend, December 4 2020. And along with the incredible educational opportunities and the wonderful social stuff that they have great meetups, I am also doing my annual game show I do a version of NPR is Wait, wait, don't tell me, which is a really fun game show. If you've ever listened to it. I do Wait, wait, don't poke me and I have taped that and we will be airing it and premiering it this Friday. So definitely come by and please check that out. I will link up all the registration information for friends for life from the wonderful folks that children with diabetes, just go to Diabetes connections.com and click on this episode. You know every episode has pretty extensive show notes where I link up information. And I also put a transcript now for every episode in 2020. And we're starting to work backwards. So hopefully eventually, I'll have a transcript for every episode of the show. Thanks for your patience on that. All right, talking to Amy Tenderich from DiabetesMine in just a moment. But first diabetes Connections is brought to you by One Drop in One Drop is diabetes management for the 21st century. One Drop was designed by people with diabetes for people with diabetes. One Drop glucose meter looks nothing like a medical device. It's sleek, compact and seamlessly integrates with the award winning One Drop mobile app, sync all your other health apps to One Drop to keep track of the big picture and easily see health trends. And with a One Drop subscription you get unlimited test strips and lancets delivered right to your door. Every One Drop plan also includes access to your own certified diabetes coach have questions but don't feel like waiting for your next doctor visit your personal coach is always there to help go to Diabetes connections.com and click on the One Drop logo to learn more. My guest this week can be summed up I think in the motto of the conference. We're about to talk about learn, connect, collaborate, Amy Tenderich was diagnosed with type one as an adult in 2003. And not long after that she started the website DiabetesMine, which is a terrific source of news and information in our community. Seriously, if you're not reading it, I'll put a link in the show notes. Make it a bookmark. They even say that anymore. You know, put it in your reading list. They say that anymore. Make sure you check out diabetes mind because all kidding aside, they do a tremendous job on reporting in depth news information in our community if you're interested at all in technology if you want to learn personal finance stories to they do that it's a great deep dive and I rely on it for a lot of information, I share her on the show, of course, I always credit them. But in 2013, Amy started organizing the D-Data exchange twice yearly events that focus on technology and breakthroughs. This year, Amy added topics about diversity and representation in the diabetes community. It's something she was already working on, as you'll hear before, the events of this year brought it to the forefront for many people who maybe hadn't considered that before. But maybe it was already on it. Lots of information here and look forward. Of course, it's always great to catch up with Amy. Amy, welcome back. Thank you so much for joining me to talk about D-Data. I really appreciate it. This conference is always so interesting to talk about. So thanks. Amy Tenderich 5:46 Oh, thank you for having me. Stacey Simms 5:49 first question really has to be just the difference this year in terms of making everything virtual. You know, I was in some of the conference presentations, I have to say this was a cool looking online conference. Do you mind share just a little bit about how were you pleased the way it went? I know at the beginning of the year, it must have been kind of crazy to regroup? Amy Tenderich 6:09 Absolutely. It was it was been a big learning curve, obviously moving from in person to online, no matter what kind of event you do. I mean, first of all, there was this, oh, my God, I'm in the events business. And now we have COVID. And you know, what's going to happen? And there was some question about whether people would still be interested. But I feel like I found that people are really anxious to connect, because we're not going to all these in person events. You know, most of us feel like we're just sort of out there some kind of juggernaut on our own trying to keep up just by clicking on links. And so having a conference that allows people to connect, I think is you know, something that people are still really looking for, we had to do it the first time for our June event, because we do these D-Data events in June and then in the fall. And so you know, that was literally starting from scratch. Our event, as you may know, is sort of like a leadership forum, we always kept it at about 150 people Max, try to keep it somewhat intimate, so that it really put an emphasis on collaboration and interactive sessions. And you know that the networking part of it is really important. So we thought, how can we recreate that. So it's not just people sitting and watching, you know, one presentation after another, especially when everyone's doing so much of that these days on zoom. So I've been working with the same event manager, actually, for years, a lovely woman who, out of San Francisco, who helped me find this platform that is really, in fact, they do use it for much larger events up to thousands of people. But the thing that's so special about it is it kind of recreates the experience of sort of walking into a live conference you like sit down at a table, and then you're able to immediately see and talk to the people who are at your table. And if you jump over to another table, then you're talking to that group. So it kind of looks like a zoom breakout room. But the idea is that it's you know, it's sort of oriented by table. And then what if you want to work together with the people at your table, there's even this whiteboard function that lets people have kind of a little sandbox to play in. And so that we do, again, a lot of interactive stuff, where we try to get people to talk with the group at their table and brainstorm things. So they were able to use that sort of shared space where you can draw pictures and you can post links and and you know, get creative. And you can actually capture whatever your your table does there as a, you know, an image and save it for later if you want. So it really it has this great functionality that allows both live presentations, pre recorded presentations, and then a lot of interactivity. Yeah, so again, it was a big learning curve. You know, it really helped me that we had done this once in June. So going into our two day event. Now in the fall, I had a better I didn't have to kind of recreate that whole wheel of just understanding how the online platform works. You Stacey Simms 8:48 know, this conference is so well known, as you said, leadership technology, things come out. And we'll talk about this that, you know, years later come to market. But one of the things that you focused on early on and or even really, before the conference was this survey and discussion of representation. Amy Tenderich 9:06 So yeah, what happened there? It's actually I'm kind of proud of myself and this was prior to the whole, you know, uprising around George Floyd and the big sort of, you know, visibility of the Black Lives Matter movement back in January, I was talking with Cherise Shockley and a few other people and said, You know, I feel like we should have a panel at our event to kind of delve into this I feel like this is a it's sort of something that's a little bit on the margins we talk about every now and then but this is so not solved, but I feel like people of color are really not represented and and Sharif was all over it said absolutely. We need to have this conversation and started recommending people and so I had already spoken to Mila Clark Buckley, who you may know and a few other people reached out to area Lawrence. And then of course, everything kind of exploded and it was like Okay, wow. And so, in our planning sessions, I basically kind of convened this group of advocates of And I said, Listen, you guys, I want to have a session, I think it'd be great to have a live kind of Roundtable. But, you know, what else can we do? Or how do you guys want this to run? What do you think would be meaningful? So what was so cool is that that group actually drove the whole content of it. So they said, Listen, we're happy to come and be on a panel and talk. But you know, we, again, people of color are not a monolith. Right? They can't represent everyone. And they sent me to get more voices involved. So they had the idea, you know, can we do some kind of research? Can we do a survey so we can gather, you know, input from a larger, you know, swath of our community? And they also said, What about a video? What if we got people to, you know, because we had done this before for diabetes mind with our winners, and you're familiar with the Stacey, where we have these people who are patient voices winners, basically applied to have a scholarship. And then if they won, we flew them out to Northern California, and put them up to be part of the event. But in years past, we'd had those winners each do a little snippet, and just them talking about, you know, who they were and what their sort of advocacy soapbox was, was in the area of diabetes, if you will. So the idea was to do something along those lines, where we ask a larger group of advocates of color, to just say a few words about what they do and about their thoughts on you know, being a person of color with diabetes, you know, what's good, what's bad, what would they like to have changed, see change, I said, it's completely up to you guys. So I don't know if you got to see that. But we created this compilation video that started off our session. And it was really impactful, because it was just people saying, their bit, you know, what's disappointed them or why they do the work they do, or what they would like to see change. And it's just what, you know, I can't I talked about this session is sort of unveiling what's been left unsaid for too long. You know, I think that a lot of this was kind of going on behind the scenes. And some of these people of color also told me that in the past, they kind of if they had a negative experience, they would kind of brush it off, they would just say, Oh, it's kind of a one off, it didn't. It's not necessarily racism, it's just, you know, I had a bad experience. But when they start to connect with each other and share these stories, they realize there's a lot of commonalities, you know, of getting brushed aside of being misdiagnosed of sort of not being proactively told about all of the latest, you know, technology options, because maybe a healthcare provider would sort of assume that they weren't going to be the ideal candidate for a pump or a CGM or something cutting edge. So, you know, it seemed that there were some themes. And when we saw this group of advocates, each recruited more people in their community. So we had a team of about 12 people who actually helped craft the survey questions and vet the survey, and then helped us get it out there to the community. So we had about about about 207 people who completed the survey, there's always some people who start and don't complete answers. And I did a whole presentation on sort of summarizing the results, which is also a video that's posted online that we'll be sharing with people. But yeah, it was just so eye opening. So so many of their concerns are similar to anyone with diabetes, right? They're worried about costs and access, and you know, finding a physician who's empathetic and, you know, who treats them as you know, as a partner in their own care, and all those things. I mean, those are things that I would say are across the board for anyone with diabetes or issues. But what also became very clear that they do not feel represented, we got very strong results that people said, both in marketing and in educational materials, they don't feel represented, they need to see more people who look like them. And that's everything from you know, skin. And he says to, you know, just, you know, seeing someone who looks like me, who might actually use that product. Stacey Simms 13:43 Wow, I mean, so much going on there. And I know a lot of people were posting that they were really excited to not only be involved in it, but to see it. And I always hate this question. But what comes next for something like that? Amy Tenderich 13:55 Is the million dollar question. And that's actually one of the things where you feel like you're sort of a victim of your own success because you have an event and people say, this was so great. What else you gonna do? I'm like, What do you mean, I'm still recovering from this. Stacey Simms 14:12 Back to our interview in just a moment, but first Diabetes Connections is brought to you by Dexcom. And when you got a toddler with type one, you do hear rumblings for a long time about the teen years, you know, hit us full force a little bit earlier than most and I'm so glad that we had dexcom Benny's influence started going way up around age 11. He's almost 16. And it has been an absolutely remarkable transformation, I think is really the only word for it. He's so much taller, everything's different. I mean, I need to tell you what puberty does, but along with the hormone swings, I cannot imagine managing diabetes during this time without the Dexcom continuous glucose monitoring system. We've been able to react more quickly to highs and lows, see trends, adjust insulin doses with advice from our endo. I know using the Dexcom G6 has helped improved Benny's a one C and overall health, if your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. To learn more, go to Diabetes connections.com and click on the Dexcom logo. Now back to Amy, where I have asked her what's next. Amy Tenderich 15:19 So I don't know. But you know what the fun thing is, I mean, not only the fun thing, but I think the important thing is to not try to decide that too soon, the world is changing. And these events are always about kind of what is timely and what you know, we try to sort of take the temperature of, you know, what is boiling up hottest in the in the patient community and in the industry. So especially with our D-Data day, with the technology side of it, you know, we try to let the dust settle from the existing event and see where things are going. What are people talking about? Is it suddenly that smart pens are all coming out to market? And people are buzzing about that? Is it some of the latest trials for the closed loop systems? You know, is it sometimes it was like accuracy of, you know, cgms, that became like a big hot button. You know, obviously right now a lot of it's just about affordability and access, it's an always an ongoing issue. But we really try to and again, especially for the day to day I try to check in with the community, you know, I'm a conduit, but I'm not one of the hardcore developers, or the people who work on loop who make these incredible tools. So I always check in with them and say, you know, what is the community buzzing about what else is you know, who's working on something new and cool? How are people feeling about the latest commercial products have come out, or a lot of people you know, chattering about that they have a lot of input, you know, and just try to sort of find out what's happening out there and then address those things. And, you know, really keep it fresh and timely. So that we're really having conversations about the things that are like currently on top of mind, Stacey Simms 16:49 it's so hard to predict, certainly, right, what's going to take off because you always have devices and people at this event that are as you said, so cutting edge and, you know, certainly the DIY crowd is always well represented. So it's hard to figure out what's really going to hit Were there any products or standouts, I saw a non invasive CGM of some kind like a bracelet that was there. I know Dexcom spoke there was the there was a loop link. I mean, was there anything that really struck you or that you want? Amy Tenderich 17:19 Thank you for asking. So the fall event is actually this two day thing where one day is kind of our broader Innovation Summit, it was our first event that we ever did. And then the second day is D-Data where we go really deep on the technology. So that's why this time, the first day, we did a featured panel on telemedicine and like whole person care. That was very cool. That included Vita Health, One Drop, health first, and what’s the fourth person, fourth group that was there. I can actually look it up. But yeah, but we really because obviously telemedicine is now just medicine. Right? Right. Right. You know, it used to be the sort of add on thing that you could do if you wanted to, but you know, now it's really how care is being delivered. And the whole notion of like, Can we get past just focus on glucose numbers and lots of coaching combined with technology. And then they're trying to help people with like a variety of health conditions while doing really high quality diabetes care. So we have this great talk about it. And I'm sorry, January AI was the fourth company and they are this amazing new machine learning based company out of the Stanford area that is actually doing a platform currently for type two diabetes, but I think they will be expanding. And that group also did a demo on day two, the first day again, was kind of this broad look at like what's going on in healthcare and diabetes care, that's when we had our inclusivity and diversity panel, we also had an interactive group problem solving exercise where we got people to we had a little It was kind of like choose your own medical adventure. It was this video of this, like a sort of mock patient and had her talk about her issues that she's facing. And then there were sort of three choices of what you could recommend for this woman to do as sort of her first line of defense with her diabetes care. And then we had people discuss that at their tables and decide and then vote on which one they would pick first. And then we showed what how they played out in real life, you know, and in order of what people chose as the first choice, so we'd have to do some really cool stuff to get put people kind of in the shoes of a health care provider but also in the shoes of the patient as in again, we have a mix of people at these events. So you've got you know, diabetes educators there and endocrinologists and even some like nutritionists and other people who are recommending stuff to patients and then you have patients who are you know, walking the walk and so it was kind of a cool way for them to discuss like, Okay, if you recommend this to this woman, like what are the pros and cons gonna be? How is this gonna play out? That was really fun. I we like to put people in the driver's seat and kind of see what they do. And a lot of this event is about the fact that you might have someone who is like, You know, really big has big following online as a patient advocate sitting next to you know, the CEO of some major pharma company, sitting next to you know, someone from FDA, and then all these DIY folks mixed in. And you know, we've got healthcare designers, and we've got educators and someone who might be the head of the you know, Joslin Diabetes Center. And so they get a chance to kind of interact and great networking, and I think really gives people a lot perspective and helps to break down barriers between these groups. You know, it really does. Stacey Simms 20:31 I was there two years ago, and it was the first time that I was in the same room as somebody from the FDA. And I remember thinking, This is amazing. And it turns out that part of it was my fault. Because as they explained to me, when I asked like, how come I haven't seen you before, you know, basically, you can come to us, and here's how, and I have put that information out, and I will again, but it was it was one of those situations that you know, I've been in the diabetes community for 12 years at that point. And it just hadn't occurred to me that I could have access to somebody like that. And this is a, you know, a public servant, really. And they explained how to do it. And you know, what the deal was, and it was funny to me, because I while I have a podcast, I'm a diabetes mom. Right? So it was a really nice, you know, lowering of by perceived at this as this boundary. And I'm sure that many other people feel that same way. It's It's nearly as you said, it's a lot of interesting people in the same room. Amy Tenderich 21:21 Yeah, thank you. And I mean, that's why I had this little panic attack when we, you know, when they close down all the Yeah, person events, like, how can we recreate that but, you know, as much as it gets old, being on online stuff all day long. It's amazing what you can accomplish, really. And you know, there are some, like I said, Great platforms that are being improved upon. So after we use this platform in June, we actually gave them feedback about what we would like to see. And they've made some progress, like, yes, it's really great. So you're asking about the non invasive cgms and whatnot. So CGM, obviously is this burgeoning area. So our opening speaker for D-Data this time on Friday, November 6, was Kevin Sayer, the CEO of Dexcom, talking about the future of CGM. And clearly, I mean, if anyone's qualified to do that, it's them. They've led the way. But there are dozens of kind of want to be you know, me to CGM companies coming out, they're doing all kinds of stuff from implantable to, you know, non invasive to semi invasive to just straight up Dexcom copies. We did a story diabetes might not long ago, something like 39 new companies working on cgms, you know, yeah, so there are many, many of them. Obviously, the non invasive or minimally invasive feature has been a dream for so many years. And there was this white paper written years ago called the deceitful Turkey, by an expert physician who had been researching it for so long, it's a very difficult thing to crack to be able to get something that is accurate and really usable. That doesn't penetrate the skin at all. But then you've got companies like bio link that are working on like they call minimally invasive with these like micro needles. So it's not drawing blood, but it's sort of like pokes into the skin very minimally. Mike Hoskins and I, who's my main man diabetes, mind, we were just talking about this the other day that it's probably time to do another story to sort of explain where we are with non invasive technology. Because Yeah, nobody's really done it yet successfully. But there are lots of companies that are just on the verge of having something really viable, which is exciting. Unknown Speaker 23:27 I'd read that story. Yes, definitely. Amy Tenderich 23:31 You know, especially now that you know, one of the big hot topics is the idea that CGM is going to become really, truly become standard of care and become more widespread use even among people who are not on intensive insulin regimen. So it's like what is going to help them be comfortable wearing it and get the most out of it. And we had another interactive session on Friday. And that was all about that it was a mock. We had people at their tables pretend that they were like a design group making a new CGM. And they had to pick their priorities for designing the CGM, and talk about why they did that. And were they trying to simplify data learnings for people? Were they trying to make it more motivational to use a CGM? Or were they trying to kind of like increase the consumer appeal and have it you know, have this kind of sexy look and feel. But I think a lot of people agree that especially for non insulin users, you know, the, the physical factor of the sensor is going to be a big deal breaker, right? But Unknown Speaker 24:26 it Yeah, Amy Tenderich 24:27 yeah, there's just so much going on. And you know, it feels like it never changes. But then again, if you look back, it's like, wow, things have really changed so much, even since we started doing this. And well, Stacey Simms 24:38 and that's what I want to ask you about too. We are not waiting. The phrase, as you obviously know was coined at the D-Data exchange. I was at the first one in 2013. Amy Tenderich 24:50 That's correct. So we started doing the Innovation Summit in 2011. So we had two of those events. And then the third year, it became clear that there were Are all these sort of people out there who were tinkering and you know, doing yourself the sort of technology savvy, it started with a group of D dads, basically diabetes dads who work in technology, who were like, Hey, we can do stuff with this. So and we decided that we would host a get together for those folks. And we were doing the summit at Stanford School of Medicine, that we just did it as a pre day to our summit, the day before, we got this sort of classroom, in this bio center directly across from the big hall, and just invited a bunch of people who were happened to be, you know, in or near the Bay Area, who would be able to come and we thought we'd have, you know, 25 people or something. And we were smashed in this classroom with like, 50 plus people, and there was all this excitement, and everybody was like, sharing their, what they're doing. And we kind of realized, like, wow, we're really onto something. And I want to give due credit to Howard Look, and Brandon Arbiter, from Tidepool, who really helped me I, you know, they were just coming on the scene then too. And so we were having all these conversations, and I said, Hey, you know, I really want to do this event, you guys want to help me, like get this group together? So we worked on it together. And what happened is the next day at the summit, I had asked Howard to get up and sort of summarize what happened at this D-Data exchange thing. And he kind of, you know, presented this term, which I believe the first person to utter it was Lane Desborough who is also a diabetes dad, as you know, and then worked at Medtronic for many years, and then was at Bigfoot for a while. But he basically said, what I'm hearing here is that we're not waiting. We're not waiting for the, you know, industry or for the FDA or for anyone to tell us it's okay to do this. We can do it. We're doing it. Yeah. And yeah. And then it's, you know, just as you know, absolutely blossom from there. So, Stacey Simms 26:38 as you look back at that, and it's been seven years, and it seems like as you had said earlier, it seems like things are moving so slowly and things would never change. And now Surely, there's a long way to go, right. It's not perfect. But now we have hybrid closed loops. On the commercial level, we have more DIY stuff, we have DIY stuff that might be going to be FDA soon, thanks to type pool when you look at the last seven years and your own diabetes management. And if you don't mind me asking, what are your thoughts about how far we've come since lane said it, and Howard wrote it on the whiteboard, you know, we are not waiting. It's pretty remarkable to look back at these seven years. Amy Tenderich 27:14 It's absolutely remarkable. And it's stuff that seemed like such a pipe dream at the time, like this whole idea of a closed loop system, it was like kind of eye roll or like, but now we have a very viable Do It Yourself homemade pancreas closed loop system, which I'm using, by the way, I've been looping now for quite a while. And it's a game changer, you know, and now the industry is coming out with them, it's a little slower. And obviously, on the industry side, you know, they have to, you know, there's so much risk averseness they need to be really careful. So they're, you know, have to make incremental changes. But we're getting there, I think soon. Again, you know, the idea of just getting a pump without a CGM, or even a smart insulin pan without something connected to it would just seem silly, because it's like, of course, you want to have the whole deal so that you can both continuously monitor your blood sugar and then also get help or have it automated to decide your dosing your ideal dosing amounts. So we've come a hugely long way. Insulin pens were done back then and talked about connecting them it took, you know, it's only very recently that the pen came out. And that we're really going to be able to actually use pens in a larger system, again, connect them to CGM and whatnot. And the apps obviously, becoming incredibly long way they were pre primitive back in the day. And, you know, I like to say the biggest problem was that so much of the stuff was being designed by people who don't, you know, not only don't have diabetes, but don't have any patient experience at all, it was being designed, it was just engineering driven, or clinically driven. And it wasn't livable, and it didn't solve real world problems for people, any devices or apps that just add more burden, it's not going to be continued to be used. And it makes absolutely no sense. You know, no, no Unknown Speaker 28:56 doubt, Stacey Simms 28:57 if you could look into your crystal ball for us just for the next year. Really, I know a lot of things were held up this year, because of COVID, things that we kind of expected in 2020 might be pushed to 2021. Or further, I won't hold you to it, we're not going to really make a bet on this. But I'd love to get your take on what you're looking forward to in 2021. Amy Tenderich 29:16 Oh, thank you so much. So we were privileged to be able to host the first ever closed loop system showcase at our fall event last year. So the end of 2019, we had six of the companies that are like getting closest to having or already have a system out. And it was just amazing. You know, they came and they talked about the details of their algorithm and you know, how they, what the targets are set out and whether the settings are customizable. And then we had patients there who had used the systems either in the real world or in studies. And I just think that there's going to be so much continued improvement on these systems. One very encouraging thing is that the studies are no longer being done in some kind of clinical environment or they are doing real world studies where they literally go out Follow people while they actually go out and do sports and eat food and do things that real people do, you know, so I think it's hugely important for kind of the form factor and just to understand how they can improve on the kind of day to day living experience with these systems. So I'm super excited about that. I do think also that insulin pens, again, gone from just being another sort of thing that you use to stick the insulin in your skin to an actual tool that can help people figure out their dosing and help people keep track of their, you know, their whole diabetes management, regime, and, you know, be connected to, you know, your stream of glucose data, which helps you understand what's happening. So, you know, all of this stuff is just getting so much more real world usable. And I think that's really going to be kind of the linchpin going forward. And it's already hard now for family for people who are newly diagnosed now, to even understand how good they have it. Compared to what it was, like, you know, even when I was diagnosed in 2003, I mean, it was a world away. I mean, right? Stacey Simms 31:06 What is the next event for DiabetesMine, I know, things are up in the air with COVID. Amy Tenderich 31:11 You know, so our, you know, traditional pattern has been that we do the D-Data exchange twice a year, so, so again, traditionally, pre COVID, it was in June, on the Friday before the big at a conference, wherever that happens to be. So we've done it in New Orleans, in San Diego, and Boston, Orlando, all the places, right. And then in fall, we would do this two day event, which was always in Northern California, it was at Stanford School of Medicine for years. It's also been at UCSF School of Medicine for the last couple years. And that was the called the Innovation Summit day, which was kind of this broader look. So it didn't only have to be technology, it could be anything that was innovative, whether that's a community program, or whether we were talking about innovations in like coverage, or community events, whatever, and just a variety of different things about improving care. And then the D-Data exchange day, which was always the deep dive into technology. And that event kind of has a pattern to it. At least we've always done it so that we have a featured DIY talk. So we try to always get some interesting speaker from the DIY community to come and talk about something that they're working on. That's cutting edge and new. And whether it be about the community itself for about a particular tool, that we traditionally had FDA come and speak because it's like, let's hear from them. They're so important in all of this. And then we have this lineup of demos that we always do kind of cutting edge stuff. And that's been everything from as you mentioned, new CGM systems to like apps that motivate teenagers to I mean, we've in the past, we've even had some I don't know things for diabetes complications, like socks that can monitor your feet for neuropathy. But right now, it's it's been also a lot of AI, you know, machine learning driven platforms that are trying to help people better calculate their insulin doses are better predict what's going to happen when they eat certain things, or do certain activities, different ways to be able to kind of glean meaning out of your data. Generally, we do June and then we do like early November, it kind of dawned on me that if if Ada does not go back in person, this coming June, which they may not, then we don't necessarily need to be tied to that date anymore. I mean, the the idea originally was, you know, everyone's in town. And it started that very first year that we did the bigger D-Data it was ADA was in San Francisco, which is my hometown. So we're like, oh, everyone's gonna be here. So we'll just do this kind of afternoon thing before and get everyone together. And that's worked really well. Because physically, people are, you know, in from all over the world. But right now, everything's kind of footloose. Because of COVID. Stacey Simms 33:44 well, thank you so much for coming on. And talking about all this and sharing these stories and for doing the conference and putting it all out there. And we'll link up as much as we can. If anybody missed it and wants to read all this stuff. It was really well covered on Twitter, I was following along the hashtag when I couldn't be there. And we'll get the word out. But he thank you so much for joining me. Amy Tenderich 34:02 My pleasure. Thank you so much. And thank you for being part of it. And I hope you will join us again sometime. Unknown Speaker 34:07 You got it. Unknown Speaker 34:13 You're listening to diabetes connections with Stacey Sims. Stacey Simms 34:19 More information about DiabetesMine the D-Data exchange. And that video we mentioned near the top of the interview the video about representation what people had to say, it's only five minutes, it's well worth your time. I'm gonna put it in the Facebook group and I will also link it up here in the show notes. Really interesting people definitely worth watching and worth possibly a follow if you're on Instagram or social media as well check them out. And I love talking to Amy because we always learn something new and see what new technology is coming. So of course more to come in the new year. Boy, I feel like there's a lot coming in 2021 that we've been waiting for. So I don't wanna get too off track or into the future but I'm excited and I'm Hoping to do an episode or two about a summary of what's coming. And I should also let you know I've also got interviews lined up with some of the people that are releasing really cool stuff coming up. We've got a lot to look forward to when it comes to technology in the new here, okay, tell me something good in just a moment. And it's an embarrassing personal story, but I will share because we're friends here, but first diabetes Connections is brought to you by Gvoke HypoPen, and you know, almost everyone who takes insulin has experienced a low blood sugar, and that can be scary. A very low blood sugar. It's really scary. And that's where Gvoke HypoPen comes in. It's the first auto injector to treat very low blood sugar Gvoke HypoPen is pre mixed and ready to go with no visible needle. That means it's easy to use in usability studies 99% of people were able to give Gvoke correctly. I'm so glad to have something new. Find out more go to Diabetes connections.com and click on the Gvoke logo. Gvoke shouldn't be used in patients with pheochromocytoma or insulinoma. Visit Gvoke glucagon comm slash risk. Tell me something good. This week is about my family. We are celebrating a diaversary my son was diagnosed with type one, as I always say right before he turned two back in 2006. Which means as hard as it is for me to believe we are marking 14 years and that kid is going to be 16 pretty soon. So the story I want to tell you here for Tell me something good. And if you're a new listener, he is doing great. Maybe that's the good news story I should start off with he is happy he is healthy is independent. He drives me bonkers. I want him to do more in his care. I want him to change his sites on the spot every three days and pre bowl is 15 minutes. Every time he eats. He doesn't do that. But you know what he does so much. He's super responsible, as far as I'm concerned. And he is almost 16. So for where he is, and what I was told could happen during the teen years. I really keep my fingers crossed, I knock wood I'll swing a dead chicken if you make me. I mean, I really feel like we have a lot to be thankful for. So having said that, this is a story about how we did everything wrong. 14 years ago, let me set the table. When Benny was diagnosed, I have a daughter. She is three years older than him. So she was just five. their birthdays fall in such a way that she just turned five he was not yet to. And my brother in law. My husband's brother was living with us. It was a temporary situation. He was with us I want to say for about, I don't know, a year, year and a half. He was between jobs. We had two little kids. We both worked full time. He asked you know Hey, can I come stay with you for a little bit while I get things settled? And we said please come down and be like a nanny. We can't have you here fast enough. And it was amazing situation. It really was uncle David was just a godsend, great guy and, you know, left us and went back to a full time job and a great life and relationship in a situation where he now lives too far away. If you're listening, David, he's up in Pennsylvania. But he was there when Benny was diagnosed, which made our lives kind of easier. He had another caretaker in the house when Slade and I took Benny right to the hospital on that Saturday morning. That first weekend in December December 2 I always have to look at the date December 2 2006. David stayed home with Lea until we were ready to trade off and have her come visit and that kind of stuff. And we all learned how to do things together. So we came home Three days later, we tried to go back with our lives. Haha, you know, we were all kind of in the thick of things. And that Saturday night, the following week, Slade and I had tickets to go see a show, you know, I'm a big Broadway fan, love that kind of stuff. And David said you should go I've got this. I know just as much as you guys do. And he really did. I'll watch the kids go and your phone call away. So the theater in Charlotte, you know, we have one of these regional theaters where the Broadway shows come traveling through. It's about 30 minutes from us. Yeah, you really put the pedal to the metal 25 but 30 to 35 minutes. So we thought okay, this is good. We're all our doctor says go on with your lives. We're going to go on with our lives. David's got this. The show was Spamalot. By the way. It was you know, very funny musical comedy. And we decided to go and enjoy ourselves. We got dressed up. We went not 20 minutes into the show, maybe 30 minutes of the show Slade's phone starts buzzing, and he gets up and leaves if you are familiar with the show, this is just after he is not dead yet. And the lady of the lakes. So I'm sitting there watching this very funny show, being amused being entertained. But my husband is no longer sitting next to me and I know something's up right. If he had come right back, it might have been something easy just to question, but he's not back. I think I made it about halfway through the song that goes like this. I remember seeing that which is the song that really just goes on and on. When that ended, because I wasn't gonna run out of the theater when someone was singing people applauded and I booked it out into the lobby. And Slade was on the phone, pacing and talking and pacing and talking. Here's what had happened. David had given Benny an injection for dinner or snack, I don't even know whatever it was it gave me an injection. And remember, at this time, we're using a syringe and we're drawing up teeny, teeny tiny doses. He's getting like point two, five, maybe for 20 carbs, I think I mean, who remembers these doses, but they were minuscule. They didn't have half unit pens at the time. And they certainly didn't have quarter unit syringes. I don't think they have that. Anything like that now. So unless you're using diluted insulin, which nobody had mentioned to me during his whole toddlerhood, you know, you're really guessing at the dosage, and you're trying to eyeball these teeny, tiny poufs and wisps of insulin. So David had tried to draw up like half a unit, I don't remember the exact dose he was supposed to give was, but he gave him two full units, which was bigger than anything we had given before. It makes me laugh now because to like, it's like a speck of dust for him now, but two units when you Wait, 27 pounds is a huge deal. So what David and Slade had already done while I was sitting there watching people singing, they had already called the endocrinologist. And they had actually already gotten a call back. And that's what the phone call and the pacing, that's what was going on. When I had walked out, he was on the phone with the doctor. And of course, they advised check the blood sugar, give more carbs if needed. You know, nobody was panicking. So we didn't panic. His blood sugar was fine. David had checked it before he called he checked it after the endocrinologist called back, he was fine. It gets a little weird, because the dose had been given Well, before the phone call. It was one of those situations where David did it. And then A while later thought, did I really do that? He absolutely swears that he gave the kid two units. But two hours later, his blood sugar hadn't dropped. So my suspicion at the time was you didn't give him two units, you probably drew it up and just misread the syringe, which was very easy to do at the time, especially when you're distracted by a toddler and a five year old or the child didn't go all the way in, or something really weird happened because his blood sugar stayed steady. You know, we were checking with a meter. We did have a dexcom at the time. But he was checking him every half an hour. We left the theater, we went home. We didn't want him to have to handle this by himself. And how are we going to enjoy Spamalot, right? Stacey Simms 41:54 We're worried about Benny. We're now home, probably close to three hours after the dose is given. His blood sugar was steady. We called the endocrinologist back and they said look, it's three hours pass the dose. If he hasn't dropped, he's not going to drop you guys are okay. So we being the terrible parents that we are looked at each other and said, you know, our friend was having a holiday party that we couldn't go to because we had tickets to Spamalot. David, do you mind if we go to the party now? I swear we did. We left we went to my friend's party. And my friend is only 10, 15 minutes away from my house. And it was what 10 o'clock at night already. So we only went out for about an hour and a half. But yes, I left my sleeping baby and he never woke up. And he never even woke up with all those pokes all those finger sticks to check his blood sugar, which I'm sure David did 10 more times before midnight, he slept through the whole thing. We were all worried but not worried enough not to go to that party. Ah, I am the worst. We have always been the worst. But you know what he was safe. And our endocrinologist gave us the correct information told us what to look for helped us through it. And there was no sense as we saw it, not going to the party. So I know I'm a terrible parent. That's why I always say I'm the world's worst diabetes Mom, I still have not seen Spamalot all the way through. So maybe when it comes back through shark, I'll go back and make it through the first half of the first act. Oh my goodness. And hey, anybody dealing with a toddler or baby with type one, and those teeny tiny doses, I salute you. It's not easy. Getting an insulin pump makes it a little bit easier. But anything under the age of five is a circus of you know, type one is never easy no matter what age you are. But we're heading into 16 year old with it. And that means driving, which is an adventure for another time. Before I let you go quick reminder friends for life is this weekend, the virtual conference. And if you were able to attend in July, you know that did an amazing job. If you were there, the one thing I will say that surprised me in a very good way was how much just schmoozing. We were able to do. They had specific zoom rooms for different ages, you know, parents and teens and young adults with type one, it was great. And I really wish I had put aside more time in July to attend the conference. Because I didn't really understand how much just hanging out and socializing we'd be able to do. So I'm putting more time aside to attend this one. And I hope you can check it out as well again, link in the show notes. Hey, in the weeks to come, we're gonna have a couple of more episodes in December probably take one off the week of Christmas, even though I celebrate Hanukkah, but you know, we go with the flow. And I also want to just point out that this time of year, there are often a lot of approvals. It just seems like that last week in December, there's usually a lot of news. So stay tuned. I know a lot of delays happened because of COVID. So, you know, I'm not even sure what's been submitted to the FDA that was planned for this year. A lot of delays that way, but we will definitely be talking about it. Make sure you follow on social media for the latest and greatest. And thank you as always to my editor John Bukenas from audio editing solutions. Thank you so much as you listen and if you've listened this long, I really appreciate it got a little chatty this week with that story about Benny and Uncle Dave. But But I appreciate you listening. I'm Stacey Simms. I'll see you back here next week until then, be kind to yourself. Unknown Speaker 45:10 Diabetes Connections is a production of Stacey Simms media, all rights reserved. All wrongs avenged.

covid-19 christmas god ceo community world ai san francisco data medicine pennsylvania mom black lives matter iphone san diego new orleans turkey george floyd broadway diy app stanford npr boy roundtable connections fda bay area diabetes audible bigfoot exchange northern california hoping generally hanukkah homemade insulin announcers slade buzzing medtronic do it yourself sharif cgm stanford school one drop spamalot g6 dexcom innovation summit uncle dave ucsf school unknown speaker innovation day tidepools joslin diabetes center stacey simms diabetes connections dexcom g6 john bukenas kevin sayer wearenotwaiting mike hoskins diabetesmine amy tenderich cherise shockley

36. Why the Affordable Care Act Did Not Make Insurance More Affordable with Jim Vollmer

Stay Young America!

Play Episode Listen Later Oct 28, 2020 36:03

Title: Why the Affordable Care Act Did Not Make Insurance More Affordable Guest: Jim Vollmer, MHA, GBA & Employer Benefit Solutions President On March 23, 2010, the signing of the Affordable Care Act (often referred to as ACA or Obamacare) rules were established for employers and insurance carriers. Why is it that those rules did everything BUT make insurance more affordable? To answer that 1question, we’ve asked Jim Vollmer the President of Employer Benefit Solutions to come in the studio and walk us through this. 1:00 Jim- What attracted you to work in insurance? 1:50 Jim- How has insurance changed over the past 18 years ago? 2:20 From a doctors perspective, how has practicing medicine under insurance changed over the past 20 years. 5:17 Quality of care- not boxes being checked, but decisions by the providers 8:00 Socialized Medicine, what it was like for Dr. Gaman to practice medicine in Canada 12:25 Preventative care is included in insurance plans, people not using them 13:15 Affordable Care Act- originated to help people with insurance, but it's not very affordable unless partially subsidized by government 14:55 Insurance companies making record profits, why do rates continue to go up? 15:55 Shut down of economy caused utilization of insurance to go down, so for over 50 employees- rates not rising 17:47 Unwrapping the Affordable Care Act 21:53 High risk pools 23:30 Guaranteed Coverage 25:53 Price increases correlate with government coverage mandates 27:23 What should insurance actually cover? Groceries, massages, etc? 31:11 Insurance companies making large, over-projected profits- should they divide excess and rebate it back? 33:00 “Executive Medicine Moment” At Executive Medicine of Texas we understand that true health can only be found when you treat the patient as a whole. That’s why our Executive Physical Exams are second to none in the amount of testing and information we gather prior to making a wellness plan for our patients. Learn more about how you can take charge of your health at http://www.EMTexas.com 33:47 “Pressing Health”- Health news that’s fresh off the press. We’ve talked before about the differences between brown fat and white fat, but as a refresher, brown fat burns calories and helps fight obesity. The problem is that brown fat is no longer in abundance as we age. But thanks to some genetic modification of white fat, through CRISPR, researchers at the Joslin Diabetes Center have found that potentially transplanting these fat cells, patients may be able to reverse diabetes. The cells (human brown-like) fat cells have been given the acronym, HUMBLE. Mice given the HUMBLE transplants displayed much greater sensitivity to insulin and ability to clear glucose from the blood, the two things that type two diabetics have trouble doing. The pre-clinical trials are promising, so this is the research to watch! https://www.sciencedaily.com/releases/2020/08/200826141413.htm Find out more about Jim: https://ebslp.com/about-us/ Website: StayYoungAmerica.com Twitter: @StayYoungPod Facebook: @Stay Young America!

Episode 5 with Maria Buckley

Around the In-house

Play Episode Listen Later Oct 1, 2020 21:25

This episode Alex Aferiat speaks with Maria Buckley, General Counsel, Joslin Diabetes Center. Maria is alumni of Boston University and received her JD from Suffolk Law School. Maria joined Joslin as their GC in September 2012 after a long and successful career at the Boston law firm of Nutter McClennen & Fish LLP where she was part of the Healthcare and Life Sciences practice groups. Prior to Nutter, Maria was Senior Counsel at Blue Cross Blue Shield of Massachusetts. She is also the author of several publications on health law and life sciences. She was named the 2015 Leader in the Law from Mass Lawyers Weekly. Alex discusses with Maria her path to GC, how COVID-19 impacted her organization and herself as a GC and her specific passions and causes she supports.

covid-19 law leader healthcare massachusetts jd boston university general counsel life sciences buckley gc blue cross blue shield senior counsel nutter joslin joslin diabetes center suffolk law school nutter mcclennen

"We Treat the Data" - DreaMed Diabetes Wants To Help Lift The Burden

Diabetes Connections with Stacey Simms Type 1 Diabetes

Play Episode Listen Later Sep 29, 2020 46:52

There's new help for doctors who want to treat the person with diabetes and not feel overwhelmed with data. The people at DreaMed Diabetes are behind the brains of the Medtronic 780G system, but they're hoping to help thousands of people who may never use an insulin pump by making diabetes data a lot easier for doctors to use. This week, CEO and Founder Eran Atlas explains their Advisor Pro system to Stacey. Study in Nature Medicine about DreaMed Diabetes Join the Diabetes Connections Facebook Group! In TMSG a big award for a doctor you all may know better as an Amazing Racer and I learn the word Soccerista. Read about Emerson in her own words here In Innovations – women and diabetes tech design. Read the DiabetesMine Article here Sign up for our newsletter here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Check out Stacey's new book: The World's Worst Diabetes Mom! ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone Click here for Android Episode Transcription (beta transcription - computer only) Stacey Simms 0:00 Diabetes Connections is brought to you by One Drop created for people with diabetes by people who have diabetes by Gvoke. hypopen, the first premix autoinjector for very low blood sugar, and by Dexcom take control of your diabetes and live life to the fullest with Dexcom. Announcer 0:23 This is Diabetes Connections with Stacey Simms. Stacey Simms 0:28 This week, there is so much data when it comes to diabetes that even your doctor would like an easier way to interpret numbers and make dosing recommendations. A new first of its kind technology called DreaMed may help Eran Atlas 0:43 with the use of your system. I can stop being a technician I can learn to being a mathematical or an engineer, I learned how to be a physician and I wanted to continue to go and practice medicine. I don't want to go and practice engineering. Stacey Simms 0:55 That's DreaMed co founder and CEO Eran Atlas, talking about the reaction he's getting from people who use their system will explain what it's all about and how it could help in Tell me something good. A big award for a doctor you all may know better as an amazing racer, and I learned the word soccerista. innovations. Let's talk about women and diabetes tech design. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of Diabetes Connections. I'm so glad to have you along. I'm your host, Stacey Simms, we aim to educate and inspire about type 1 diabetes by sharing stories of connection, as well as stories of technology. And that's what I'm talking about this week. And I went into this episode, I gotta tell you sort of thinking it would be one thing, because I know many of you are very familiar with the technology and these companies. DreaMed is behind the algorithm that's inside the Medtronic 780 G, which was just approved in the US. And we actually are talking to Medtronic and our very next episode about that many other things. But the agreement with Medtronic and DreaMed was it was done several years ago. And DreaMed while I'm sure very proud of that algorithm, they've moved forward, they moved on they want to talk about something else. It was very interesting for me to go through this interview, and I hope you enjoy it as well, for more of the mundane, less technology and more basic, how much more basic can you get with diabetes and insulin? I'll give a quick update at the very end of the show. I had mentioned in a previous show, we had some insurance changes, a bunch of you wants to know how that was going. Hey, yay, insurance changes are always fun. So I will talk more in detail about that at the end of the show. But in terms of insulin, yeah, we're switching types. Don't you love that? We had been on novolog for many years. And then when Benny was I want to say about eight or nine. We switched insurance and they switched us to human log and we have been on that ever since he's 15 and I guess it's time to go back to no vlog. So I'll talk more about that at the end of the show. Luckily, we don't have any issues or haven't had so far I know a lot of people do. Fingers crossed. So yeah, insurance update and more at the end of the show. All right. Interview with the CEO of DreaMed in just a moment. But first diabetes Connections is brought to you by One Drop. One Drop is diabetes management for the 21st century. One Drop was designed by people with diabetes for people with diabetes. One Drops glucose meter looks nothing like a medical device you've seen this. It is sleek, compact, seamlessly integrates with the award winning One Drop mobile app, sync all your other health apps to One Drop to keep track of the big picture and easily see health trends. And with a One Drop subscription, you get unlimited test strips and lancets delivered right to your door. Every One Drop plan also includes access to your own certified diabetes coach have questions but don't feel like waiting for your next doctor visit your personal coach is always there to help go to Diabetes connections.com and click on the One Drop logo to learn more. My guest this week is the co founder and CEO of DreaMed and is really company with the slogan we treat the data you treat the person Eran Atlas talked to me about everything from their partnership with Medtronic. As I said they develop the algorithm that's inside the newly approved 780 G to their newer technology. And this is all about helping doctors better interpret the data they're getting from CGM and pumps. He mentioned a brand new study on this, comparing their algorithm very favorably to outcomes from Yale and Barbara Davis diabetes centers. And I will link that up in the show notes at Diabetes connections.com. I learned a lot from this conversation. I really hope you enjoy it as well. Here's my talk with Eran Atlas of DreaMed. Eran, thank you so much for joining me. I'm excited to learn more about this. Thanks for coming on. Eran Atlas 4:49 Thank you very much for having me. Stacey Simms 4:50 All right. Tell me just generally, what is DreaMed What does this mean for the diabetes community? Eran Atlas 4:56 Well, you know, for a certain amount of years A lot of effort has been invested on, let's get more accurate glucose measurements, let's get more continuous glucose measurements, let's get those glucose measurements and insulin measurements being connected. And everybody told us that if we will have more data, more accurate data, more accessible data, all the problems about managing people with diabetes will be solved, right, because the patient will be more knowledgeable, the providers will be more knowledgeable, will have the tools to get into a better decision. Now DreaMed started as a technology team within one of the biggest Institute's that treat people with diabetes, Type One Diabetes here in Israel. And what we saw there is that data is not all and and sometimes in order to make this analogy, these logic thinking between data and decisions, there is a lot of gap that you need to jump in order to make that move. You need to be experience, you need to know what is important, what's not important, and you need to be able to make the right decision in the right time for the right patient. So what dreamed is taking on is we would like to take the responsibility of allowing providers and patients to make better decisions about insulin dosing. When we started in 2007, the Holy Grail was okay, let's try to develop these automated insulin delivery algorithm that will make these decisions in real time. And we managed to do a prototype and we published these results as were the first publication in New England Journal of Medicine. And finally, after didn't several clinical trials send people home, we were the first group in the world that sent people home with automated insulin delivery, we licensed that to Medtronic diabetes. But the cohort of people that are going to be using are currently being using automated insulin deliveries pretty small depend on the amount of people with diabetes type one type two that needs to make decisions about insulin. So what dreamed is now focusing is on developing those and commercializing those algorithms that will be able to take all the vast amount of data that's out there, and it can be accessible from cloud to cloud, mobile and everything. And how do we get into the most accurate, personalized decision about how much insulin a specific person with diabetes need to infuse? Not just in terms of real time, but more about looking on the treatment plan? How to optimize carb ratios? How to optimize basal treatment, how to optimize insulin sensitivity factor? What is the difference between a patient on an insulin pump to a patient that is using multiple daily injections based on only different kinds of types of injection regimen? That's what DreaMed right now to do. So we would like to make sure that we will treat the data. So a person with diabetes can continue to live in a provider can start dealing with the person that is in front of them and not just looking into the computer, making himself a technician with numbers and decide what to do. Stacey Simms 8:04 you have heard the podcast. So you know, I'm easily overwhelmed by data and information. I listened to everything you said. And here and I'm trying and here's what I heard. We want to make life easier for you. There's too much information that comes your way even with accurate CGM. Even with automated insulin delivery, there's so much data and information that unless you are a numbers person, you know, you may not be able to crunch it yourself. And I know you, you mentioned already a lot more down the road. But if I could focus on that the automated insulin for just a moment and come back to some of the other things. Can you just tell me as I'm listening and please correct me if I'm wrong, Vinnie, my son is using control IQ with the algorithm that's inside the Tandem pump using partnering with Dexcom. Is this sort of that? Is that the first step that you're talking about when you talked about automated insulin? Is it the algorithm that controls the pump in the CGM together? Eran Atlas 8:56 Correct. We started in 2007. Building such an algorithm at the time we called him the medical doctor, the MD logic artificial pancreas. And the idea of what is different between the algorithm that we developed back then and the one that you have right now in control IQ, is how do you make these real time decision about how much insulin to infuse and, and while control IQ, as you may know, is using MPC technique, a Model Predictive Control, and you have that model of Medtronic that uses a different kind of type of control. It's coming from the engineering world, we were strong in understanding how physician analyze data and what we did is we took a technology called fuzzy logic, and I thought you know what fuzzy logic is but I'm sure you have it in your washing machine, and you have it in trains in China and everything. And the idea behind fuzzy logic is that you know why the world is not one and zero black and why there has to be a mathematical way to make decisions based on gray areas. And it's pretty much the way that we're thinking as a person. So, we took his the way that physicians analyze data, make a decision and automated using dispatches fuzzy logic. And we develop these automated insulin delivery algorithm. And we tested it and when he got the the ability to communicate with Medtronic pumps, and now, we have our some part of our algorithm is going is inside the Medtronic 780G that they announced that they got to see mark for that in June DC or in there, I'm sure that they're going after that the FDA, the main difference between what we did and what happened in control IQ and Medtronic 670 G, is the fact that we were the first that play with the changing automatically both the basal and bolus. And we have the ability to predict glucose into the future and dose insulin based on the predicted glucose. Some of the elements that we have, you have also in control IQ. And I noticed Ctrl Q is working pretty well. But one of the things that we had in that time is the understanding that there's a lot of sensitivities off the patient that these AI D algorithm will need to use. So for example, when you are using your control IQ, you still need to go through your meals, right? So you need to optimize your carb ratios. And some of the safety limits are still dependent upon the insulin sensitivity factor off the pump or the open loop basal rate of the pump. So the algorithm is like riding on that basal rate. So we had a similar methodology. And we developed these what we call today, the DreaMed Advisor. It's that algorithm that optimize the sensitivity factors. So I back into the time we have two pieces of our technology. We only licensed one of it to Medtronic. And we continue to develop the other one because we believe that the other one will have a much more larger number of people with diabetes. Stacey Simms 12:01 So tell me about that other one, where will it be used? Or you're talking about people with type two or people who use insulin, any type? Eran Atlas 12:08 So that's an interesting question. So we just we started with an algorithm that basically optimize open loop pump therapy, and we took data from CGM at the beginning. And history of pump delivery basically did an automated way what any physician is doing in the clinic right now. And we developed that technology we got we won a grant from Helmsley Charitable Trust back then in 2015. I out of 70 applicant applicants got $3.5 million to evaluate the performance of this algorithm versus doctors from Joslin Diabetes Center, the School of Medicine yell, Barbara Davis in Colorado University of Florida, within three sites in Europe, with the intention to show that if you are a physician, any kind of type of physician that uses all algorithm, you'll get into the same clinical outcome as if that patient data was analyzed by doctors from these leading academic diabetes centers. And yesterday, the results of the study were published in Nature medicine, showing that we are doing the same outcome. As expert Doc's. If you can think about it, 60% of the cohort, we type 1 diabetes, the adults one are being treated by primary cares where we can do to the to the glucose control of these patients, if we will equip those primary cares with a technology that helps them analyze data and get the same performance as special endocrinologist, what we can do to the touchpoint of changing the insulin treatment of a patient, if instead of the patient will need to wait 3, 4, 6, 8 months to see his endo will have some sort of virtual place that he can send the data and share the data with the algorithm the algorithm will make all the calculation and recommend how to change the insulin dosage or the insulin treatment plan of that patient. So that was the what we did so far. And when we approach FDA, we that FDA didn't know how to regulate such a device. Yeah, because there was no predicate to what we offer to FDA to do. So what we managed to do with a very strong partnership with the FDA team is to decide and we will regulate this device as a new product. So in 2018, we got FDA clearance based on 510 k de novo. So we are the first in the US system that regulated a product that an algorithm can take continuous glucose sensor data and make recommendations to our healthcare providers how to optimize insulin treatment for our patients. Stacey Simms 14:44 So I'm trying to break it down because that does sound like such a useful tool. I'm an adult with type one, I'm seeing a general practitioner who may not know the nuances of treatment, they take my CGM data, they take my dosing data either I'm assuming either from a pump or from me They send it to your service, the care provider, the doctor then gets the data back and can give the patient advice based on your technology using the expertise and you know, from the algorithm. And that new study said that advice is comparable to Yale and Barbara Davis and all the places that you indicated. Did I get that right? Unknown Speaker 15:21 Exactly. Stacey Simms 15:28 Right back to Eran in just a moment. And he's going to be explaining their agreements with other diabetes groups like Glooko, like Tidepool, but first diabetes Connections is brought to you by Dexcom. And do you know about Dexcom clarity, it's their diabetes management software. And for a long time, I just thought it was something our endo used, you can use it on both a desktop or as an app on your phone. It's an easy way to keep track of the big picture. I try to check it about once a week, it really helps Benny and me dial back and see longer term trends, and help us not to overreact to what happened for just one day or even just one hour. The overlay reports help add context to Benny's glucose levels and patterns. You can even share the reports with your care team, which makes appointments a lot more productive. managing diabetes is not easy, but I feel like we have one of the very best CGM systems working for us Find out more at Diabetes connections.com and click on the Dexcom logo. Now back to my interview with Eran Atlas Eran Atlas 16:27 And the way that it has been flowing in so we sign a data partnership with gluco. With Dexcom, we take all we have our own platform, so the patient can download the data at home, he doesn't have to get physically to see the provider, which is super important, especially now when it COVID-19 is and then the data is coming to our system, all the provider needs to do is just push a button request the recommendation here we'll get that recommendation and nothing's going to get you know, blurred the things you know, please consider looking on. He will get exact numbers that the algorithm will tell them listen at 6am change the call ratio, that specific patient from one to 15 to one to 10 exact numbers. Stacey Simms 17:11 All right, I have two questions. From a very practical point of view. I'm curious if you've run into a provider who says I can do this better? I don't need this. Sure. I don't know the difference between Lantus and Tresiba. I'm a general practitioner. But why do I need something like this? Have you run into resistance from providers? Or are they I could see the flip side, thank goodness for taking this off my hands because I don't have the time to learn all of this. Eran Atlas 17:37 So there are two types of providers. So first of all, that the approval that we have right now the clearance that we have with FDA is just for type one people on insulin pump, we are pursuing the advance of the indication for use for the injection cohort and with the intention to submit it by the end of the year. But in the study that we did, and right now we are we already deployed the system in several clinics around the US. You know, we are in Stanford University, University of Florida, New York University, Texas Children's so that we are already people who have already more than 1000 people that use the technology. And so when we heard for them, these couple of things. So number one, it became they curious, they want to check, we want to make sure that we didn't make any false recommendations. And they're not agreeing 100% with anything that we are recommending. So we always allow them to edit. If there's anything that they would like to edit, they can edit it before they share it with a patient. But as time goes on, and they building their confidence with a system, they are relying on the system, and they're really feeling how they've helped them. So for example, Dr. Greg Forlenza from Barbara Davis said, you know, what would you use of your system, I can stop being a technician, I can learn to be a mathematical or an engineer, I learned how to be a physician. And I wanted to continue to go and practice medicine, I don't want to go and practice engineering. So this is one of the feedbacks. And I think that when we'll code to the mass numbers of providers, there will be different kind of providers, some of them will be resistance, but I think that one thing we'll see the clinical benefit and the response of their patients, I think that it will endorse that and it will build our confidence with it. Stacey Simms 19:17 I love that that he doesn't want to be an engineer, he wants to be a physician. We should all be so lucky to have a doctor who wants to do that. My other question on this and I'm apologizing just throw things at you to mess up the system. But the first thing I thought of was somebody like my son who's a not an unbiased person, but he's a great kid. He is not a perfect diabetes person. Perfect example that I think would mess up your algorithm. This morning. He had I don't even know coffee, hot chocolate glass of juice. I don't know what he had. But he had something as he's going to virtual school to. He's he's right down the hall for me so I could go ask him, but I can see that his blood sugar has already gone up to 140 it'll drift back down thanks to control IQ. I don't know if he bolus for that drink. If or If people just after, what is the algorithm do when people aren't, quote, perfect diabetics, because you can adjust the carb ratio and the basal rate all you want, but most people with type one aren't automatons who are going to fit an algorithm? Eran Atlas 20:14 Oh, that's an excellent question. I think that at the end, if you are creating something for the use of people, you have to understand that nobody's perfect. And you have to make sure that the recommendation that you are providing will be a right on the spot, because otherwise it will cause safety issues. So what we are doing, when we're taking the data, number one that we are doing, we are trying to split that data into events, and understand, okay, that's a meal event, that's a bonus event, that is events that usually debatable could make an influence because there's no BOCES a meal. Before afterwards, we also apply different kinds of techniques to automatically detect places where the patient ate, and the bowls for that, or didn't report the name use these calculator in order to calculate the amount of light and and then for each one of the events, we are trying to ask the algorithm is asking himself Okay, is it a issue of dosing problem? Or is it an issue of behavioral problem? Do we see the high glucose posted meal because the carb ratio is wrong, or because the patient just deliveries, bolus 1520 minutes after the meal, and there's no way that the glucose could be down? So we are from our experience, because we are so much integrated with doctors that understand data. And because you know, I'm here, ces 2007 is closing my 14th. year on February, we know so much about people with diabetes, how they behave. So we programmed the algorithm in that way. So the recommendation that we are delivering is on the spot. If we're saying that we don't have enough events that imply on changing and dozing will not issue that we can personalize even the behavioral messages and calculate what is the most important behavioral that will improve the timing range. And we're not issuing 20 types of behavioral messages. Learn to be have a message note, we're issuing no more than three. And we're very specific. So if we're seeing something that happened specifically on the breakfast of Benny world, tell him listen, Benny, please pay attention on breakfast, deliver the insulin, 10 minutes before the meal, because that's what's set what makes your entire day being hot. Or if we're seeing that when he has an iPhone, you just eat whatever he finds in the refrigerator. And we see it from from the dynamics, we're trying to teach him how to compensate for a high pole in a better way. Stacey Simms 22:46 It's absolutely fascinating. I think that's tremendous that you're building in the behavior as well. And you can really account for it back to the automated systems. And forgive me, Eran, you used a term open loop rather than closed loop and pardon my ignorance, you explain what that is? Eran Atlas 23:02 Sure. So open loop is what we call using pump therapy with CGM or with self management blood glucose meters without any ID system. So though some people call it sensor augmented pump therapy, some people say just a regular insulin pump therapy. Some people say it's open loop, there is no algorithm that closed the loop in real time and command in real time how much insulin to infuse on an insulin pump based on CGM data. Stacey Simms 23:33 Okay, if we go back to the algorithm that is more closed loop and kind of looking ahead for what you're planning on that we've already talked about mealtime, boluses, and how challenging they are for people, whether it's estimating correctly or remembering to do them or doing them late. What's your plan for that? I know there were a few AI systems that are looking to try to do away with a manual mealtime bolus is that in the cards here. Eran Atlas 23:56 So for us is not on the cards at a moment. I think that what we are trying to look is is beyond the AIP system. It is how to help those with type two on insulin, how to have those on injections because think about it a couple of years ago, nobody knew what's going on with people that still doing injections, right? None of them knew CGM you didn't know what's going on with injections because they didn't record that or they just cheating and when they sat in, in the reception area of the clinic, they to complete the paper and and try to make lottery on when they did at those doors. They're instantly now these days been available thanks to the hard work that Dexcom you know avid Medtronic is doing on the CGM space and companies like companion medical and others they're doing you're connected to and and we know other efforts of other companies. You know, no voice is doing that Louie's doing that. So all of a sudden the same problem that we had a couple of years ago when people on CGM and pumps for the type one persons and depression And the amount of data, we're not going to have it in a much, much broader population, you have about 12 million people that dose insulin in the US, but only 1 million of them are on pumps with type one. So the question is, what are you going to do with these 11 million people? And that's where our focus on that's number one, another focus that we are looking at is going into contextual data? And how can we know and combine the fact that we can know where you are from your personal life in terms of you know, if you are driving or you are walking, or you are going into a restaurant? And how to combine that information with the glucose data? And what predictive real time notification we can give you in order to improve that, and the glucose control? Stacey Simms 25:49 Alright, wait, wait, you're gonna know where I'm driving? I'm walking to a restaurant. Wait a minute back up? Are you in my this is something in my phone? Are you using cell data? Eran Atlas 25:58 That's easy. You know, when you're driving? Do you have a Bluetooth in the car? Yes. So the phone knows that you are connected to the Bluetooth of the car, right? Yes. So for example, if you will give the permission, our application will be have the knowledge that you are driving? Are you using navigation software? Stacey Simms 26:17 Yes. Do you have to lift or no, I don't mean to interrupt your train of thought here. But for some reason, I just thought of the Pokemon Go app from a couple of years ago, because it knew when my kids were in the car and not walking, right. I mean, I know I sent you're probably laughing because I sound so ignorant with this stuff. But yeah, with our cell phones, I'm sure that everybody knows where we are at all times. It's Eran Atlas 26:37 amazing. That's right. But I think again, so I'm not talking about you know, poking your privacy and everything. And it's have to be on a certain things that that the user will need to authorize, or the benefit of the user, but but potentially, many will learn driving, like they will go into any driving license, I'm sure that nobody wants a person with diabetes, that these glucose is going down or predicted to be down in next 30 minutes to start driving. Stacey Simms 27:05 So would it give in your system, would it then give a reminder, um, you know, I'm walking into a restaurant time to bolus Is that what you're envisioning. Eran Atlas 27:13 So again, your glucose is dropping in the next 30 minutes it please take something before you start to drive. Or we're seeing that you're going into a restaurant and you're using glucose is sky high, or going high and the high trend, please correct your glucose now before start eating, because then it will be much more difficult to correct your glucose. These are the types of things that you know are examples of how you take context and combine it together with glucose and insulin data. Stacey Simms 27:41 It's so interesting to me, because I think, especially with the type two community who use insulin, it's a very different world than the type one community where most people well, I'm biased, because my podcast audience is so well educated. But people are thinking about it so much more often. I have lots of friends with type two, who dose insulin who don't really think about it, who don't really know, just because they're, as you said, they're seeing a general practitioner, they're not as educated. It's not a it's not a personality flaw. And I could see where this would be so helpful. Just these reminders with people with type two, have you already learned any nuances of how they want to use this kind of system? Is it different than people with type one? Eran Atlas 28:22 So I think that within the type two population is very much dependent when there are on multiple daily injection therapy, or they're just doing basic only. So that's one big difference between type two and type one another big difference is Yeah, like you said, they're thinking about the condition differently. They are denying the fact they have a condition. I think that's much stronger than people with type one, especially teenagers with type one that you know, try to break the system and try to see what's going on. But it's still you need to find other ways to do that. And we're still studying eighth, what is the best way to deliver that to people that have type two diabetes. And that's why initially we're focusing on their providers, and try to better understand what people that are treating people with type one diabetes would like to see how we can help the providers provide a better treatment for them. That will be our first step, then when we will get these endorsement and understanding about the actual users will be much more comfortable to offer something that will go directly to the user because as you said it truly it's a different population. I remember Stacey Simms 29:31 years ago, there was a big push and I know you were you were around. If you started in the mid 2000s, there was this big push to almost gamify type 1 diabetes, right with apps that kind of gave you rewards for checking or here's a game that would help kids learn or even adults. And it turns out that most people didn't want to think that much about it. They just wanted the system to take care of it like stop reminding me to log stop reminding me to dose handle it. Talk to me about how DreaMed will do that. Even though You are talking about reminders, Eran Atlas 30:02 because I think that the difference between the reminders that are in the market, they used to be in the market. And what I'm trying to talk about is that those reminders were based on general timeframe. So for example, you know, you're logging into the app that you need to take your basal insulin between seven and 9am. And and now it doesn't matter if you are going just to go into deliver that it will be some sort of mechanism to just ping that, that reminder to you and will drive your crazy, right? I think that what dreamin is trying to do is a couple of things. Number one, we're not just giving them regular reminders, we're giving actionable reminders, so it will tell you to do something, because this is the right time for you to do these actions. And number two, we are trying to take off the burden of treating diabetes, you know, taking the burden off thinking about your glucose and thinking about what you need to do right now, for people that use a ID system. This is exactly what he gave them, you know, you know that there is something that looks on your glucose on a regular basis every five minutes, analyze the situation and provide your the actual dozy, but on people with with multiple daily injections are not using pumps. So there is the only way to make the insulin injected is to make some sort of a partnership with a user. So that's what we're trying to do. We're trying to create all the mechanisms that will bring this partnership between the person with diabetes on injections and the algorithms, we're trying to make sure that wherever we are issuing some sort of reminder, it will be an actionable one. And and hopefully it will be within a certain timeframe that the user is willing to accept such a reminder, because for example, if you're driving and then the system is shouting out, give insulin right now there's no way that you're going to give that insulin right because right now you're driving. But if we're able to capture the exact moment that you're open to get that reminder, and this international reminder, it's not a general one, I hope that people with diabetes will find it useful. And I think that's the thing that we are trying to learn together with the community. And to be are we personally diabetes at work for us, because at the end, it's a partnership between the person, the provider and the industry. And that's what we're trying to create. It's important for people to know that there are companies that are not in the US and might be a little bit small, but they are trying to make a difference for you. And I hope that together with what we're trying to do and what the community is trying to do, when we are partnership, we really, really be able to make that difference. Because the culture of dream ed is coming from a clinic. It's a company that the importance of making lives better is on our culture. Another thing in our countries, make sure that whatever we're issuing has a clinical benefit. We're just not not just want to have a cool product and just get more money. And I really, really optimistic about the impact that we can do on people with diabetes. And we're committed to do that Stacey Simms 33:14 around before I let you go. Do you mind if I ask about the population with type one in Israel? Sure. I'm trying to think I know in Scandinavian countries, it's very high. Eran Atlas 33:23 it's debatable, but it's between 30 to 50 k people in type 1 diabetes in Israel, this is it. But we don't have a lot of people with type 1 diabetes. If you're looking on the pieds all the peas are being treated by you know, academic centers, big hospital clinics, the clinic that I'm coming from, is pretty much treating a very large portion of this of the kids and adults are usually go in the same way either to a specialist, but the most of them are going into two primary cares. Where were very techie we were had a lot of a lot of people on CGM and insulin pump. We currently don't have control IQ and ease rail. It's not approved so and 670 G is not reimbursed so the majority of the cohort here in Israel are on regular pump and CGM. Stacey Simms 34:11 This is well as I said, before we started taping, my son is planning a long trip to Israel next summer. So maybe knocking at your door if you're just some hand holding. Eran Atlas 34:22 I will be happy to I will be happy. Don't worry. Yeah, I think I can vouch for that. Stacey Simms 34:29 Everyone, thank you so much for joining me in explaining all this. I really appreciate it. I hope we can talk again soon. Announcer 34:39 You're listening to Diabetes Connections with Stacey Simms. Stacey Simms 34:45 More information in the show notes Just go to Diabetes connections.com. And every show has show notes we call them I call it an episode homepage as well because not every podcast player supports the amount of stuff I put There, every episode this year has a transcript. Every episode ever has links. And so sometimes if you go to Apple podcasts or if you listen on, you know, Stitcher or Pandora, or wherever you listen, and we are everywhere, right now, they don't support the links. So if you're ever curious, or you can't get to something, just go to the homepage and find the episode, there's a very robust search, because we're up to 325 episodes. So I wanted to make it easy for you to find what you were looking for. But when you do that, you can find more information about DreaMed, and I linked up the study as well that he mentioned, comparing their algorithm to doctors at Yale, that sort of thing. You know, I'm curious, as you listen, what you think about something like this, I feel like this podcast audience is so involved in their numbers in a way that most people in diabetes land are not. I mean, let's face it, there's very few people who are interested in DIY stuff like this audiences. I mean, I know you guys, you're very technical, you're very involved, even if you're listening, saying, hey, that's not me, the very fact that you're listening to a podcast about diabetes puts you in a different educational plane, then, you know, 90 95%, let's say, of all people with all types of diabetes, which is not a knock on them, it's just the reality of diabetes and education. So I'm really curious to see how this can help. Because as he's saying, you have a general practitioner, who's treating people who's dosing insulin, right, they're given the prescriptions out. And an algorithm like this can make it so much more precise and safe for the people who are getting those recommendations from these doctors who, you know, might really want to do good, but do not have the experience of the education in at a chronology. So that's my stance on it. We'll see what happens I'd love to know what you think. All right, innovations coming up in just a moment. And I want to share this article I found about women in diabetes a device design, but first diabetes Connections is brought to you by a new sponsor this week. I am so excited to welcome g Volk hypo pen. You know, almost everyone who takes insulin has experienced a low blood sugar. And that can be scary. A very low blood sugar is really scary. And that's where evoke hypo pen comes in Jeeva is the first auto injector to treat very low blood sugar. evoke hypo pen is pre mixed and ready to go with no visible needle. That means it's easy to use, how easy is it, you pull off the red cap and push the yellow end onto bare skin and hold it for five seconds. That's it, find out more go to Diabetes connections.com and click on the G Vogue logo. g Vogue shouldn't be used in patients with pheochromocytoma or insulinoma, visit Jeeva glucagon.com slash risk. saw a great article that I wanted to pass along to you from the wonderful folks at diabetes mine. And the headline on this is where are the women in diabetes device design? And I'm not going to read the whole thing to you I will link it up. But the question here was all about our the shortcomings of diabetes technology a result of just the the functional design requirements the way it has to be made? Or could it be related to the fact that there aren't enough women in the medical technology design field, they did a whole survey about you know wearing this stuff, and you know where to attach it, how to put it, you know, dresses, things like that, which you know, at first, listen may sound kind of silly. But when you think about it, wearing the device, the comfort of wearing the device, the mental stress about wearing the device, these are so incredibly important, because people with diabetes men and women, as you know where this stuff 24 seven, I mean, you think about the difference between something that is clunky, that looks outdated, that, you know, just doesn't feel right in your hand. I mean, these things make a big difference in terms of how I hate to use the word compliant, right, but you know, how well we use them how much we use them how comfortable we are with them, in addition to focusing on the pump companies, and in particular Omni pod, very, very interesting take on women who work at Omnipod there, they also focus on women designed accessories for diabetes tech, because when you think about it, and they list all of these companies, you know, we've talked about a bunch of them in the past myabetic and funky pumpers spy belt tally gear pump peels, one of my book to clinic sponsors, thank you very much pump peels, these are all founded by women, because they saw the need and wanted to make life easier and better. So I'll link that up. I really thought it was a great look at a topic that we hadn't thought a lot about before. We focus a lot on what patients need to be involved people with diabetes who actually wear the gear need to be involved. But what about people who wear the gear differently and have different expectations and that by that I mean women. My daughter when she was in high school, wrote a whole paper on pocket equality and did hard research into why women's clothing doesn't have pockets and rarely has pockets that are big enough. I mean, my son puts his phone and his palm I don't know, you know, a lunchbox in his pocket, and he can fit everything in there. He doesn't think twice about it. But sometimes I think about where the heck would I put a pump, if I was wearing what I'm wearing today, right, I have any pockets. Really interesting discussion and hats off to diabetes mine for focusing on that innovations is also your chance to share hacks and tips and tricks that work for you, you know, just little things that make life better with diabetes. So you can post in the Facebook group, or you can email me, Stacey at Diabetes connections.com. Didn't tell me something good this week, a big award for a familiar face around here. Most of you remember Dr. Nat Strand from The Amazing Race. She was the in the team of Nat and cat. And that was The Amazing Race 17, which I can't believe was 10 years ago. We talked to Dr. strand, earlier this year about working as a physician. And during this time of COVID. And how she was treating her patients. She treats patients with chronic pain and that sort of thing. And we're talking about her on tell me something good, because she is the inaugural winner of the Lisa Stern's legacy Diversity Award from the American Society of pain and neuroscience. So congratulations, Dr. strand. Of course, the ceremony was virtual, but you could follow her on Twitter and see the pictures and see what nice things people are saying about her and I will link up her Twitter account if you don't follow her already. Also, in Tell me something good. Something that popped up in my local group. Brian shared a post about his daughter Emerson about diabetes and soccer. And he said I could share it. And it's actually a story about her. It's a story by her. It is Emerson's sucker rista story playing with diabetes. And this is a column that Emerson wrote that is published on the girls soccer network, I would really urge you to read it especially if you have a child who is a high performing or wants to be a high performing or elite athlete. She talks about no days off. And how well you know I'm sure your mind went to diabetes. That was her mantra in terms of sports. And it has really helped her she says deal with soccer. And with diabetes. I'm not going to read her words here. I just think it's a great column I would urge you to read it I'll link it up on the episode homepage and I'm going to put it in the Diabetes Connections Facebook group as well. Well done Emerson really great to see the incredible hard work that it looks like you've been putting in and what a wonderful column as well. So thank you so much Brian for sharing that and for letting me talk about it a little bit here. If you have a Tell me something good story could be a birthday a diverse serie, you know, your child has published in a national print publication, you know, anything you want to focus on, that is good news in the diabetes community, please reach out and let me know, just tell me something good. Tell me something annoying, could be the name of this segment, I just want to talk a little bit about our insurance changes, mostly to commiserate with with many who have gone through this. So as I said at the top of the show, our biggest change is now that they're going to switch insulin on us. You know, I talked to Benny about this, we are so fortunate to have a frankly, have a pretty good stockpile of insulin that we've built up. If you follow the show for a long time, you know that I've discussed his insulin needs went way up. And they have gone back down to almost pre puberty levels. But we never changed the prescription. So you know, I have unfortunately or fortunately, I don't know I have shared insulin in the Charlotte area with adults in need. We have some great local groups. And it is ridiculous that we need to do this, but we do share with each other. And I've been happy to help out on that. But we are basically out of pins. And I like to use pins as a backup. And Benny likes to have them for flexibility. You know, he'll take them sometimes. And if something's wonky with his pump, he knows he can get himself a shot, that sort of thing. But I hate the idea of changing insulins right everything's cookin right now everything's chugging along really well. I don't want to rock the boat. But I also don't want to pay $300 for a pen. So I'm going to be talking to our endocrinologist, Vinny has an appointment in two weeks, as I'm taping probably more like a week and a half as you listen. And we know we'll talk about it, then maybe have some samples, but most likely we will be switching and we did not have an issue when we switched in the past. So I have fingers crossed that it will be fine. It'll be fine. But that is annoying. And I know I don't feel like appealing and fighting if we don't need to. It's possible that novolog will work just as well for him. So let's at least find out and we'll go from there. The other issue was, of course, that we are now dealing with edgepark. And I will spare you all of the details. But I tried to do a workaround. And I'm laughing because I should know better by now. I tried to get the Dexcom prescription to stay at our pharmacy because man we've been filling it at the pharmacy for the last couple of years. And if you have already been able to do that, you know, it's like a dream. At least it is for us. It may take an extra day to get it but it's a day. It's not like they're mailing it out for you and it takes three weeks. It's been wonderful. And I just had on auto refill. And it's been great. But edgepark told me, we don't filter your pharmacy, you only can do it mail order. Well, I didn't want to wait. I didn't want to be cut short. So I let edgepark go ahead and fill the order. But then I did some detective work. And I kept calling and talking to people, because what else do I have to do, but be on the phone with these people? And I finally got someone at my insurance company to admit they would fill it at the pharmacy. But here's what she said. She said, Well, we don't like you to go to the pharmacy, because they don't often have it in stock. And I said, Come on, you know, that's not true. They can fill it in a day. They've been filling it for four years. And she said, Okay, well, you can you do a pharmacy benefit and, you know, blah, blah, blah. So I hung up the phone, and I will fill it at the pharmacy next time. I already have the order from edgepark through the mail. And I thought you know, that's just because my insurance company has a deal with edgepark. That's all that is. She's trying to discourage me from going to the pharmacy because that's their business. I get it. But how stupid is that? How outrageous is that? Oh, now you know why I saved it to the end of the show. I will keep you posted on our many adventures as this moves forward. Because Up next, I have to fill Benny's tandem pump supplies. And we've never been able to do that at the pharmacy. So I'm sure it'll be more adventures with edgepark my new pals. Ah, goodness gracious. All right. Thank you to my editor john Kenneth for audio editing solutions. Thank you. If you are still here, listening to me rant. I love you. Thank you so much for listening. I'm Stacey Simms. I'll see you back here next week. Until then, be kind to yourself. Benny 46:35 Diabetes Connections is a production of Stacey Simms Media. All rights reserved. All rounds avenged Transcribed by https://otter.ai

The Gary Null Show - - 07.22.20

The Gary Null Show

Play Episode Listen Later Jul 22, 2020 57:28

The Gary Null Show is here to inform you on the best news in health, healing, the environment. Study: Regular mushroom consumption can lead to lower prostate cancer risk Tohoku University (Japan), July 20. 2020 Regular mushroom consumption can lead to a 17 lower risk of prostate cancer, according to a team of researchers from Tohoku University's School of Public Health in Japan. Lead author and doctoral student Shu Zhang noted that the cancer-fighting effects of mushrooms appeared to be more significant in men aged 50 and older. That said, Zhang clarified that her team did not collect information on specific mushroom species and, as such, did not elucidate the molecular mechanisms behind the fungi's cancer-fighting effects. Their findings have been published in the International Journal of Cancer. Habitual mushroom consumption linked to a reduced risk of prostate cancer To see if mushrooms are potent against prostate cancer – the second most common cancer among older men – Zhang and her team looked at the data of 36,000 men between the ages of 40 and 79 for a median period of 13.2 years. Each participant had been part of either the Miyagi Cohort Study in 1990 or the Ohsaki Cohort Study in 1994. Upon analysis of the pooled data from both cohorts, Zhang and her team found that 3.3 percent of the participants had incidents of prostate cancer based on responses from questionnaires regarding their medical histories and their eating, smoking and drinking habits. It also appeared that mushroom consumption is inversely related to incident prostate cancer. In particular, participants who regularly ate mushrooms once or twice a week had an eight percent lower risk of prostate cancer. Those who ate mushrooms more than three times a week, on the other hand, had an incredible 17 percent lower risk of prostate cancer. Furthermore, Zhang notes that these effects had been especially pronounced in men aged 50 or older and in men whose diets consisted of low fruit and vegetable intake but high meat and dairy intake. Unfortunately, the team was unable to collect information on mushroom species involved in either cohort. As such, they could not specify the species responsible for the reductions in prostate cancer risk. Because of this, Zhang stated that the underlying mechanisms behind the beneficial effects of mushrooms on prostate cancer remain uncertain. At High Doses Turmeric Compound Kills Virus Particles Wuhan Institute of Bioengineering (China), July 20, 2020 Curcumin, a natural compound found in the spice turmeric, could help eliminate certain viruses, research has found. A study published in the Journal of General Virology showed that curcumin can prevent Transmissible gastroenteritis virus (TGEV) – an alpha-group coronavirus that infects pigs – from infecting cells. At higher doses, the compound was also found to kill virus particles. Infection with TGEV causes a disease called transmissible gastroenteritis in piglets, which is characterised by diarrhoea, severe dehydration and death. TGEV is highly infectious and is invariably fatal in piglets younger than two weeks, thus posing a major threat to the global swine industry. There are currently no approved treatments for alpha-coronaviruses and although there is a vaccine for TGEV, it is not effective in preventing the spread of the virus. To determine the potential antiviral properties of curcumin, the research team treated experimental cells with various concentrations of the compound, before attempting to infect them with TGEV. They found that higher concentrations of curcumin reduced the number of virus particles in the cell culture. The research suggests that curcumin affects TGEV in a number of ways: by directly killing the virus before it is able to infect the cell, by integrating with the viral envelope to ‘inactivate' the virus, and by altering the metabolism of cells to prevent viral entry. “Curcumin has a significant inhibitory effect on TGEV adsorption step and a certain direct inactivation effect, suggesting that curcumin has great potential in the prevention of TGEV infection,” said Dr Lilan Xie, lead author of the study and researcher at the Wuhan Institute of Bioengineering. Curcumin has been shown to inhibit the replication of some types of virus, including dengue virus, hepatitis B and Zika virus. The compound has also been found to have a number of significant biological effects, including antitumor, anti-inflammatory and antibacterial activities. Curcumin was chosen for this research due to having low side effects according to Dr Xie. They said: “There are great difficulties in the prevention and control of viral diseases, especially when there are no effective vaccines. Traditional Chinese medicine and its active ingredients, are ideal screening libraries for antiviral drugs because of their advantages, such as convenient acquisition and low side effects.” The researchers now hope to continue their research in vivo, using an animal model to assess whether the inhibiting properties of curcumin would be seen in a more complex system. “Further studies will be required, to evaluate the inhibitory effect in vivo and explore the potential mechanisms of curcumin against TGEV, which will lay a foundation for the comprehensive understanding of the antiviral mechanisms and application of curcumin” said Dr Xie. Nitric oxide may slow progression of COVID-19 A recent review published by GW researchers suggests that nitric oxide has promise as a therapeutic to control the replication and rapid spread of SARS-CoV-2 George Washington University, July 21, 2020 Nitric oxide treatment can be pivotal in the world's fight against SARS-CoV-2, the coronavirus that causes COVID-19, according to a review from the George Washington University (GW). The article is published in the journal Nitric Oxide. Nitric oxide is an antimicrobial and anti-inflammatory molecule with key roles in pulmonary vascular function in the context of viral infections and other pulmonary diseases. In SARS-CoV-1 infection, which led to the outbreak of SARS (severe acute respiratory syndrome) in 2003, nitric oxide inhibited viral replication by cytotoxic reactions through intermediates such as peroxynitrite. It is one of several potential COVID-19 treatments included in the U.S. Food and Drug Administration's emergency expanded access program. "Nitric oxide plays key roles in maintaining normal vascular function and regulating inflammatory cascades that contribute to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)," said Adam Friedman, MD, interim chair and professor in the Department of Dermatology at the GW School of Medicine and Health Sciences and co-senior author of the review. "Interventions that are protective against ALI and ARDS can play a critical role for patients and health systems during the pandemic." Coronaviruses are RNA viruses that primarily infect birds or livestock, but can mutate to be highly infectious and lethal in humans. There is currently no registered treatment or vaccine for COVID-19. The absence of a specific treatment and the high mortality rate of the virus dictate an urgent need for therapeutics that may control the replication and rapid spread of the virus. The team, led by first author Nagasai Adusumilli, MBA, a fourth-year medical student at the GW School of Medicine and Health Sciences, reviewed data from between 1993 and 2020 on the pathogenesis of coronaviruses and the use of nitric oxide as a treatment for respiratory illness. The authors highlight the potential for inhaled nitric oxide contributing to better clinical outcomes and alleviating the rapidly rising strain on health care capacity due to COVID-19. As groups continue to publish more results with their respective nitric oxide platforms, the team recommends that dosing and protocol variations should be examined in evaluating the studies. "With the emergence of COVID-19 as a pandemic with the ability to overwhelm the body and our health care infrastructure, patients have a pressing need for effective agents that can slow the disease in their bodies and in their communities," Friedman said. The authors suggest that if nitric oxide's efficacy is illustrated for COVID-19, its use as a treatment can be pivotal in the fight against the pandemic. Friedman has been collaborating with co-senior author Joel Friedman, MD, PhD, professor of physiology and biophysics and of medicine at Albert Einstein College of Medicine, on research related to the use of nitric oxide in a broad range of medical indications for close to two decades, and together are developing nitric oxide-based therapeutics for COVID-19. Cinnamon may improve blood sugar control in people with prediabetes Joslin Diabetes Center (Boston), July 21, 2020 Cinnamon improves blood sugar control in people with prediabetes and could slow the progression to type 2 diabetes, according to a new study published in the Journal of the Endocrine Society. It is estimated that nearly 90 million people in the United States have prediabetes, which occurs when blood sugar levels are higher than normal and often leads to type 2 diabetes. Identifying strategies to prevent the progression from prediabetes to type 2 diabetes is challenging, yet important for a large population. "Our 12-week study showed beneficial effects of adding cinnamon to the diet on keeping blood sugar levels stable in participants with prediabetes," said the study's corresponding author, Giulio R. Romeo, M.D., of Joslin Diabetes Center in Boston, Mass. "These findings provide the rationale for longer and larger studies to address if cinnamon can reduce the risk of developing type 2 diabetes over time." The randomized clinical trial investigated the effects of cinnamon supplementation in 51 participants with prediabetes. Participants were given a 500 mg cinnamon capsule or placebo three times a day for 12 weeks. The researchers found that cinnamon supplements lowered abnormal fasting glucose levels and improved the body's response to eating a meal with carbohydrates, which are hallmarks of prediabetes. Cinnamon was well tolerated and was not associated with specific side effects or adverse events. Supplements with potential to prevent Alzheimer's affect blood, but less so the brain Omega-3 fatty acids might require larger doses to be effective -- especially for people with high-risk gene University of Southern California, July 21, 2020 For years, a scientific puzzle has bedeviled researchers aiming to fight Alzheimer's disease, a common and incurable form of dementia. The results of numerous lab investigations and population studies support the preventive potential of omega-3 fatty acids, "good fats" found abundantly in fish. However, to date the majority of studies evaluating omega-3s for averting or curtailing cognitive decline in human participants have failed to show benefits. Now, a small clinical trial from USC provides important clues about this discrepancy, in the first Alzheimer's prevention study to compare levels of omega-3s in the blood with those in the central nervous system. The findings suggest that higher doses of omega-3 supplements may be needed in order to make a difference, because dramatic increases in blood levels of omega-3s are accompanied by far smaller increases within the brain. Among participants who carry a specific mutation that heightens risk for Alzheimer's, taking the supplements raised levels of a key fatty acid far less compared to those without the mutation. "Trials have been built on the assumption that omega-3s get into the brain," said senior author Dr. Hussein Yassine, associate professor of medicine and neurology at the Keck School of Medicine of USC. "Our study was specifically designed to address this question." The paper was published today in the journal EBioMedicine. The researchers recruited 33 participants who had risk factors for Alzheimer's but were not cognitively impaired. All participants had a family history of the disease, a sedentary lifestyle and a diet low in fatty fish. Fifteen carried a gene variant called APOE4, which is linked to inflammation in the brain and increases Alzheimer's risk by a factor of four or more; the other 18 were noncarriers. At random, participants were assigned to a treatment group or control group. Members of the treatment group were asked to take supplements containing more than 2 grams of an omega-3 called docosahexaenoic acid (DHA) daily for six months. Control group members took placebos each day over the same period. Participants in both groups also were asked to take daily B-complex vitamins, which help the body process omega-3s. Dr. Yassine and his colleagues gathered samples of blood plasma and cerebrospinal fluid -- a gauge for whether the omega-3s reached the brain -- from participants at the outset, and again at the end of the study period. The scientists looked at levels of two omega-3 fatty acids: DHA and eicosapentaenoic acid (EPA), a potent anti-inflammatory that the body derives from a small portion of its DHA intake. Higher doses for omega-3s to be effective? The researchers found that at the end of the six months, participants who took omega-3 supplements had 200 percent more DHA in their blood compared to those who took placebos. In contrast, the DHA found in cerebrospinal fluid was only 28 percent higher in the treatment group than the control group. This result hints that measuring omega-3 levels in the blood may not indicate how much is reaching the brain. Dr. Yassine and his co-authors also report that, within the treatment group, those without the risk-inflating APOE4 mutation showed an increase of EPA (anti-inflammatory omega-3 fatty acid) in their cerebrospinal fluid three times greater than what was seen in carriers of the gene. "E4 carriers, despite having the same dose, had less omega-3s in the brain," he said. "This finding suggests that EPA is either getting consumed, getting lost or not getting absorbed into the brain as efficiently with the E4 gene." Notably, the 2-gram dose of DHA in this study far exceeded what has been used in major clinical trials testing the preventive power of omega-3s, which typically administer 1 gram or less daily. "If you use a lower dose, you can expect a less-than-10-percent increase in omega-3s in the brain, which may not be considered meaningful," Dr. Yassine said. The sacrifice of study participants advances Alzheimer's research The investigators worked for two years to recruit participants for the trial. The barrier to entry came from the only method capable of extracting cerebrospinal fluid: a lumbar puncture, also known as a spinal tap. It proved challenging to find people willing to undergo that procedure, which involves a hollow needle piercing the lower back, two times. Dr. Yassine had high praise for the study participants. "They were generous with their time, and they were courageous to do the lumbar punctures," he said. "The main reason they did this was their desire to advance science." The participants' bravery may pay off in the creation of even more knowledge about omega-3s and Alzheimer's. The preliminary data from the current study was intriguing enough that the scientists were able to attract funding for a larger trial for which recruitment is underway. Following 320 participants over two years, it will examine whether high doses of omega-3s can slow cognitive decline in carriers of the APOE4 gene. Dr. Yassine believes that the progression from a small study to a bigger one is a good model for developing therapies and preventions targeting the brain. "These pilot studies are so important as a step toward much larger, more complicated studies," he said. "The bottom line is, before you embark upon very expensive clinical trials, you need to show proof of concept, that your drug is getting into the brain and changing biomarkers of disease in the right direction." Efficacy of acupuncture in insomnia treatment Beijing University of Chinese Medicine, July 17, 2020 In this study, researchers provided updated evidence from randomized controlled trials (RCTs) of the effectiveness and safety of acupuncture for primary insomnia. Their findings were published in The Journal of Alternative and Complementary Medicine. Acupuncture is widely used in Asia as an alternative therapy for insomnia. In Western countries, the use of acupuncture is increasing. To determine the suitability of acupuncture as insomnia treatment, the researchers searched 11 databases from January 2008 to October 2017 for relevant RCTs. Two authors independently extracted data and assessed risk of bias. The researchers performed statistical analysis using RevMan 5.3 software then combined data in a meta-analysis according to a predefined protocol. They also performed trial sequential analysis when appropriate and assessed the quality of evidence using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). The researchers analyzed 73 RCTs that involved 5,533 participants. Their results showed that real acupuncture treatment yielded better results than no treatment by reducing the Pittsburgh Sleep Quality Index (PSQI) scores. Acupuncture, combined with medication, also showed better results than medication alone by decreasing PSQI total scores. Compared with estazolam, acupuncture exerted better effects on PSQI scores. It also caused fewer adverse events than western medications. Based on these findings, the researchers concluded that acupuncture benefits people with insomnia by improving their sleep quality. The researchers recommend a larger sample size and more rigorously designed RCTs to explore this benefit further. Dietary guidelines advisory committee reinforces need for increased choline intake Vulnerable populations, including infants, toddlers, pregnant and lactating women, are at greatest risk for choline deficiency HHS and Cornell University, July 20, 2020 The Dietary Guidelines Advisory Committee (DGAC or Committee) - a group comprised of 20 nationally recognized health and nutrition experts - published the Scientific Report of the 2020 Dietary Guidelines Advisory Committee: Advisory Report to the Secretary of Agriculture and the Secretary of Health and Human Services. Among its findings, the Committee concluded that current choline intake levels are too low for most Americans and found low intake levels among infants and toddlers, as well as vulnerable populations like pregnant and lactating women, especially concerning. "The Committee's scientific report shines a light on the growing body of evidence that shows choline plays a critical role in health during specific life stages," says Marie Caudill, PhD, RD, Professor, Cornell University and an internationally recognized choline researcher. "Unfortunately, consumption data tell us choline is widely under-consumed, and it's concerning that those populations who would benefit most from choline, such as pregnant and lactating women and infants and children, fall short of meeting intake targets. In fact, only 8 percent of pregnant women are meeting choline recommendations." Choline is an essential nutrient that supports a variety of processes at all stages of life and throughout the body, including fetal and infant development; cognition and memory; energy and fitness; metabolism; and liver health. While more research is needed for choline to reach the level of a 'nutrient of public health concern,' the Committee recognized choline as a 'nutrient that poses public health challenges' for all infants and toddlers between ages 12 and 24 months; and special attention around choline inadequacies was specifically noted for girls and boys ages 9 to 14; and the vulnerable pregnant population and women who are lactating. Choline is naturally found in some foods; yet, based on typical and recommended eating patterns, it is difficult to meet daily choline needs through foods alone. In fact, the DGAC presented three food pattern styles, which generally meet all nutrient needs across the lifespan, except for a few such as choline. Importantly, the Committee noted that many supplements do not yet contain sufficient amounts of choline, indicating an important opportunity for both supplement innovations, as well as food fortification, in the future. "The Committee's report clearly highlights the challenges of meeting choline intake targets through food alone," added Caudill. "Americans need guidance on how to choose supplements to help fill nutrient gaps, particularly for pregnant women as most recognized prenatal vitamins don't contain enough--if any--choline." "Choline's increased recognition in the DGAC report is an important scientific milestone for the public health community," says Jonathan Bortz, MD, Senior Director, Nutrition Science, Balchem. "We are quickly approaching an inflection point in time for choline awareness. In addition to the findings released in this report, Balchem has, and will continue to support research needed to develop a blood biomarker for choline, which will provide a more accurate understanding of the level of deficiency among Americans and help to generate stronger guidance and messages." Choline can be purchased online or in specialty stores as a stand-alone, over-the-counter supplement; incorporated into some prenatal vitamins or packaged along with prenatal vitamins; and fortified in branded milk products, specifically: - Bayer recently launched a "One A Day Women's Prenatal Advanced Complete Multivitamin with Brain Support," that includes a side-by-side prenatal multivitamin plus a supplement that provides 110mg of choline, helping to substantially close the gap in pregnant women's daily needs. - Danone's Horizon Organic brand developed milk for young children--Growing Years--that is fortified to contain 55mg of choline per serving, providing between 10 percent to 27 percent of children's daily needs, depending on age and gender. "The Committee's report has provided critical research directions to help inform Balchem's long-standing commitment to choline research and science communications," added Bortz. "We look forward to continuing to support science and product innovation to ensure all Americans throughout the lifespan can benefit from increased choline, as part of healthy diets." Older adults who can really smell the roses may face lower likelihood of dementia University of California San Francisco, July 20, 2020 Seniors who can identify smells like roses, turpentine, paint-thinner and lemons, and have retained their senses of hearing, vision and touch, may have half the risk of developing dementia as their peers with marked sensory decline. In a study by UC San Francisco, researchers tracked close to 1,800 participants in their seventies for a period of up to 10 years to see if their sensory functioning correlated with the development of dementia. At the time of enrollment, all participants were dementia-free, but 328 participants (18 percent) developed the condition over the course of the study. Among those whose sensory levels ranked in the middle range, 141 of the 328 (19 percent) developed dementia. This compares with 83 in the good range (12 percent) and 104 (27 percent) in the poor range, according to the study, which publishes in Alzheimer's and Dementia: The Journal of the Alzheimer's Association on July 20, 2020. Previous research has centered on the link between dementia and individual senses, but the UCSF researchers' focus was on the additive effects of multiple impairments in sensory function, which emerging evidence shows are a stronger indicator of declining cognition. "Sensory impairments could be due to underlying neurodegeneration or the same disease processes as those affecting cognition, such as stroke," said first author Willa Brenowitz, PhD, of the UCSF Department of Psychiatry and Behavioral Sciences, and the Weill Institute for Neurosciences. "Alternatively, sensory impairments, particularly hearing and vision, may accelerate cognitive decline, either directly impacting cognition or indirectly by increasing social isolation, poor mobility and adverse mental health." While multiple impairments were key to the researchers work, the authors acknowledged that a keen sense of smell, or olfaction, has a stronger association against dementia than touch, hearing or vision. Participants whose smell declined by 10 percent had a 19 percent higher chance of dementia, versus a 1-to-3-percent increased risk for corresponding declines in vision, hearing and touch. "The olfactory bulb, which is critical for smell, is affected fairly early on in the course of the disease," said Brenowitz. "It's thought that smell may be a preclinical indicator of dementia, while hearing and vision may have more of a role in promoting dementia." The 1,794 participants were recruited from a random sample of Medicare-eligible adults in the Health, Aging and Body Composition study. Cognitive testing was done at the beginning of the study and repeated every other year. Dementia was defined by testing that showed a significant drop from baseline scores, documented use of a dementia medication or hospitalization for dementia as a primary or secondary diagnosis. Multisensory testing was done in the third-to-fifth year and included hearing (hearing aids were not allowed), contrast-sensitivity tests for vision (glasses were permitted), touch testing in which vibrations were measured in the big toe, and smell, involving identifying distinctive odors like paint-thinner, roses, lemons, onions and turpentine. The researchers found that participants who remained dementia-free generally had higher cognition at enrollment and tended to have no sensory impairments. Those in the middle range tended to have multiple mild impairments or a single moderate-to-severe impairment. Participants at higher risk had multiple moderate-to-severe impairments. "We found that with deteriorating multisensory functioning, the risk of cognitive decline increased in a dose-response manner," said senior author Kristine Yaffe, MD, of the UCSF departments of Psychiatry and Behavioral Sciences, Epidemiology and Biostatistics, and Neurology, as well as the San Francisco VA Health Care System. "Even mild or moderate sensory impairments across multiple domains were associated with an increased risk of dementia, indicating that people with poor multisensory function are a high-risk population that could be targeted prior to dementia onset for intervention." The 780 participants with good multisensory function were more likely to be healthier than the 499 participants with poor multisensory function, suggesting that some lifestyle habits may play a role in reducing risks for dementia. The former group was more likely to have completed high school (85 percent versus 72.1 percent), had less diabetes (16.9 percent versus 27.9 percent) and were marginally less likely to have cardiovascular disease, high-blood pressure and stroke.

covid-19 united states health school japan americans phd professor food development medicine cancer mba md southern california trials identifying alzheimer's disease mass secretary public health agriculture usc neuroscience committee senior director previous medicare dementia cornell university psychiatry cognitive epa infection human services acupuncture sars cov friedman notably neurology health sciences sars bayer zhang alternatively sensory interventions epidemiology behavioral sciences gw rna chinese medicine drug administration zika ucsf dermatology habitual danone dha body composition bioengineering nutrition science california san francisco albert einstein college biostatistics curcumin ards rcts wuhan institute uc san francisco complementary medicine traditional chinese yassine coronaviruses xie apoe4 choline in western nitric caudill multisensory adam friedman endocrine society transmissible ucsf department joslin diabetes center bortz gary null dgac

NL Interview: Harvard researchers on myths and realities of the coronavirus pandemic

Newslaundry Conversations

Play Episode Listen Later Apr 1, 2020 56:25

Bhargav Krishna is a doctoral student at Harvard University’s TH Chan School of Public Health in the United States, and serves as adjunct faculty at the Public Health Foundation of India. Atif Adam holds joint faculty positions in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health and the Joslin Diabetes Center of Harvard Medical School. They are both Newslaundry subscribers. In this conversation with Abhinandan Sekhri, Bhargav and Atif discuss the coronavirus pandemic and its implications, especially for India.They start with pandemic prediction models, how accurate they are, and how seriously we should take them. Adam explains what various models show, and how a static model differs from a variable one. He emphasises the short-term, mid-term, and long-term actions that the government can take, to flatten the curve of the outbreak. Moving on, Bhargav explains the possible outcomes of the pandemic, including the chances of India developing herd immunity against the novel coronavirus, and how it worked during the SARS epidemic. He emphasises the importance of collecting as much data as possible on infections, deaths. Giving the example of South Korea, he points out how the government there did a stellar job of contact tracing and rapid testing. What we are seeing in India is more “reactive planning”, Adam says, comparing it to fixing a leaky balloon where everyone tries different methods to see what works. Talking about how India can deal with the situation better, he says, “Rather than copy and paste, pick up key things from these countries that have managed to flatten the curve, see what we can learn, what we can’t do. And then create public messaging that is appropriate.”They also discuss what contracting coronavirus entails for people with underlying health conditions such as diabetes, hypertension and respiratory ailments; the possibility of the virus mutating into a deadlier strain; and when a vaccine may be available. And, of course, they talk about the media’s coverage of the pandemic. For this and a lot more, tune in. See acast.com/privacy for privacy and opt-out information.

united states mental health moving giving harvard myths south korea public health researchers harvard university realities harvard medical school coronavirus pandemic sars atif johns hopkins bloomberg school joslin diabetes center newslaundry abhinandan sekhri

ENP31: Closed-Loop Glucagon Pump for PBH

md obesity pump endocrine bariatric hypoglycemia closed loop glucagon joslin diabetes center

Play Episode Listen Later Mar 20, 2020 9:38

We hear from Christopher Mulla, MD, from the Joslin Diabetes Center in Boston, about his research about the closed loop glucagon pump as a strategy for post-bariatric hypoglycemia. For more information, including helpful links and other episodes, visit our website at https://www.endocrine.org/podcast.

ENP31: Closed-Loop Glucagon Pump for PBH

md obesity pump endocrine bariatric hypoglycemia closed loop glucagon joslin diabetes center

Play Episode Listen Later Mar 20, 2020 9:38

ENP31: Closed-Loop Glucagon Pump for PBH

md obesity pump endocrine bariatric hypoglycemia closed loop glucagon joslin diabetes center

Play Episode Listen Later Mar 20, 2020 9:38

We hear from Christopher Mulla, MD, from the Joslin Diabetes Center in Boston, about his research about the closed loop glucagon pump as a strategy for post-bariatric hypoglycemia.

Harness the Power of Accountability to Grow Your Practice with Amanda Kirpitch | ep. 58

Fearless Practitioners

Play Episode Listen Later Jan 28, 2020 32:26

Are you missing the key ingredient that can take your practice to the next level in 2020? This episode with a member of the Fearless Practitioners Boss Club, Amanda Kirpitch, is a reminder of how powerful accountability can be to grow your business. I’m delighted to have Amanda Kirpitch of Nutrition Perspectives on this episode of the Fearless Practitioners Podcast. As a member of the Fearless Practitioners Boss Club, I’ve had the pleasure of watching Amanda make use of everything the Boss Club has to offer, and rock it in her practice! As a dietitian for 17 years, Amanda shares how she started in pediatrics, and then transitioned to adults and niched down to diabetes and eating disorders. Tired of the long commute and struggling with work-life balance, she took the scary but necessary leap we all take, and realized her vision of starting a private practice just one year ago. We discuss her common experience of not feeling totally ready, but how she trusted her gut and knew she didn’t need to have it all figured out, and that it’s okay to learn as she goes. Can any of us ever be totally prepared? Sharing your struggles and goals helps make your dreams you’re trying to build a reality. Amanada Kirpitch ABOUT AMANDA KIRPITCH, MA, RDN, CDE Located in Jersey City, NJ, Amanda Kirpitch is a nutrition and diabetes educator who specializes in inspiring patients to manage their diabetes and make healthy choices around food and activity. Amanda previously worked as a nutrition and diabetes educator at Columbia University as well as the Joslin Diabetes Center in Boston, MA providing individual and group counseling on topics including weight management, sports nutrition, and eating disorders. Amanda worked with the Why WAIT Program (Weight Achievement Intensive Treatment) helping patients make effective and lifelong commitments to healthy eating. Amanda received her bachelor of science in human nutrition, foods, and exercise from Virginia Tech and completed her dietetic internship at the University of Medicine and Dentistry in New Jersey and a Masters in Nutrition at Boston University Medical School. [click_to_tweet tweet="Want to know how to build your practice through community? In this #FearlessPractitioners episode, I interviewed @AmandaKirpitch to learn how she took her practice to the next level! #FearlessPractitioners #podcast via @AdrienPaczosa #RDchat #RDtobe" quote="Want to know how to build your practice through community? In this #FearlessPractitioners episode, I interviewed @AmandaKirpitch to learn how she took her practice to the next level! #FearlessPractitioners #podcast via @AdrienPaczosa #RDchat #RDtobe"] TOPICS DISCUSSED IN THIS EPISODE: Transition from full-time to private practice. Community and support are critical for learning, skills building, and accomplishing goals. Accountability helps to grow your practice. MORE FROM AMANDA Website: Nutrition Perspectives Connect on Instagram and Twitter Decoding Insurance, HIPAA and Billing for Private Practice Owners Happening February 19th, 2020! If you're already in private practice, or starting one this year, you simply don't want to miss this special training. Join the waitlist and get advanced notice when this Special Workshop opens for registration. **People on the waitlist will enjoy an additional special offer!** Click HERE to secure your spot! RESOURCES FROM ADRIEN Free Download - Planning out 2020 7 Simple Strategies to Get More Clients in your Private Practice All the Resources and Tools that I LOVE Boss Club is Open! Schedule Your FREE 15 Min Fearless Steps Call Fearless Practitioners Instagram Fearless Practitioners Facebook Subscribe & Review on iTunes Are you subscribed to my podcast? If you’re not, I encourage you to do that today, so you don't miss an episode. I’ll be adding an episodes each week and if you’re not subscribed there’s a good chance you’ll miss out on those. Click here to subscribe in iTunes! Now if you’re feeling extra loving, I would be really grateful if you left me a review over on iTunes, too. I will be highlighting some of the reviews on future podcasts so be sure to listen and see if yours is featured. Just click here to review, select “Ratings and Reviews” and “Write a Review” and let me know what your favorite part of the podcast is. Thank you!

Episode 19: Dairy's Role in Type 2 Diabetes Prevention and Management

Dairy on the Air

Play Episode Listen Later Sep 27, 2019 33:29

Cara Schrager, registered dietitian and clinical programs manager at Joslin Diabetes Center; and Julie Mattson Ostrow, registered dietitian and vice president of Dairy Experience-Wellness at Midwest Dairy discuss current and emerging research which points to dairy’s positive effects on type 2 diabetes prevention and management.

management products diabetes dairy type 2 diabetes mattson diabetes prevention schrager ostrow joslin diabetes center midwest dairy lentsch

Supporting our client’s emotional wellbeing’ with Dr Linda Beeney

ADEA Podcast

Play Episode Listen Later Sep 17, 2019 31:20

Dr Linda Beeney completed her PhD in Medicine at The University of Sydney and further developed her skills in Diabetes Psychology at the Joslin Diabetes Center during her Post-doctoral Clinical Fellowship at Harvard Medical School. This Podcast explores issues that we face more often as Diabetes Educators and health professionals surrounding psychological health and emotional well-being of our clients. We aim to identify the emotional themes patients face living with a new diagnosis or ongoing emotional needs related to living with a chronic health condition, in this case Diabetes. We aim to learn from clinical expertise what sort of triggers or red flags we should be aware of and who can we refer to for further assistance.

university phd medicine clients diabetes harvard medical school emotional wellbeing diabetes educators joslin diabetes center clinical fellowship

A Discussion on Managing and Treating Type 2 Diabetes

Managed Care Cast

Play Episode Listen Later Aug 6, 2019 17:07

As a progressive disease diabetes presents an ongoing challenge for physicians to provide adequate control of patients’ diabetes, and new agents with novel mechanisms of action help reduce the burden in the management of diabetes. In a recent Peer Exchange discussion, Dr Peter Salgo, of Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, led a discussion on novel agents and their role in treating patients with and with cardiovascular disease. On the panel was Dr. Om Ganda of Joslin Diabetes Center; Jim Kenney of JTKenney, a managed care consulting practice; and Dr Helena Rodbard, past president of the American College of Endocrinology and past president of the American Association of Clinical Endocrinologists. Listen to the full discussion: https://www.ajmc.com/peer-exchange/new-classes-for-treatment-of-type-2-diabetes/

managing physicians treating surgeons american association american colleges type 2 diabetes endocrinology new york presbyterian hospital columbia university college joslin diabetes center jim kenney clinical endocrinologists peer exchange

The One with the Second ADHD PhD w/ Janice Nieves-Bonilla

The Faster Than Normal Podcast: ADD | ADHD | Health

Play Episode Listen Later May 8, 2019 16:33

We are joined today by a scientist! I love interviewing scientists! Although diagnosed as a child, Janice did not get fully treated for ADHD until her second year at Harvard. She is doing amazing research as she finishes her fifth year of the Biological and Biomedical Sciences PhD program there, and has found her way to rock life with ADHD! Enjoy! In this episode Peter and Janice discuss: :46- Intro & welcome Janice Marie Nieves Bonilla de Ouellette! 1:40- You didn’t get diagnosed until you got to Harvard, correct? Tell us your story. 2:56- How was growing up for you; how did school & your classes go? 4:36- Can you tell any of our listeners who may be feeling like: “My ADHD is preventing me from being smart, or from being brilliant” exactly what it is that you are studying at Harvard? ref: Biological and Biomedical Sciences, Immunology and Autoimmunity, Joslin Diabetes Center 6:02- Your first language is Spanish. Sometimes people with ADHD are not great with languages; how are you with learning new ones? 7:04- Tell me about the medication you are on and how it’s working out for you? 8:08- What is your dosage frequency? 8:55- You have been very active in Theater, Dance, etc. Do you find that physical activity helps you? 10:47- You mentioned in your 3 page bio that you didn’t have many friend that were your age growing up. Do you think that’s an ADHD thing- to have friends that are older or younger? 12:26- Your husband does not have ADHD. If you had to tell the non-ADHD listeners of this podcast what the one thing they could do to survive someone with ADHD, that they love, what would that be? 14:37- How can people find you if they want to learn more about you and what you are doing? INSTA & Twitter @Janice_Nieves Email: JNievesBonilla@g.harvard.edu 15:22- Thank you Janice!! And thank YOU for subscribing, reviewing and listening. PLEASE.. stop right now and write us a review so that we will all be able help more people! You can always reach me at peter@shankman.com or @petershankman on all of the socials. Also at @FasterThanNormal on all of the socials. 15:47- Faster Than Normal Podcast info & credits As always, leave us a comment below and PLEASE drop us a review on iTunes and of course, subscribe to the podcast if you haven’t already! The more reviews we get, the more people we can reach. Help us to show the world that ADHD is a gift, not a curse! Know of anyone you think should be on the FTN podcast? Shoot us a note, we’d love to hear!

spanish dance theater harvard adhd shoot biological immunology nieves bonilla autoimmunity biomedical sciences ouellette ftn joslin diabetes center faster than normal podcast

The Good, The Bad, and The Nutrients – Dr. Jake Kushner, Medical Director for McNair Interests – A Fascinating Discussion of How the Body Processes Foods and a Closer Look at Diabetes from a Preeminent Pediatric Endocrinologist

Finding Genius Podcast

Play Episode Listen Later Apr 23, 2019 66:26

Jake A. Kushner M.D., Medical Director, McNair Interests, provides a thorough overview of his research and study of diabetes. Currently, Dr. Kushner serves as the Medical Director for McNair Interests. He is a renowned diabetes researcher as well as a pediatric endocrinologist with a particular expertise in biotechnology, biomedical research, type 1 diabetes and other specific endocrine disorders. Dr. Kushner is the former Chief of Pediatric Diabetes and Endocrinology and McNair Medical Institute Scholar at the Baylor College of Medicine and Texas Children's Hospital. He has worked with the National Institutes of Health, served on the type 1 diabetes advisory council for Lexicon Corporation, and been a strategic advisor for Sanofi. Dr. Kushner discusses his background as a pediatric endocrinologist and how he came to be interested in the research and study of diabetes. Dr. Kushner is a respected, nationally recognized expert in type 1 diabetes research. His background in medicine is significant and includes endocrinology and diabetes, specifically caring for children with type 1 diabetes, as well as cystic fibrosis-related diabetes, and treating children who have hypoglycemia. He explains type 1 diabetes, and talks about how it affects many people worldwide. Dr. Kushner delves into the complex issue of insulin and how the body reacts and responds to nutrients. He explains in detail, the storage of glucose, carbohydrates, and how the body processes everything that comes into it, as well as how stress affects everything. He talks at length about the kinds of meals that people eat, and explains how specific foods are processed by the body for use, including what the body needs, especially for those who have special dietary requirements due to health conditions or disease. Dr. Kushner is a UC Berkeley graduate and earned a medical degree from Albany Medical College in New York. Dr. Kushner completed his medical residency in pediatrics at Brown University. Additionally, Dr. Kushner engaged in a clinical fellowship at Children's Hospital Boston and a prestigious research fellowship at the Joslin Diabetes Center, the world's largest diabetes research center, at Harvard Medical School in Boston.

Circulation February 5, 2019 Issue

Circulation on the Run

Play Episode Listen Later Feb 4, 2019

Dr Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr Carolyn Lam, from National Heart Center and Duke National University of Singapore. Dr Greg Hundley: And I'm Greg Hundley, associate editor for circulation from VCU Health Systems in Richmond, Virginia. Dr Carolyn Lam: What does cardiac autoimmunity, glycemic control, and cardiovascular disease risk and Type I diabetes have in common? Well, you've got to wait for our feature discussion. This one's such a hot one, don't you agree, Greg? We could hardly finish talking. Dr Greg Hundley: Absolutely, and Myra, you're just going to love listening to her. Dr Carolyn Lam: Yep, but stay tuned. First, we're going to discuss a couple of papers each. Greg. Dr Greg Hundley: Thanks Carolyn. So, the first paper I've got is from Professor Van Rein at Leiden University Medical Center. And basically he's getting at the issue of bleeding in patients with atrial fibrillation. So this is a retrospective cohort that evaluates different anticoagulation strategies for atrial fibrillation. They examined 272,315 patients that had a median age of 75 years and followed them longitudinally over time. These individuals experience 31,459 major bleeding events, and what he did is he evaluated whether they were not taking anticoagulant therapy, whether they were on a vitamin K antagonist, a DOAC, antiplatelet therapies, and then all combinations of the above, including single, double and triple therapy. What he observed is relative to taking a vitamin K antagonist alone. The hazard ratios range from 1.13 to 3.73 in those that were receiving dual antiplatelet therapy of vitamin K antagonist plus antiplatelet therapy, a DOAC plus antiplatelet therapy, and then of course triple therapy, which had that highest hazard ratio. Dr Carolyn Lam: But were there particular combinations within these groups that had particularly high bleeding risk? Dr Greg Hundley: Well, yeah, Carolyn. As we might expect, triple therapy was the worst, but those that were receiving triple therapy, there were two subgroups that were particularly susceptible to having a bleeding episode. First, those that were greater than 90 years of age, and second, those that had CHADS-VASc 2 scores greater than six. Of course, these are very complicated patients, often particularly that latter group. So there are clinical implications. I mean, clearly, this isn't a randomized trial, but what we should take away from this is that if we have one of those two patient groups, age greater than 90, CHADS-VASc score greater than six, that we ought to minimize the time that those individuals are on that triple therapy. Dr Carolyn Lam: Talk about and bleeding, I've got a paper, and it's on the performance of the ABC scores for assessing the risk of stroke and systemic embolism or bleeding in patients with atrial fibrillation. This is a study that actually looked at the performance of these scores in an external cohort, which actually hasn't really been done. Now, as a reminder, the ABC score is actually the age biomarker clinical history stroke score, which helps to estimate the risk of stroke or systemic embolism. The ABC bleeding risk score incorporates biomarkers along with the clinical variables to estimate the risk of bleeding. All of these were tested in the ENGAGE AF-TIMI 48 trial, which was that multinational randomized trial of the oral factor Xa inhibitor edoxaban in patients with atrial fibrillation and a CHADS-VASc 2 score of two and above. Now, this was from Dr Morrow and the TIMI study group in the Brigham and Women's Hospital, Harvard Medical School in Boston, Massachusetts. Basically what they found was that the ABC stroke and ABC bleeding risk scores performed well in stratifying the risk for stroke or systemic embolic events or major bleeding in this multinational trial. Compared to the CHADS-VASc score, the ABC stroke score provided both correct upward and downward reclassification of the stroke systemic embolism risk. Compared with the HAS-BLED score, the ABC bleeding score resulted in a predominantly correct downward reclassification of the bleeding risk. Dr Greg Hundley: So, this new ABC score, do we integrate it with HAS-BLED? Do we integrate it with CHADS-VASc 2? How do we use this clinically? Dr Carolyn Lam: So first of all, there are some important remaining unanswered questions, and this was really nicely discussed in an accompanying editorial by Dr Hylek from Boston University School of Medicine. Among this, first of all, the ABC scores need to be validated in patients outside of a clinical trial. Remember, this was a clinical trial cohort. Then there are questions about the timing of measurements of the score, the different settings, hospital and otherwise. Do these scores perform equally well across different vascular beds and in diverse patient populations at the same thresholds used? So, all these things still need to be addressed. And really, in Dr Hylek's words, the work has just begun. Dr Greg Hundley: This is an issue with the theme that might be bleeding, and I'm going to talk about a study from Professor Huisman from Leiden University again, and this is the RE-VERSE AD study. Again, patients that are receiving dabigatran and that may have a GI bleed or patients that are on this therapy and unexpectedly need an emergent surgical procedure, this investigative team evaluated the utility of idarucizumab on reversing that anticoagulant dabigatran. So what did they do? They administered 2.5 milligrams of idarucizumab twice separated by 15 minutes. And again, the study population was uncontrolled GI bleeding or those in need of an emergent procedure. The types of GI bleeds that were involved in this study, a third were upper GI bleeds, a third lower, and then a third, it was either unknown, or there was a mixture of both upper GI or lower GI bleeding. So how do we know that dabigatran is effective? We use a DTT time, and 98% of those with an elevated diluted thrombin time had that reduced after receiving these two twin 2.5 milligram doses at a time point of four hours after administration. Dr Carolyn Lam: Okay, but were there any complications? Dr Greg Hundley: Yeah, there were. So first of all, something to think about is that this is a high-risk group. In this study, 14.6% of the cohort actually later died either from the bleeding or what have you. Then another thing we need to be thinking about is when we reversed this anticoagulant, do patients experience thrombotic events? So what this group reported is 4.4% did within 30 days. What were those? Myocardial infarction, deep venous thrombosis, and subsequent PE. Then also at the 30-day time point, one patient experienced an ischemic event. Another question is once you've administered this, you've gone through the procedure. You stopped the GI bleeding, or you've had the surgery. In this particular study, 66% of those individuals had restarted their DOAC. Those events occurred on top of that. So, interesting information. Looking at administration of idarucizumab, and we'll be using this I think frequently as DOACs are used more frequently in the population, particularly dabigatran, so some important data in guiding us on what we might expect when we administer this therapy. Dr Carolyn Lam: I think going back to atrial fibrillation though, this is my other selected paper, and it's actually results from the GARFIELD-AF Registry. It's from Dr Bassand from University of Besançon in France, and colleagues, and basically, they looked at the early risks of death, stroke, systemic embolism and major bleeding in patients with newly diagnosed atrial fibrillation in the GARFIELD-AF Registry. They basically found that the rates of all three major clinical events was significantly higher during the first month than in the subsequent period set following up to 12 months. The leading causes of early death were heart failure, sudden death, acute coronary syndromes, infection or sepsis, and respiratory failure. Dr Greg Hundley: So, what's the take-home message here? Dr Carolyn Lam: This is observational, so the key thing to understand here, it's a registry. It's observational. We can't really tell chicken from egg with regards to its newly diagnosed AF verses events, which comes first, which causes what. But nonetheless, the increased hazards of an early event and especially cardiovascular mortality in these newly diagnosed AF patients really point to the importance of comprehensive care for such patients and really should alert physicians to detect warning signs of possible early mortality in these newly diagnosed patients. Dr Greg Hundley: Very good, Carolyn. Dr Carolyn Lam: I think that wraps it up. Let's hop to our feature discussion, shall we? I'm so super excited about today's feature paper because it may explain that strong link between hyperglycemia and cardiovascular disease in type one diabetes and all by revealing a potential novel pathway that may have been hiding in plain sight. And yes, I'm stealing the words of editorialists and our associate editor, Dr Naveed Sattar from University of Glasgow, and we're all so pleased to have with us the corresponding author of today's feature paper, Dr Myra Lipes from Joslin Diabetes Center in Boston, Massachusetts. Myra, start us off by telling us a little bit about your study please. Dr Myra Lipes: Sure. So we were interested in examining the role of whether chronic hyperglycemia could trigger cardiac autoimmunity in type one diabetes, because chronic hyperglycemia is associated with subclinical myocardial damage, and we had actually previously observed just unexpectedly in a young adult cohort that ... Actually from Italy, where unexpectedly, we noticed that patients with the poorest glycemic control expressed cardiac antibodies. There's a lot of interesting people who are autoimmune-proned may overreact to injury of certain tissues. So, type one diabetes, it's a classical autoimmune disorder. So we examined, really tested this hypothesis, in stored samples from the DCCT/EDIC study, and this is a very landmark study where patients were randomized to tight glycemic control, intensive glycemic control. Then another group had just conventional control, and this was done over an average of six and a half years. So during this time, the samples were stored. Every year samples were stored from participants, and this was quite a rich data set that is publicly available. So we studied the development of autoimmunity in two groups that had very distinct separations of the A1C level. We specifically excluded people who developed kidney disease or cardiovascular disease events during the study. So this is a cohort that had relatively recent onset type one diabetes. They're relatively healthy, and again, groups were matched with cardiovascular risk factors at the beginning and the end of this DCCT period. And of course with our studies, we've also looked genetically because your HLA immune response genes can influence susceptibility to autoimmunity. These patients were actually matched in HLA genotypes. So what we found was that patients with poor glycemic control, there was expression over time. You could see a time course relationship between expression of antibodies over time on the levels of the antibodies that were different in the two A1C groups. The number of antibodies were different in that with the high group expressing more antibodies, more different types of antibodies. These are antibodies ... might say antibodies as like proteins in the blood, and they're actually directed against parts of the myocytes, the myofibrillar complex, and a major target is cardiac myosin heavy chain. We saw the different parts of the myosin heavy chain retarded, and the presence of two or more antibodies, different types of antibodies, different regions of the myosin to different isoforms. Also, we saw antibodies, the troponin, troponin I. So the number of antibodies with different ... with almost a complete absence of antibodies in a tightly controlled group. I might mention the A1C average was 6.5%, so this is a very tightly controlled group whereas the poorly controlled group is at the opposite extreme, the average A1C during DCCT. The mean updated A1C was about 10%. So, it was a very clean group, two different groups, and we could see that the number of the types, the number over time, very different in the two groups. In fact the profiles of these antibodies were almost very similar to patients with Chagas cardiomyopathy. That was our positive control group. Chagas cardiomyopathy is possibility to be a form of chronic myocarditis directed against cardiac myosin. So the profiles are almost indistinguishable. So on one hand, you have relatively healthy patients with type one before glycemic control, and that was very unexpected that this would look pretty similar. But very interestingly, and I might say unexpectedly, we saw ... It was very clear that the people with the highest titers of antibody and the most different types of antibodies, particularly two or more, were subsequently ... We noticed that those patients were at high risk for developing CVD events. And that's while the number of events was slow, we noticed that all the patients, some 60%, had two or more antibodies and developed cardiovascular events. Perhaps one more striking example is a single patient in the study could die of cardiovascular death, had a positivity for all five antibodies at highest titer. Then we looked at coronary calcification just to measure subclinical atherosclerosis. We noticed that the same numbers, two or more, and also the same antibody specificities that were the highest predictors of CVD events were also predictive of coronary ... had detectable coronary calcification. In addition, we looked at the levels trying to find mechanistically what could explain the link between cardiac autoimmunity and an increased risk for atherosclerosis. We looked at CRP, high sensitivity CRP levels. Again, these were measured about a decade after the antibody samples were obtained, and we saw that the positivity for multiple antibodies was also associated with markedly elevated ... subsequently elevated high sensitivity CRP levels with levels of six versus something like 1.4 in a group with one or less antibody. So these were very intriguing findings, suggesting a role for autoimmune pathways as a susceptibility to cardiovascular disease in type one diabetes. Dr Greg Hundley: Myra, that was absolutely incredible description of the study and all the particulars of the findings. I wonder if I could ask both you and Naveed, where do you see the next steps moving forward with this research in the future? Number one. And number two, is this in any way can be used to segregate patients that may need, for example, really aggressive glucose control with an insulin pump or something of that nature? Naveed Sattar: I think we left this study as beautifully described as you see by Dr Lipes. I think the context ... We looked at this from editorial perspective ... is that most people don't realize if you have a middle-aged person with type one, their hazard ratio for cardiovascular risk is about somewhere between four to six fold for men and women respectively, which is much higher than type two. It's often thought that it's the area under the curve for hyperglycemia. But what this paper throws up is actually maybe there's another pathway, which we just didn't understand that this wasn't a permanent autoimmunity closing subclinical myocardial disease and inflammations. But potentially, for me though, there's a saying in British that one swallow does not make a summer. So, it would be nice for other groups to replicate this. I think the findings are, as they stand in isolation, fantastically well done. But it would be lovely if other groups had accessible samples, and I knew of several groups that have up towards tens of thousands of samples, maybe even not 10,000. Certainly 10,000 or so plus or minus samples for type and prospective outcomes to potentially validate the findings and extend them. And really, if the antibodies do help protect people at higher risk in a meaningful way and improve beyond what we can already do, then you're right. Absolutely. If we can pick up early people who are going to have substantially higher risk, you would want to potentially improve glycemic control, potentially pumps, CGM, closed-loop systems or more intensive statins or lower blood pressure targets or other types of antihyperglycemic agents, which seem to be being tested in type one as well. So that's really one example. And for me, the other thing would be really nice is to pull up any inflammation. Is this high systemic inflammation? Is it IL-6 level? Is it something else? What about troponin and BNP levels, et cetera. I'd be interested to hear what Dr Lipes thinks and how do you think to take it forward as well. Dr Myra Lipes: So, this is something Dr Sattar said and I completely agree. Actually, right now, we're looking at the DCCT cohort as a whole for already. It's relatively small compared to the population-based studies. But there's 1,400 patients, and the subjects had CMR studies that were published in Circulation. So we're going to actually study next whether we see CMR evidence of systolic dysfunction and looking at the broader DCCT cohort. So, those studies are underway. But of course the ultimate test would be looking at if there were samples available from the Swedish NDRs, Scottish registry. I think it's something that's not often done prospectively. So that would be incredibly exciting, and that's the important thing. I'd say with type one diabetes, for screening for type one diabetes, the use of autoantibodies and particularly two or more different types of islet autoantibodies, and this is just putting things in a broader context, is the entry criteria for type one diabetes prevention trials and something cardiologists wouldn't be aware of but this particular thing. So in decades, people, researchers, in the field has spent decades optimizing islet antibody assays. So by analogy, it would be really important to standardize assays so that they can be done in Sweden and Scotland and so that other groups could confirm this, and I'm confident that this could be done, since the setting up of our assays was really built on the experience of people of developing standardized assays and rigorous cutoff points for antibody positivity. So it would be really important to work internationally to try to tap into this. Dr Carolyn Lam: Oh, my goodness. Myra, Naveed, these are such insightful comments. I think as Greg said earlier, I think we could go on forever discussing this paper, but I'm so sorry. Our time is up. Before we go though, I must point all readers to look at figure five of this marvelous paper. It puts together the whole schema of how autoantibodies can play a role both in myocardial and atherosclerotic cardiovascular disease and type one diabetes. Thank you so much. Greg and I loved having you. Listeners, don't forget to tune in again next week. This program is copyright American Heart Association 2019.

Dietary Psychiatry

Live Right Now

Play Episode Listen Later Sep 24, 2018 37:49

Live Right Now - Episode 014 - Dietary Psychiatry Dietary Psychiatry: malnutrition and cognitive function After locking my keys inside the car while it was still running and Sandra rolling over one morning asking, “Who are you and why are you in my bed”; both in our early 70’s, we acknowledged our mental health is indeed fading. But seriously, there is mounting acceptance on the use of food and supplements to provide essential nutrients as part of a treatment for mental health disorders relating to depression, cognitive function, and dementia. As we age, memory blips will increase, although you needn’t put out the welcome mat. Widespread senior malnutrition in America is serious biz. According to the National Resource Center on Nutrition, Physical Activity, and Aging, 1 in 4 older Americans has poor nutrition… in America, in the 21st century. Looking back, I’m certain the quality of Mom’s late life would’ve have been richer if she’d chosen or been encouraged to eat more than a processed deli turkey sandwich on nasty white bread with Miracle Whip and a sweet pickle every day, 365 days a year. A paper napkin has more nutrition for goodness sake. Saturated fat, white flour, chemical preservatives, and sugars fertilize mental decline and starve the cells of much needed vitamin nutrition. All life’s food choices profoundly affect their mental health. The NIH reports a lack of wholesome vitamin nutrition from fresh, not canned, frozen or processed institutional food, contributes to the onset of poor mental health in people suffering from anxiety and depression, bipolar disorder, and schizophrenia. Because we’ve become somewhat disconnected from the garden since the Industrial Revolution and plugged in to “Man’s egoic genetically manipulated version of a garden”, modern seniors are woefully deprived in foods and nutrients considered “brain food”: omega-3 fatty acids from cold water fish, flax and chia seeds, walnuts, cholesterol (yes cholesterol), D-3, B-complex, especially B12. Regarding cholesterol, aka, brain food, at least a dozen reports show the risk of suicide may be substantially higher in people with low cholesterol. In a French study that tracked 6,393 men, published in the September 1996 issue of the British Medical Journal, those with low cholesterol were three times more likely than the other men to kill themselves. A link between low cholesterol and depression has turned up in other studies. Hmm? cholesterol was never really the health boogeyman the medical community made it out to be. Your brain needs cholesterol to grow new nerve cells and for these nerve cells to work properly. And when your brain is deprived of cholesterol, things don’t go so well up there. In fact, researchers at Joslin Diabetes Center say without enough cholesterol, you may even develop serious brain diseases like Alzheimer’s and Parkinson’s. Of course, "Physical exercise has the best evidence for preserving memory and mental function with aging," says R. Scott Turner, MD, PhD, director of the Memory Disorders Program at Georgetown University Medical Center In a world where we’ve been programmed to let others form our thoughts and opinions, we’ve long forgotten who calls the shots and knows what’s best, and it’s not a food corporation. We’ve departed the road of nutritional righteousness: disconnected earth’s apothecary. It’s happened so slowly we’ve not noticed how far we’ve strayed from the perfect plant-based diet or cells understand. Man cannot outsmart the mechanics of a universe he’s incapable of understanding and will never improve on Mother Earth. During this magnificent golden period of your life, give extra consideration to what foods you choose to eat. You were gifted one strong, sacred and beautiful temple by the One Divine Mind. Embrace it with dietary self-love. Choose to focus your thoughts on remaining the clear-headed, beautiful unique being you are for as long as you can and not lock your keys in the idling car or waking up next to a stranger. https://www.webmd.com/men/features/can-your-cholesterol-be-too-low-feature#1 https://theconversation.com/why-nutritional-psychiatry-is-the-future-of-mental-health-treatment-92545?utm_medium=ampemail&utm_source=email https://pilotonline.com/inside-business/news/columns/article_42cec91a-7158-5d52-92b8-97b46bc145ff.html?__vfz=medium%3Dsharebar FACTORS LEADING TO NUTRITIONAL DEFICIENCY AND INSUFFICIENCY A divorce from nature-disconnected to source Start paying attention to how eating different foods makes you feel — not just in the moment, but the next day. Try eating a “clean” plant food diet for two to three weeks. Cut out all processed foods and sugar. Add fermented foods like kimchi, miso, sauerkraut, pickles, or kombucha. try going dairy-free — Some feel better when their diets are grain-free. See how you feel. Then slowly introduce foods back into your diet, one by one, and see how you feel. Studies show when people take probiotics (supplements containing the good bacteria), their anxiety levels, perception of stress, and mental outlook improve, compared with people who did not take probiotic (Lancet and Harvard.) Vitamin DEFICIENCY / INSUFFICIENCY. FOLATE Folate is especially promising for depression-Dark leafy greens, asparagus, broccoli and cauliflower, citrus, beans, peas, lentils, avocado, seeds and nuts, beets. Omega-3 Fish oil is rich in omega-3 fatty acids, a major building block in optimal brain chemistry. Americans get adequate amounts of omega-6 fatty acids, we often come up short in omega-3s. Without enough omega-3s, "you tend to not transmit nerve signals properly, "When your brain isn't running properly, you can feel depressed or anxious. VITAMIN D Vitamin D helps combat anxiety and depression. A 2008 study of 441 overweight and obese men and women in Norway found that those given 20,000 and 40,000 IUs per week of vitamin D supplements had significantly less depression symptoms after one year than those in a placebo group. B-COMPLEX VITAMINS Mild depression is an imbalance of brain neurotransmitters-natural chemicals that can act as mood enhancers by helping transmit signals between brain cells. A 2004 Danish study of 140 people found that those who were clinically depressed had low levels of vitamin B6 in their blood. If upping serotonin levels through B6 and B3 doesn't help, turning to vitamin B12 plus folic acid, A 2002 Dutch study of nearly 4,000 elderly people backs up this suggestion: Researchers found that many of those who had depression symptoms also had vitamin B12 deficiency. Richest among all the vitamin B complex foods are milk, yeast, liver, whole-grain cereals, nuts, eggs, yogurt, fruits, meats and leafy vegetables. B-Complex sources: Sublingual B-12 Pork, berries, legumes, lean meats. Nuts, soy milk (Vitamin B1) Eggs, dark green vegetables, fish, grains, lean meat, mushrooms (B2) Sunflower seeds, tuna, poultry, potato, cottage cheese, liver (B3) Organ meats, avocados, broccoli, mushrooms(B5) Green beans, whole grains, spinach, fish, bananas(B6) Soy products, egg yolks, fish, organ meats, cheese, sweet potatoes(B7) Green leafy vegetables, citrus juice, legumes, tofu, tomato juice (B9) Milk, fish, fortified breakfast cereal, eggs, shellfish (B12) For more from Chef Wendell including the “Eat Right Now” books and info on how to book Chef Wendell to speak to your group go to http://www.chefwendell.com. To connect with the Live Right Now Podcast “like” our Facebook page or email us at LiveRightNowRadio@gmail.com. The Live Right Now theme music is “future soundtrack II” by Adam Henry Garcia from the Free Music Archive licensed under CC BY-NC-SA 4.0

025: Q&A, funny moments and why a CGM is a game changer for T1’s - with Heather Lampert

DiabeticTim Podcast: Type 1 Diabetic Interviews

Play Episode Listen Later Sep 5, 2018 17:23

In this episode of the podcast, Tim welcomes back Heather Lampert. Heather is a Doctor who is involved in diabetes research at Joslin Diabetes Center. Tim asks a few questions around her experiences of being a type 1 so far. We also get her unique perspective on why owning a CGM is a game-changer. Heather on Instagram Heather's Website: doctordiabeatit.com Please don’t forget to subscribe to the podcast to get new episodes early! Please check out diabetictim.com You can find me here: Instagram Facebook Twitter YouTube

doctors game changers cgm lampert funny moments joslin diabetes center heather's website

016: Talking Type 1 with a Type 1 Doctor - diabetes research and more - with Heather Lampert

DiabeticTim Podcast: Type 1 Diabetic Interviews

Play Episode Listen Later Jul 4, 2018 28:41

Today on the Podcast, Tim has a chat to Heather Lampert. Heather is a Doctor who is involved in diabetes research at Joslin Diabetes Center. Heather is also a fairly new Type 1 diabetic herself which makes her story so interesting. We get into interesting discussions around the future of type 1 and more. Heather on Instagram Heather's Website: doctordiabeatit.com Non-Diabetic Wears Dexcom: YouTube (Ali - The Diabetes Daily Hustle) Please don’t forget to subscribe to the podcast to get new episodes early! Please check out diabetictim.com You can find me here: Instagram Facebook Twitter YouTube

doctors type1 lampert diabetes research joslin diabetes center heather's website

New Science In The World Of T1D With Heather Lampert, MD

Bravest Podcast

Play Episode Listen Later Jul 2, 2018 74:25

On today's show, we have Dr. Heather Lampert. Heather is a Postdoctoral Research Fellow at the Joslin Diabetes Center in Boston, Massachusetts, and she holds the William Randolph Hearst Fellowship in Clinical and Translational Research. She is not only super smart and insightful, she also happens to be someone living with type 1 diabetes. In this episode, we go deep into Heather's background, and we talk about three key areas that are of critical importance to anyone living with type 1 diabetes. We talk about exciting research in the area of diagnosis and the gut microbiome as it relates to type 1, Heather then zeros in on new technologies in the world of treatment and management, and we wrap up with a conversation about the potential for a cure for type 1. This is a unique opportunity to dive into the clinical and research science as it relates to type 1 diabetes, and learn from someone who is not only directly impacted by type 1, but also someone who is embedded in cutting edge of science. www.thebravestlife.com/047 www.imgreaterthan.com www.doctordiabeatit.com

research massachusetts diabetes clinical microbiome new science cgm postdoctoral research fellow translational research lampert joslin joslin diabetes center

The Resonance Test 16: John Brooks of Healthcare Capital, LLC

The EPAM Continuum Podcast Network

Play Episode Listen Later Nov 2, 2017 32:05

John Brooks—the managing director of Healthcare Capital, LLC and former president and CEO of the Joslin Diabetes Center—is a something of a legend in the diabetes sector. As much an inventor as an investor, he brings a spirited intelligence and diverse experience to fighting this chronic disease. We're pleased to welcome him to *The Resonance Test.* In this energetic conversation, Brooks and Continuum SVP Mike Dunkley range all over the diabetes ecosystem, covering the move from a technological focus to more holistic solutions, how AI and machine learning might provide new opportunities, what future business models might look like, and in general, how we need to develop new approaches to diabetes. Tune in to hear Brooks say: • “I just have a strong passion to see what I can do to try and help the now 461 million people around the world that have diabetes.... We all look at the numbers. It's only escalating. We need to think differently.” • “All of the players need to be in the solution business.” • “Part of the problem is there hasn't been a lot of economics to reward helping people not develop a chronic condition.” • On doctors: “They've got 15 minutes to try to come up with something intelligible and if they're spending 10 minutes to try to get the bottom of it, that's not a good use of their time.” • “If the AI enables better understanding of what's going on with people with diabetes, the key is: How do the healthcare providers, nurse educators, clinicians, partner care doctors, endocrinologists, how do they adopt? Because, at the end of the day, their economics are important.” Host: Pete Chapin Editor: Kyp Pilalas Producer: Ken Gordon

ceo ai healthcare llc capital resonance john brooks joslin diabetes center

Ketones, Insulin and the Physiology of Fat Cells

Nourish Balance Thrive

Play Episode Listen Later Oct 21, 2017 45:44

Dr. Ben Bikman is an Associate Professor of Physiology & Developmental Biology at Brigham Young University. He has a PhD in Bioenergetics and did his postdoctoral work in Cardiovascular and Metabolic Diseases such as obesity. In this interview with Dr. Tommy Wood, MD, PhD, Ben talks about his recent tenureship and research on the metabolic effects of insulin and ketones on fat cells. Also discussed are two schools of thought in obesity research and how both groups may be right about various aspects of weight loss. As you might be able to tell, I struggled a bit to find a picture of Tommy in the lab to match Ben's. Props to Tommy for allowing me to use the pic on the left (taken in jest), I thought it too funny to go to waste. Here’s the outline of this interview with Ben Bikman: [00:01:59] Dr Ben Bikman recently made tenure. [00:02:46] The tenureship process. [00:04:14] Presentation: Insulin vs. Ketones - The Battle for Brown Fat by Dr Ben Binkman. [00:05:16] Podcast: Recap: Icelandic Health Symposium 2017 and Satchidananda Panda. [00:06:20] The Pubmed warrior; Ivor Cumins aka the The Fat Emperor. [00:07:16] Publishing a book. [00:07:44] Dr Jeff Gerber and Dr Rod Tayler organizers of Low Carb Breckenridge. [00:09:40] Removing the invisible barrier between the scientists and the public. [00:12:36] American Heart Association. [00:13:01] Study: Hall, Kevin D., et al. "Energy expenditure and body composition changes after an isocaloric ketogenic diet in overweight and obese men." The American journal of clinical nutrition 104.2 (2016): 324-333. [00:14:33] Calorie type is more important. [00:14:58] Study: Walsh, C. O., Ebbeling, C. B., Swain, J. F., Markowitz, R. L., Feldman, H. A., & Ludwig, D. S. (2013). Effects of diet composition on postprandial energy availability during weight loss maintenance. PloS one, 8(3), e58172. [00:15:58] The Biggest Loser. [00:16:58] The importance of protein. [00:18:22] Protein increases glucagon. [00:20:16] Just eat real food. [00:20:48] Ben's research on adipocytes, studies not completed yet. [00:22:20] White vs brown fat. [00:22:50] Uncoupling to create heat. [00:24:18] Fat mass also changed. [00:24:49] Study: Roberts, Megan N., et al. "A Ketogenic Diet Extends Longevity and Healthspan in Adult Mice." Cell Metabolism 26.3 (2017): 539-546. [00:25:35] Study: Lim, Gareth E., et al. "14-3-3 [zeta] coordinates adipogenesis of visceral fat." Nature communications 6 (2015). [00:27:15] Wasting away in T1D. [00:27:35] Elliot Joslin of the Joslin Diabetes Center and Francis Benedict. [00:28:55] Ketones can be insulinogenic. [00:29:33] Study: Biden, Trevor J., and Keith W. Taylor. "Effects of ketone bodies on insulin release and islet-cell metabolism in the rat." Biochemical Journal 212.2 (1983): 371-377. [00:30:12] Exogenous ketones and weight loss. [00:30:59] Study: Holdsworth, David A., et al. "A ketone ester drink increases postexercise muscle glycogen synthesis in humans." Medicine and science in sports and exercise 49.9 (2017): 1789. [00:33:16] Human clinical studies. [00:37:26] Ben is not an advocate of chronic ketosis. [00:39:17] Breakfast and lunch are easy to change. [00:40:49] Study: (PURE) Dehghan, Mahshid, et al. "Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study." The Lancet(2017). [00:43:43] Dr Ben Bikman on social media: Instagram, Facebook, Twitter.

How to Reverse Insulin Resistant Type Two Diabetes in 100 Million People in Less Than 10 Years

Nourish Balance Thrive

Play Episode Listen Later Sep 16, 2017 62:48

For decades we’ve heard that diabetes prevention is simple—lose weight, eat less, and exercise more. But something is wrong with the conventional wisdom. Nearly 115 million people live with either diabetes or prediabetes in the United States, and that number is growing. It is time to reverse this trend. Virta was founded in 2014 with the goal of reversing diabetes in 100 million people by 2025. They have made this possible through advancements in the science of nutritional biochemistry and technology that is changing the diabetes care model. James McCarter, MD, PhD, is Head of Research at Virta, and in this interview, Dr McCarter explains how Virta is using a combination of a very low carb, ketogenic diet together with 1-on-1 health coaches and some sophisticated machine learning techniques to predict sentiment in natural language and spot anomalies in blood biomarkers. After the recording was made, Dr McCarter realised that he was off by about a decade on Joslin. Rather than 1920s, Dr. Elliott Joslin actually began keeping a diabetes registry early in the 20th century and published The Treatment of Diabetes Mellitus in 1917. “Joslin carried out extensive metabolic balance studies examining fasting and feeding in patients with varying severities of diabetes. His findings would help to validate the observations of Frederick Madison Allen regarding the benefit of carbohydrate- and calorie-restricted diets.” Here’s the outline of this interview with James McCarter, MD, PhD: [00:01:00] Divergence, Inc. [00:01:43] Presentation: The Effects of a Year in Ketosis with James McCarter, MD, PhD at the Quantified Self Conference and Exposition. [00:02:44] Books by Gary Taubes. [00:03:13] Omega 3:6 ratios. [00:05:54] Rapeseed and Canola. [00:06:44] Wild Planet sardines. [00:07:11] The Virta story. [00:07:18] Sami Inkinen. [00:07:38] Study: SD. Phinney, BR. Bistrian, WJ. Evans, E. Gervino, GL. Blackburn, The human metabolic response to chronic ketosis without caloric restriction: preservation of submaximal exercise capability with reduced carbohydrate oxidation., Metabolism, volume 32, issue 8, pages 769-76, Aug 1983, PMID 6865776. [00:08:48] Jeff Volek, PhD, RD on PubMed. [00:09:51] Fear of fat. [00:10:13] USDA dietary guidelines. [00:12:59] The goal is to reverse T2D in 100M people. [00:14:09] Study: NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. Lancet (London, England). 2016;387(10027):1513-1530. doi:10.1016/S0140-6736(16)00618-8. [00:14:29] Joslin Diabetes Center. [00:16:37] The causes of T2D. [00:17:35] Calories are now more accessible. [00:18:22] Sugar and refined carbohydrate intake. [00:20:26] Prerequisites for the Virta program. [00:22:19] Telemedicine, health coaches, online nutrition and behaviour education, biometric feedback, peer community. [00:23:53] Getting off meds. [00:24:50] HbA1C > 6 or glucose > 120 mg/dL [00:25:32] Purdue University. [00:26:28] Podcast: Econtalk: Mark Warshawsky on Compensation, Health Care Costs, and Inequality. [00:29:02] Study: American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033-1046. doi:10.2337/dc12-2625. [00:29:27] Study: McKenzie AL, Hallberg SJ, Creighton BC, Volk BM, Link TM, Abner MK, Glon RM, McCarter JP, Volek JS, Phinney SD. A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes. JMIR Diabetes. 2017;2(1):e5. [00:30:45] Discontinuing 2/3 of the meds. [00:32:54] Health coaching. [00:34:18] Behaviour change. [00:35:30] Biometrics, blood BHB. [00:38:10] Reducing blood pressure and CRP. [00:38:30] Study: Youm, Yun-Hee, et al. "The ketone metabolite [beta]-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease." Nature medicine 21.3 (2015): 263-269. [00:39:49] Blood levels of BHB and weight loss. [00:41:36] STEM-Talk #43: Jeff Volek Explains the Power of Ketogenic Diets to Reverse Type 2 Diabetes. [00:43:33] Machine learning. [00:45:57] The Team at Virta including Nasir Bhanpuri, Catalin Voss and Jackie Lee. See article Will robots inherit the world of healthcare? For links to their talks. [00:46:49] Random Forest. [00:47:06] Nourish Balance Thrive 7-Minute Analysis. [00:48:05] Natural Language Processing. [00:48:57] Nourish Balance Thrive Highlights email series. [00:50:26] Finding purpose in your work. [00:51:59] Using machine learning to change behaviour. [00:53:25] Book: Hooked: How to Build Habit-Forming Products by Nir Eyal. [00:54:11] Podcast: How to Avoid the Cognitive Middle Gear with James Hewitt. [00:55:37] $400 per month for one year. [00:57:58] Blog Post: Does Your Thyroid Need Dietary Carbohydrates? By Stephen Phinney, MD, PhD. [01:00:21] Article: Understanding Local Control of Thyroid Hormones:(Deiodinases Function and Activity) and Podcast: The Most Reliable Way to Lose Weight with Dr. Tommy Wood. [01:02:12] Podcast: How Busy Realtors Can Avoid Anxiety and Depression Without Prescriptions or the Help of a Doctor with Douglas Hilbert.

united states fear head health power england books doctors phd research nature blood team md weight treatments sugar diabetes evans reverse worldwide reducing omega activity behaviour lose weight 100m inequality compensation usda metabolism calories dl insulin purdue university exposition blackburn telemedicine resistant biometrics ketogenic diet million people nir eyal ketosis pmid healthcare costs pubmed divergence crp natural language processing prerequisites diabetes mellitus build habit forming products diabetes care hba1c canola gary taubes mccarter joslin t2d phinney tommy wood virta bhb wj reverse type james hewitt joslin diabetes center nourish balance thrive wild planet sami inkinen jackie lee nlrp3 random forest jeff volek type two diabetes stem talk quantified self conference

Dr. Rani Polak: Chef and Doctor, Where True Healing Begins

Healthy Human Revolution

Play Episode Listen Later Aug 16, 2017 39:52

Why would a medical student quit medical school, go to culinary school and then back to medical school? Well that is the story of Dr. Rani Polak. Dr. Polak has an impressive resume and was a delight to talk to how he prescribes food as medicine and practices in the USA and Israel. Rani Polak, MD, Chef, MBA is founder and director of the Culinary Healthcare Education Fundamentals (CHEF) Coaching program at the Institute of Lifestyle Medicine, Spaulding Rehabilitation Hospital, and a Research Associate, PM&R Department, Harvard Medical School. Prior to this position he completed a Research Fellowship in Lifestyle Medicine at Joslin Diabetes Center, Harvard Medical School, and a residency in Family Medicine at the Hebrew University Medical School, Jerusalem, Israel. Dr. Polak had the good fortune to be the founder of the Hadassah Healthy Cooking and Lifestyle Center, and the Israeli Society of Lifestyle Medicine. His first lifestyle intervention won the Hebrew University’s Kaye Award Price for innovation, and his book, Delicious Diabetic Recipes is a gold best seller. Dr. Polak’s current focus is in nutrition education, and clinical and translational research relating to culinary medicine and medical education. His work focuses on CHEF Coaching utilizing evidence-based medicine to help individuals and professionals efficiently and cost-effectively improve nutrition. Aspects of this work includes a Patient CHEF Coaching program to improve the eating behavior of patients with cardio-metabolic risk factors, and a Clinician CHEF Coaching program that trains clinicians on how to provide effective culinary healthcare education. The Clinician CHEF Coaching program has been implemented into the Yale Preventive Medicine/Internal Medicine residency program and was recently approved by Harvard Medical School for Continuing Medical Education credits. Follow Dr. Polak on Twitter, @RaniPolakMD. Thank you for listening to the podcast and please share and rate wherever you listen!

SNR #186: Dr. Jake Kushner, MD - Nutrition for Type 1 Diabetes

Sigma Nutrition Radio

Play Episode Listen Later Jul 5, 2017 65:56

Dr. Jake Kushner is leading the efforts in Diabetes and Endocrinology at Texas Children's Hospital. Dr. Kushner is a McNair Medical Institute Scholar at the Baylor College of Medicine. As the Chief of Pediatric Diabetes and Endocrinology at Baylor College of Medicine, he is a major thought leader in type 1 diabetes care and research. His overarching career goal is to help children and young adults with diabetes and other endocrine disorders live long, healthy lives. His administrative priorities focus upon developing and promoting innovative new models of patient-centered care, education, and cutting edge research. A graduate of the University of California at Berkeley, Dr. Kushner earned his medical doctorate from Albany Medical College in New York. He completed a residency in pediatrics at Brown University. He then completed a clinical fellowship in Pediatric Endocrinology at Children's Hospital Boston, Harvard Medical School, followed by a 5-year research fellowship at the Joslin Diabetes Center at Harvard Medical School. Prior to arriving at the Baylor College of Medicine Dr. Kushner was at the University of Pennsylvania School of Medicine and the Children's Hospital of Philadelphia (CHOP). Dr. Kushner has received national awards, including elected membership to the prestigious American Society of Clinical Investigation. He currently serves as the president of the Society for Pediatric Research. Dr. Kushner's research has been supported by the National Institutes of Health, the Juvenile Diabetes Research Foundation and the March of Dimes, amongst other sources. His clinical interests include the care of children with type 1 diabetes. Dr. Kushner's research is focused upon of the insulin-secreting beta cells of the pancreas. A major theme of the Kushner lab includes studies to understand the origins of adult beta cell growth and regeneration. Until recently it was not clear exactly where adult beta cells came from during postnatal life. Dr. Kushner and colleagues have carried out studies in adult mice with a variety of advanced tools. In contrast to the dominant views, they do not observe any contribution to beta cell growth in adult mice from "tissue stem cells". Instead, they find that beta cells expand by simple division "self-renewal". Dr. Kushner and colleagues are currently extending this work, with the goal of studying beta cell regeneration under a variety of normal and disease conditions. In This Episode We Discuss: The intricacies of type 1 diabetes Beta cell dysfunction Nutritional approaches to type 1 diabetes: standard care and carbohydrate restriction Issues with low-carb for T1D: hypoglycaemic episodes? ketones? long-term safety unknown? "Low carb is not for everyone with T1D. Frankly, there is so much that we don’t know. But, low carb management of T1D can be quite advantageous for those who choose it." - Jake Kushner, MD

Diabetes Reset

Get Connected

Play Episode Listen Later Jun 25, 2017 12:52

THE DIABETES RESET by Dr. George King has practical strategies to improve your health, based on research conducted by Joslin Diabetes Center. joslin.org

reset diabetes george king joslin diabetes center

Diabetes Reset

Get Connected

Play Episode Listen Later Jun 25, 2017 12:52

THE DIABETES RESET by Dr. George King has practical strategies to improve your health, based on research conducted by Joslin Diabetes Center. joslin.org

reset diabetes george king joslin diabetes center

#167 RICHARD JACKSON, MD - GRASSROOTS DIABETES

Play Episode Listen Later Jun 1, 2017 45:55

This week, we were in Boston, on lots of Diabetes-related business. We were able to spend some time at Joslin Diabetes Center, and on campus at Harvard Medical. We also enjoyed the company of some old friends in the “D” community, and met some new ones. A fantastic week in the historic city of Boston. On today’s DiabetesPowerShow, Charlie Cherry, Chris Daniel, and Lori Cherry are broadcasting from the offices of GrassrootsDiabetes.org in Boston, Massachusetts. We are honored to speak with the Founder and Executive Director, Richard A Jackson, MD. Richard A Jackson, MD - Founder and Executive Director of Grassroots Diabetes. Dr. Jackson is an Endocrinologist and founder and President of Health Analytics Solutions, which provides proprietary data analysis and visualizations from a variety of healthcare databases, as well as consultations on chronic disease management. He is an Assistant Professor of Medicine at Harvard Medical School, and an adjunct investigator at the Joslin Diabetes Center. He is an avid Red Sox fan, and enjoys spending time at Fenway Park throughout the baseball season. More About Dr. Jackson The On the Road program was developed in 2001 collaboration with colleagues at the Joslin Diabetes Center, Dr. Bill Polonsky, a world-renowned diabetes psychologist, Melinda Maryniuk, an award-winning diabetes educator, the USDA, and the National Institute of Food and Agriculture (NIFA) Extension Services. For more than a decade, OTR was field-tested and modified with over 15,000 participants across the US. In 2012, Dr. Jackson and the On the Road team were awarded the prestigious Medicare and Medicaid Innovation Center award, as a part of the Affordable Care Act, to assess new types of low-cost approaches to healthcare. This 3 year award further validated and refined the OTR program, prompting Dr. Jackson to found Grass Roots Diabetes, in the hopes that the OTR program reaches as many people as possible around the world. In addition to being Founder and Executive Director of Grassroots Diabetes, Dr. Rich Jackson is also Founder and President of Health Analytics Solutions, which provides proprietary data analysis and visualizations from a variety of healthcare databases, as well as consultations on chronic disease management. During his 30 years at Joslin, Dr. Jackson was a Mary K. Iacocca Fellow, and received the Cookie Pierce Research Award from the Juvenile Diabetes Research Foundation, became head of the Immunology Section, and started the Hood Center for Prevention of Childhood Diabetes at the Joslin. He was involved with early trials to prevent type 1 diabetes, and was a Principal Investigator for the Diabetes Prevention Trial - Type 1 (DPT-1), the first NIH funded multi-center study for type 1 diabetes prevention. Beginning in 2001, he developed outreach programs in underserved areas, and was awarded a prestigious 5 million dollar Medicare/Medicaid Innovation award, to further develop these programs, using community health workers. His non-profit, Grass Roots Diabetes, is extending the impact of these programs. In addition, Dr. Jackson served as Director of Medical Affairs for Joslin’s extramural programs, with a variety of outside partners. He was also Medical Director for Joslin’s national clinical affiliation program, for which he established and tested a new set of clinical metrics for evaluating practices.

#166 Behavioral Diabetes Institute

Dr Ron Unfiltered Uncensored

Play Episode Listen Later Apr 10, 2017 48:13

On today’s DiabetesPowerShow, Charlie Cherry, Chris Daniel, and Lori Cherry are broadcasting from the offices of the Behavioral Diabetes Institute in San Diego, California. We are honored to speak with William H. Polonsky, PhD, CDE and Susan Guzman, PhD. Today, it’s all about what we at DiabetesPowerShow refer to as the people with Type 3 Diabetes…AKA Family Members, Loved Ones, and Friends of People with Diabetes. Dr. Polonsky and Dr. Guzman help us explore the many dynamic emotions and challenges that are experienced, not only by the people with Diabetes, but by those who love them. Diabetes is not a solo act…family and friends are as much a part of the process as the person with Diabetes. William H. Polonsky, PhD, CDE Dr. Polonsky is President and Founder of the Behavioral Diabetes Institute, the world's first organization wholly dedicated to studying and addressing the unmet psychological needs of people with diabetes. He is also Associate Clinical Professor in Psychiatry at the University of California, San Diego. Dr. Polonsky received his PhD in clinical psychology from Yale University and has served as Senior Psychologist at the Joslin Diabetes Center in Boston, faculty member at Harvard Medical School and Chairman of the National Certification Board for Diabetes Educators. A licensed clinical psychologist and certified diabetes educator, he received the American Diabetes Association’s 2014 Richard R. Rubin Award for distinguished contributions to behavioral medicine and psychology. An active researcher in the field of behavioral diabetes, Dr. Polonsky’s most recent research projects have focused on quality of life in diabetes, diabetes-related distress and depression, hypoglycemic fear, and glucose monitoring behavior and attitudes in people living with diabetes. Susan Guzman, PhD Susan Guzman, PhD is a clinical psychologist specializing in diabetes. Her clinical and research focus areas include overcoming barriers to management, family issues, and promoting attitudes that support living well with diabetes, from diagnosis throughout the lifespan. Dr. Guzman is co-founder and Director of Clinical/Educational Services at the Behavioral Diabetes Institute (BDI), the first non-profit organization devoted to the emotional and behavioral aspects of living with diabetes. At BDI, she developed programs for people with diabetes and their families and co-facilitates CME programs for Healthcare Professionals.

Dr Ron Unfiltered and Uncensored Guest Marc Blastein

Play Episode Listen Later Nov 29, 2016 64:00

Dr. Ron Marc sat on the board of the Diabetes Stakeholders Group, a Pennsylvania state-run board, located in Harrisburg, Pennsylvania, that helps to design and implement diabetes education and outreach programs for the state of Pennsylvania. He also sat on two diabetes boards at Philadelphia’s Jefferson Hospital. Marc has been a guest speaker on many television and radio programs over his lengthy career and has been a speaker at hundreds of diabetes-related events. He has written many stories that have been published in national diabetes publications and in a number of books in the diabetes field. Marc is the recipient of The Joslin Diabetes Center’s 50-Year Medal. This award is given to people who have lived with Type 1 diabetes for 50 years or more who are currently in the Joslin Diabetes Center’s International Study for 50-Year Medalists. Approximately 4,500 people have received this award among the more than 300 million people worldwide who live with diabetes. Marc is also a certified health coach teaching people how to “Win With Their Diabetes” as he has. He has counseled, coached and taught thousands of people. Marc is a graduate of the Institute for Integrative Nutrition in New York City. Dr. Ron has over 50 years experience as an MD with specialties in Family Practice and Emergency Medicine and he is a licensed Acupuncurist. Drs Gerry and Dan join us weekly for our discussions. This is a weekly program that tells it like it is with no influence from the Drug Companies. We are like Paul Harvey with the "Rest of the Story" We always discuss and comment on drug reactions, EMF radio frequencies and the tesla effect. Our goal is to give you information that you and your family can act upon and be able to make objective decisions. We will have interesting and informative guests for you to make decisions about your health. Look to February, Auto Immune Disease

#143 William Polonsky, PhD, CDE

university chicago science doctors home executive director numbers hospitals stanford public health diabetes south florida miss america nicole johnson lurie children joslin diabetes center

Play Episode Listen Later Mar 25, 2016 56:10

On today’s DiabetesPowerShow, Charlie Cherry, Chris Moore, Theresa Moore, and Chris Daniel welcome William H. Polonsky, PhD, CDE. Dr. Polonsky shares his wisdom on dealing with Diabetes Burnout and the emotional aspects of Diabetes. About William H. Polonsky, PhD, CDE Dr. Polonsky is President and Founder of the Behavioral Diabetes Institute, the world's first organization wholly dedicated to studying and addressing the unmet psychological needs of people with diabetes. He is also Associate Clinical Professor in Psychiatry at the University of California, San Diego. Dr. Polonsky received his PhD in clinical psychology from Yale University, and has served as Senior Psychologist at the Joslin Diabetes Center in Boston, faculty member at Harvard Medical School, and Chairman of the National Certification Board for Diabetes Educators. Most recently, he received the American Diabetes Association’s 2014 Richard R. Rubin Award for distinguished contributions to behavioral medicine and psychology. An active researcher in the field of behavioral diabetes, Dr. Polonsky has served on the editorial boards of Diabetes Care, Diabetes Forecast, Clinical Diabetes, Diabetes Self-Management and Diabetes Health. His most recent research projects have focused on quality of life in diabetes, diabetes-related distress and depression, hypoglycemic fear, blood glucose monitoring behavior and attitudes in people living with diabetes, physician and patient attitudes towards insulin and oral medications, group-based behavior change programs, the influence of continuous glucose monitoring on quality of life, and emotional and behavioral responses to the diagnosis of diabetes.

Diabetes By The Numbers

Diabetes by the Numbers

Play Episode Listen Later Jul 29, 2015 10:17

It seems nearly everyone knows Nicole Johnson. They remember her as Miss America 1999, they’ve seen her at conferences, on social media. All that, plus the fact that she always seems to have a smile on her face, makes people forget that she is actually Doctor Nicole Johnson, who is the first person to earn a Doctor of Public Health degree at the University of South Florida. Moreover, she is actually doing something important and meaningful with that distinction. That’s why you’ll hear me refer to her as Dr. Johnson, rather than Nicole, throughout our talk. She’s earned that right.In this episode of Diabetes By The Numbers, Dr. Johnson lets us in on the groundbreaking Postdoctoral Diabetes Fellowship Program that she’s running out of the University of South Florida.Part patient-facing, part research, five women from around the country will be taking part over the next year in a program that will develop and enhance their understanding of the complex relationship between human behavior and diabetes. Definitely a subject worth further scrutiny. The fellows will be mentored by doctors at the head of the class in this subject, including Dr. Johnson herself, Dr. Korey Hood at Stanford, Dr. Lori Laffel at Joslin Diabetes Center in Boston, and Dr. Jill Weissberg-Benchel at Lurie Children’s Hospital in Chicago.I would tell you more, but I prefer to defer to Dr. Johnson for the rest.Dr. Nicole Johnson is Executive Director of Bringing Science Home:http://bringingsciencehome.com Bringing Science Home is involved in a number of initiatives, including, but not limited to:Students With Diabetes http://hscweb3.hsc.usf.edu/studentswithdiabetes/Diabetes Partners http://hscweb3.hsc.usf.edu/bringingsciencehome/diabetes-partners/ ©Stephen Shaul

Diabetes Reset and Elder Chicks

The Kathryn Zox Show

Play Episode Listen Later Apr 15, 2015 54:23

Kathryn interviews George L. King MD, Research Director at Harvard's Joslin Diabetes Center and author of “The Diabetes Reset: Avoid It. Control It. Even Reverse It.” Imagine controlling, avoiding, or reversing diabetes – that's what 106 million Americans are searching for. Dr. King busts the media myths that keep Americans from changing their habits, outlining a clear twelve-week implementation plan for taking control over diabetes. Kathryn also interviews Thelma Reese EdD, former Hooked on Phonics spokesperson and author of “The New Senior Woman: Reinventing the Years Beyond Mid-Life”. Today's senior women are healthier, better educated, and more active than the women who preceded them. Reese and co-author Barbara Fleisher EdD bring us stories from women in their sixties and beyond that reveal the realities of the challenges faced by retirement-age women. Fleisher and Reese host the popular blog Elder Chicks.

americans harvard reset diabetes elder chicks research director fleisher hooked on phonics internet talk radio joslin diabetes center thelma reese

Diabetes Reset and Elder Chicks

The Kathryn Zox Show

Play Episode Listen Later Apr 15, 2015 54:23

americans harvard reset diabetes elder chicks research director fleisher hooked on phonics internet talk radio joslin diabetes center thelma reese

The Diabetes Breakthrough: Dr. Osama Hamdy on his 12-week Plan

Book Club

Play Episode Listen Later Aug 27, 2014

Host: Maurice Pickard, MD Obesity and sedentary activities have contributed to an epidemic of diabetes mellitus in the US. Is there an answer that is not simply a "fad" diet? Joining host Dr. Maurice Pickard to address this important question is Dr. Osama Hamdy, Medical Director of the Weight Management Program at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School. Dr. Hamdy is co-author of Diabetes Breakthrough: Better Health in Just 12 Weeks.

medicine nutrition breakthrough diabetes assistant professor book club harvard medical school medical director integrative medicine osama rmd week plan hamdy reachmd joslin diabetes center diabetes and endocrinology weight management program maurice pickard

The Diabetes Breakthrough: Dr. Osama Hamdy on his 12-week Plan

Book Club

Play Episode Listen Later Aug 27, 2014

Dr. Rani Polak: Chef & Fellow of Harvard's Institute of Lifestyle Medicine

The Wellness Coach: Take Time to Tune In

Play Episode Listen Later Apr 26, 2014 75:00

Dr. Rani Polak is currently a Research Fellow in the Institute of Lifestyle Medicine, Joslin Diabetes Center, Harvard Medical School. Dr. Polak is board certified in Family Medicine at the Hebrew University Medical School and completed an MBA degree in the Technion, the Israeli Institute of Technology and a Cuisine degree at the Le Cordon Bleu, Sydney, Australia. Dr. Polak founded the Hadassah Healthy Cooking and Lifestyle Center where his first lifestyle medicine intervention won the Hebrew University's Kaye Award for Innovation. Dr Polak is co-founder of the Israeli Society of Lifestyle Medicine and the author of the bestselling book Delicious Diabetic Recipes (Pen & Imagine Publishing, 2009) .He joined the ACLM at 2010. His current focus is in clinical and translational research relating to lifestyle medicine especially in the areas of healthy food preparation and medical education. Currently he works under the mentorship of Dr. Edward Phillips, focusing on incorporating healthy food preparation into Joslin's lifestyle programs, food preparation coaching, and lifestyle medical education. https://www.linkedin.com/pub/rani-polak-md-chef-mba/44/787/225 http://www.amazon.com/Delicious-Diabetic-Recipes-Gourmet-Cookbook/dp/B0071UHHSA

#110 The Diabetes Breakthrough-Osama Hamdy, MD, PHD, FACE

Hope, Healing and WellBeing – Mary O’Keefe

Play Episode Listen Later Apr 15, 2014 43:56

Osama Hamdy, MD, PHD, FACE is the Medical Director of the Obesity Clinical Program, at Joslin Clinic and Director of Inpatient Diabetes Management. He is a Clinical Investigator and attending Adult Endocrinologist at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School. On today's show, we talk with Dr. Hamdy about his new book, The Diabetes Breakthrough.

Hope, Healing and WellBeing – The Diabetes Breakthrough with Sheri Colberg, PhD

Play Episode Listen Later Mar 30, 2014 36:13

Uncontrolled diabetes can lead to extraordinary complications—heart disease, stroke, kidney failure, nerve damage, vision loss, hypertension. But according to research done at Joslin Diabetes Center, type 2 diabetes doesn’t have to end up that way. You can halt its progress—and even prevent it. Sheri Colberg, PhD is a professor of exercise science at Old Dominion University and an adjunct professor … Read more about this episode...

phd breakthrough wellbeing diabetes old dominion university uncontrolled hope healing joslin diabetes center

The Beta Cell in Diabetes and Obesity f/ Gordon Weir, MD (2/27/14)

Diabetes Research Center - Seminar Series

Play Episode Listen Later Feb 27, 2014 44:04

Gordon Weir, MD, Joslin Diabetes Center, TOPIC: “The Beta Cell in Diabetes and Obesity” DATE: Thursday, February 27, 2014, TIME: 9:00 AM, Russ Berrie Pavilion, 1st Floor Conference Room 2

time md diabetes beta obesity weir joslin diabetes center

Founder of Wellcoaches, Author, & Wellness Visionary Margaret Moore

The Wellness Coach: Take Time to Tune In

Play Episode Listen Later Dec 4, 2013 36:00

Margaret Moore, MBA (aka Coach Meg) is a 17-year veteran of the biotechnology industry in the UK, Canada, US, and France. She served in executive roles at three companies which later joined Sanofi, and served as CEO and COO of two early stage biotech companies. In 2000, Margaret shifted from high tech medicine to coaching in healthcare and wellness, and founded Wellcoaches Corporation - strategic partner of the American College of Sports Medicine, now a standard-bearer for professional coaches in healthcare and wellness. The Wellcoaches School of Coaching has trained more than 7,500 health and wellness coaches in 47 countries. Margaret is co-founder (with Carol Kauffman) and co-director of the Institute of Coaching at McLean Hospital, an affiliate of Harvard Medical School, and co- course director of the annual Coaching in Leadership & Healthcare conference offered by Harvard Medical School. Margaret's collaboration with Edward Phillips, MD, to create a Harvard Medical School CME program to teach physicians basic coaching skills, led to the launch of the Institute of Lifestyle Medicine now based at Joslin Diabetes Center, of which Margaret is an advisor. She is a co-founder and co-leader of the National Consortium for Credentialing Health & Wellness Coaches (www.ncchwc.org) which is developing national standards and certification of health and wellness coaches. http://www.wellcoachesschool.com/index.cfm?page=AU_coachmeg Organize Your Mind, Organize Your Life a Harvard Health book published by Harlequin

The Methodical Adventurer

Harvard Medical Labcast

Play Episode Listen Later Apr 29, 2013 7:21

Amy Wagers, professor of stem cell and regenerative biology at Harvard and Joslin Diabetes Center, is motivated by both the prospect of treating disease and the thrill of discovery. Watch for the Winter 2013 issue of Harvard Medicine magazine for a Q&A with her.

harvard adventurers methodical joslin diabetes center

NEJM Interview: Dr. Allison Goldfine on statins, the associated risk of diabetes, and the FDA's response.

New England Journal of Medicine Interviews

Play Episode Listen Later May 9, 2012 9:56

Dr. Allison Goldfine is the head of the Section of Clinical Research at Joslin Diabetes Center and an associate professor of medicine at Harvard Medical School. Stephen Morrissey, the interviewer, is the Managing Editor of the Journal. A.B. Goldfine. Statins: Is It Really Time to Reassess Benefits and Risks? N Engl J Med 2012;366:1752-5.

doctors medicine risk journal diabetes physicians harvard medical school managing editors primary care health policy clinical research clinical practice statins nejm joslin diabetes center stephen morrissey

Insulin-Like Effects on Exercising Muscles

Focus on Sports Medicine

Play Episode Listen Later Nov 12, 2008

Guest: Laurie Goodyear, PhD Host: Larry Kaskel, MD Dr. Laurie Goodyear, a senior investigator and head of the section on metabolism at the Joslin Diabetes Center in Boston, discusses with host Dr. Larry Kaskel how exercise impedes the development of type 2 diabetes. Tune in to hear the implications of Dr. Goodyear's research on exercise and how it works to promote the uptake of glucose into muscles. Could an exercise pill mimic the exercise-activated glucose uptake?

effects exercising muscles insulin goodyear preventive medicine rmd md dr business of medicine reachmd joslin diabetes center general medicine and primary care diabetes and endocrinology focus on sports medicine larry kaskel

Intensive Therapy for Type 1 Diabetes

therapy md associate professor genetics harvard medical school investigators pediatrics pediatric epidemiology intensive type1 type 1 diabetes rmd phd dr business of medicine reachmd joslin diabetes center general medicine and primary care diabetes and endocrinology

Play Episode Listen Later Apr 16, 2007

Guest: Lori Laffel, MD, MPH Host: Cathleen Margolin, PhD Dr. Lori Laffel, chief of the Pediatric and Adolescent Section at Joslin Clinic and an Investigator in the section on Genetics and Epidemiology at Joslin Diabetes Center as well as an Associate Professor of Pediatrics at Harvard Medical School discusses intesive therapy for Type 1 diabetes.

Trends in the Treatment of Type 1 diabetes

journal md treatments associate professor genetics harvard medical school investigators pediatrics pediatric epidemiology type1 type 1 diabetes rmd phd dr business of medicine reachmd joslin diabetes center general medicine and primary care diabetes and endocrinology

Play Episode Listen Later Apr 16, 2007

Guest: Lori Laffel, MD, MPH Host: Cathleen Margolin, PhD Dr. Laffel, chief of the Pediatric and Adolescent Section at Joslin Clinic and an Investigator in the section on Genetics and Epidemiology at Joslin Diabetes Center as well as an Associate Professor of Pediatrics at Harvard Medical School discusses her latest research published in the Journal of Pediatrics reporting on trends in the treatment of pediatric Type 1 diabetes.

Adjustment to Diabetes Diagnosis / New Technology

md associate professor genetics harvard medical school investigators pediatrics pediatric epidemiology new technology adjustment rmd phd dr business of medicine diabetes diagnosis reachmd joslin diabetes center general medicine and primary care diabetes and endocrinology

Play Episode Listen Later Apr 16, 2007

Guest: Lori Laffel, MD, MPH Host: Cathleen Margolin, PhD Dr. Laffel, chief of the Pediatric and Adolescent Section at Joslin Clinic and an Investigator in the section on Genetics and Epidemiology at Joslin Diabetes Center as well as an Associate Professor of Pediatrics at Harvard Medical School discusses adjustment to the diagnosis of Type 1 diabetes. She also talks about the latest technological and educational techniques being used to promote optimal glycemic control.

Diabetic Kidney Disease Prevention